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Abstract
The infiltration of leukocytes across the BBB is thought to be mediated by chemokines 
released in the CNS. This study investigated the production of chemokines and expression 
of chemokine receptors by human brain endothelial cells (HBEC) as well as the 
consequences of CXCL10 stimulation on brain endothelial function in terms of leukocyte 
migration and endothelial permeability.
Purified primary HBEC as well as a novel human brain endothelial cell line, called 
hCEMC/D3 and generated in collaboration with the Institute Cochin, were used in the 
present study. Characterisation of hCMEC/D3 cells was effected by determining the 
expression and localisation of HBEC markers such as tight junction and adherens junction 
proteins. Both primary and immortalized HBEC were tested for the production of four 
chemokines (CCL2, CCL5, CXCL8 and CXCL10) considered to play a role in multiple 
sclerosis. CXCL8 and CCL2 were constitutively released, whereas CXCL10 and CCL5 
could not be detected at basal levels. By contrast, all these chemokines were up-regulated 
in response to either TNF-a or IFN-y or a combination of both. TNF-a had the most 
striking effect, up-regulating the production of CCL2, CCL5 and CXCL8, while IFN-y up- 
regulated CXCL10 exclusively. The chemokine receptors CXCR1 and CXCR3, whose 
ligands include CXCL8 and CXCL10, were expressed constitutively by HBEC both in 
vitro and in vivo, and only CXCR3 was up-regulated in response to cytokine stimulation in 
vitro. Furthermore, CXCR3 on endothelial cells is functional as CXCL10 induces 
phosphorylation of p42/44 MAP kinase, p38 MAP kinase and JNK/SAPK. However, 
activation of HBEC by CXCL10 did not induce any permeability change nor did it 
modulate leukocyte adhesion.
These results demonstrate that endothelial cells could play an important role in chemokine 
production and hence leukocyte infiltration during inflammatory pathologies such as MS. 
The role of chemokine receptors requires further investigation.
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1. Chapter 1: General Introduction
21
1.1 Multiple sclerosis
Multiple sclerosis (MS) is considered to be an autoimmune disorder affecting the central 
nervous system (CNS). It is characterized by the infiltration of leukocytes from the 
systemic compartment into multifocal areas in the CNS where active demyelination of 
neuronal axons occurs. The regions of inflammation and demyelination are named plaques 
or lesions. MS affects 2 500 000 people worldwide, and represents the most frequent cause 
of neurological disability in young adults, with an average age of onset between 20 and 40 
years old, predominantly affecting women over men at a ratio of 2 to 1 (Confavreux et al., 
1980). This female: male ratio in morbidity is commonly observed in many autoimmune 
disorders, including Graves’ disease, rheumatoid arthritis, systemic lupus erythematosus 
and Hashimoto's disease.
MS was first identified and characterised in 1865 by the French clinician Jean-Martin 
Charcot and his pupil Alfred Vulvian (Charcot, 1865). He named it la sclerose en plaques 
disseminees, la sclerose multiloculaire or la sclerose generalisee. Despite extensive 
research over the last 140 years, the aetiology of the disease is still unknown and much 
debated.
1.1.1. Aetiology
MS is a disease with uneven geographic and ethnic distribution. The overall risk of 
developing MS is higher in northern (the prevalence, meaning the number of individuals in 
whom the diagnosis has been made in a given population, is around 100/105 in 
Scandinavian countries) and southern (a prevalence of around 60/105 in New-Zealand) 
hemispheres, than in equatorial regions (occasional cases) (Rosati, 2001). The aetiology of 
MS is extremely complex but it appears to be triggered by environmental factors in
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genetically-susceptible individuals. Table 1.1 lists some of the major factors that have been
currently proposed to contribute to MS.
Genetic major
histocompatibility 
complex (MHC) 
class I
HLA-A3 (Fogdell-Hahn et al., 
2000)
Genetic MHC class I HLA-B7 (Bertrams and Kuwert, 
1976)
Genetic MHC class II DRB1*1501- 
DQB 1*0602
(Barcellos et al., 2003)
Environmental Virus Human herpes virus 6 (Clark, 2004)
Environmental Virus Epstein-Barr virus (Wagner et al., 2004)
Environmental Virus Varicella zoster virus (Ross, 1998)
Environmental Bacteria Chlamydia pneumonia (Contini et al., 2004)
Environmental Solar UV 
radiation
Biosynthesis of vitamin 
D
(Hayes, 2000)
Other Sex hormones Female hormones (Coo and Aronson, 
2004)
Table 1.1: List of some proposed factors contributing to MS as reviewed by Sospedra and 
Martin (2005).
Several studies have indicated that MS may be causally linked to one or several genetic
components. Indeed, a small but significantly higher incidence rate of MS has been
observed within families (approximately 20% higher than in the general population) (Pratt
et al., 1951). The prevalence in monozygotic twins ranges from 21% to 30% and in
dizygotic twins is around 5% (Ebers et al., 1986; James, 1982; Mumford et al., 1994).
Adopted siblings of MS patients do not appear to have a higher tendency to develop MS
(Ebers et al., 1995). However, the inheritance of the genes involved does not follow
classical Mendelian patterns. The first candidate gene suspected to confer susceptibility to
MS is the MHC encoding region on chromosome 6q21. Other genes that may be
implicated are on chromosome 14 in the area encoding the variable region of the
immunoglobulin heavy chain, involving several genetic regions, as well as on
chromosomes lp, 17q, Xq,10p, 1 lp, 19p and 20p as reviewed by (Hensiek et al., 2003). At
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present, the MHC region on chromosome 6p has given the most reproducible data for 
establishing a relationship of MS with a genetic component. The human leukocyte antigen 
(HLA) complex consists of 4000kb DNA mapped to chromosome 6q21.3. It consists of 3 
classes of genes, MHC class I, MHC class II and MHC class III. A strong association with 
MS has been reported for HLA DR2 (Olerup et al., 1987; Heard et al., 1989), mainly 
among Caucasians in northern and central Europe, northern America and Australia, but this 
association was weak or lacking in other ethnic groups (Spurkland et al., 1991; Clerici and 
Fernandez, 1992).
Studies on the prevalence of MS carried out on migrants from Europe underline the 
importance of environmental factors in the aetiology of this disease. In some cases, those 
migrants show lower prevalence rates than in their country of origin, and the residential 
place during childhood appears to be of critical importance. For example, observations 
made in Israel (Alter et al., 1962) suggested that the place of residence in early life affects 
the probability of developing MS as migrants from northern Europe had lower MS 
prevalence rates when they had migrated before the onset of puberty therefore emphasizing 
the importance of environmental factors. While this indirect evidence suggests that a 
pathogen, whose infection was acquired most certainly during childhood, may represent an 
environmental factor that determines the onset of MS, no one as yet has identified a 
specific agent. Instead, a variety of common viral disorders developing in late childhood 
(measles, mumps, rubella, and mainly Epstein-Barr virus) have been proposed over the 
years as significant factors predisposing to MS (Operskalski et al., 1989) (some of these 
are reported in table 1.1).
Another suggested environmental factor, reported in table 1.1, that may protect individuals 
from developing MS is sunlight and its effect through vitamin D production on the immune 
system. In a study involving American women, vitamin D supplementation in the diet has
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been shown to be inversely correlated with the risk of developing MS (Munger et al., 
2004). Furthermore, the finding of seasonal variation of immune function in serially 
magnetic resonance imaging (MRI)-monitored MS patients suggests an environmental role 
in T-cell activation (Killestein et al., 2002).
1.1.2. The symptoms of multiple sclerosis
The clinical course of MS can follow different patterns, and this observation has led to the 
classification of distinct types of MS. In the majority of cases, the disease follows a 
relapsing-remitting (RR-MS) course, where the initial attack is followed by partial or 
complete recovery, with relapses occurring months or years later. Around 50% of RR-MS 
patients will convert to a secondary progressive (SP-MS) form, in which the progression 
towards incapacitating manifestations of the disease will be gradual with or without 
relapses. Another form of MS is called primary progressive (PP-MS), where the disease 
follows a progressive course from the onset. The PP-MS form is usually diagnosed at an 
older age and with a greater proportion of male to female patients than in the RR-MS form. 
Finally, in fewer than 5% of the cases, the disease is manifested as a progressive relapsing 
(PR-MS) form, which is similar to the PP-MS but displays one or more exacerbations 
(Noseworthy et al, 2000).
The symptoms displayed by MS patients are related to the distribution of their CNS lesions 
which varies from patient to patient. There is a higher probability that lesions affect the 
white matter of the cerebrum, cerebellum, brain stem, spinal cord, the optic nerves and 
chiasm (Poser et al., 1979). Because areas in the CNS where lesions can develop are 
different amongst individuals, the resulting symptoms are also extremely varied from 
patient to patient. Table 1.2 describes symptoms associated with the location of lesions in 
the CNS (adapted from Compston and Coles, 2002).
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Site Symptoms
Cerebrum Cognitive impairment; Hemi-sensory and 
motor disturbances;
Affective disorder (mainly depression); 
Epilepsy (rare) Focal cortical deficits 
(rare)
Optic nerve Unitateral painful loss of vision
Cerebellum and cerebellar pathways Tremor, Clumsiness and poor balance
Brainstem Diplopia, Oscillopsia; Vertigo; Impaired 
speech and swallowing; Paroxysmal 
symptoms
Spinal cord Erectile impotence; Bladder dysfunction; 
Weakness; Stiffness and painful spasms
Other Pain; Temperature sensitivity and 
exercise intolerance; Fatigue
Table 1.2: Lesion sites and corresponding syndromes developing in MS. Adapted from 
Compston and Coles (2002).
Many of these symptoms are also related to the neuropathology of the lesion (see section
1.1.3. below), as a result of either demyelinated axons, or partially demyelinated axons. 
Demyelinated axons can discharge spontaneously and show increased mechanical 
sensitivity. This accounts for the sensation of seeing light flashes triggered by eye 
movement (phosphenes) and for the electric shock-like sensation running down the spine 
or limbs on neck flexion (Lhermitte’s symptom and sign). Symptoms and signs 
characteristically appear after exercise or a hot bath (Uhthoff s phenomenon) and are 
related to the sensitivity of partially demyelinated axons which cannot sustain the fall in 
membrane capacitance induced by a rise in temperature leading to electrical conduction 
failure (Compston and Coles, 2002).
1.1.3. The pathology of multiple sclerosis
The predominant pathological features of MS lesions are inflammation, axonal 
demyelination and gliosis (see sections 1.1.3.1 to 3 below). The pathology of MS lesions 
varies due to a number of factors, related to the temporal state of activity of the lesions. 
Histological studies of MS lesions have attempted to provide a system of classification. 
The following paragraph will describe some lesion classification systems.
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MS lesions may be divided into active, chronic active and chronic silent according to Bo et 
al (1994). This classification reflects the pathological characteristics of the lesions. Active 
lesions are composed of infiltrating leukocytes positive for MHC class II, and are 
hypercellular (Gay et al., 1997). Chronic active lesions are characterised by a central 
hypocellular gliosis area surrounded by an active MHC class II positive hypercellular 
border, where both demyelination and inflammation occur concomitantly. In the centre of a 
chronic active lesion, demyelinated axons and reactive astrocytes are found. In chronic 
silent lesions, there is apparent demyelination of the axon, but the inflammation is not 
visible and the staining for MHC class II is negative. Mainly microglia and macrophages 
are present, as indicated by CD68 positive staining (Bo et al., 1994).
Sanders et al. (1993) has proposed classifying the lesions into four different sub-types, 
type I, type II, type III and type IV, based upon cellularity criteria, oil-red O (ORO) 
staining (ORO stains lipids, and when it is present in leukocytes, it is thought to reflect 
phagocytosed degraded myelin), and expression of HLA-DR, which is one of the MHC 
class II molecules and a marker for leukocyte activation. As a result, active lesions from 
the classification above are subdivided into two sub-types: type I lesions, corresponding to 
the earliest lesion, where there are HLA-DR positive cells which are negative for ORO, 
hence no evidence of myelin degradation; and type II lesions, where HLA-DR/ORO 
doubly positive cells correspond to activated macrophages and microglia. The ORO 
staining of type I lesions has proven to be controversial. Li et al. (1993) described the 
earlier stage of the lesion as being ORO positive, implying myelin degradation as an early 
event whereas Gay et al. (1997) described the early lesions as being ORO negative, but 
with signs of myelin phagocytosis and digestion. Type III lesions correspond to the chronic 
active lesions with a hypocellular centre and a hypercellular edge constituted by HLA- 
DR/ORO positive cells. Type IV lesions are equivalent to chronic silent lesions, with
demyelinated axons, amoeboid microglia, and macrophages which are positive for CD68 
(Bo et al., 1994), but little HLA-DR/ORO positive staining. Interestingly, the majority of 
the lesions present are different in type depending on the duration of the disease. Around 
80% of lesions are type I in patients with disease duration of less than 5 years, whereas 
very few are present in patients that have been diagnosed over 30 years earlier (2%). The 
relation is inversely true for type IV lesions (around 20% of all lesions in patients with less 
than 5 years of clinical history compared to 85% in those with a 30 year clinical history) 
(Sanders et al., 1993).
Even more detailed characterisation of MS lesions has been carried out, using a wider 
range of histological markers for macrophage activation such as MRP 14, 27E10 or 25F9 
and CD3, a marker for lymphocytes. Two other types of lesions have thus been added, the 
early remyelinating stage and the late remyelinating stage, the latter also named shadow 
plaque and recognisable by their pale appearance (Bruck et al., 1996). These shadow 
plaques were described very early on by Marburg (1906) and were first thought to reflect 
the degree of demyelination. It has since become clear that they represent remyelination of 
complete plaques (Lassmann et al., 1983). The early remyelinated lesion is characterised 
by the presence of many cells, both lymphocytes and macrophages, and by clusters of 
thinly myelinated axons, while in the late remyelinated lesion, only a few macrophages are 
present among the thinly myelinated axons. The abundance of remyelinated lesions is 
apparent from studies of acute or early multiple sclerosis (Prineas et al., 1993).
Inter-individual differences in MS lesions have also been reported, suggesting that the 
pathology of this disease may be heterogeneous (Lassmann et al, 2001). The authors 
investigated active and inactive MS lesions in different patients and reported four different 
patterns of inflammation. These are macrophage-mediated demyelination (pattern I),
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antibody-mediated demyelination (pattern II), oligodendriopathy (pattern III) and primary 
oligodendrocyte damage (pattern IV) (Lassmann et al, 2001).
1.1.3.1 .Demyelination
The loss of myelin sheaths around axons is the earliest pathological feature of MS plaques. 
The myelin sheath is formed by gyring of several layers of the plasma membrane of an 
oligodendrocyte around a portion of an axon. An oligodendrocyte may be responsible for 
the myelination of several axons. In MS, disruption of the myelin sheath may lead to the 
death of the oligodendrocyte. Oligodendrocytes are found in reduced numbers in lesions 
especially in chronic silent and/or active lesions (Mews et al., 1998; Prineas et al., 1984), 
whereas in earlier lesions, their numbers may appear unchanged and there is even some 
active remyelination (Ozawa et al., 1994). It has been suggested that in the early stage of 
the lesion, the destruction of oligodendrocytes is followed by recruitment of progenitor 
cells from surrounding areas. This may explain the remyelination observed by MRI and the 
shadow plaque (Li et al., 2003b).
The extent of axonal damage varies greatly between individuals and lesion types. It is 
characterised by transacted axons and axonal swelling with the formation of spheroids and 
regeneration sprouts (Dahl et al., 1989). These phenomena are most evident in active 
lesions (Trapp et al., 1998). In chronic silent lesions, axonal damage may lead to Wallerian 
degeneration (corresponding to the degeneration of an axon and its myelin sheath distal to 
the site of an injury), which is manifested by brain atrophy. As neurons are not replaceable 
and do not regenerate, neuronal loss is most certainly responsible for the neurological 
deficits observed in patients as demonstrated by magnetic resonance spectroscopy (Davie 
etal., 1997).
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\ .\  3.2.Gliosis
Glial scar formation, also known as gliosis, is one of the features of demyelinated MS 
lesions. Gliosis generally consists of highly reactive astrocytes, microglia and 
oligodendrocyte precursors but in demyelinated plaques in MS, it consists mostly of scar- 
type astrocytes and naked axons (Fawcett and Asher, 1999). The two most commonly used 
markers for gliosis in MS are the intermediate filament glial fibrillary acidic protein 
(GFAP) and vimentin (Holley et al., 2003), whose up-regulation is associated with 
hypertrophy of astrocyte processes. Early on, in active lesions, astrocytes show signs of 
reactivity with increased expression of lysosomal enzyme (Allen et al., 1981). In chronic 
silent lesions, the demyelinated axons are embedded in an important fibrillary network of 
astrocyte processes. It has been suggested the astrocyte reactivity is a secondary response 
to the immunological factors present in the lesion, such as tumor necrosis factor alpha 
(TNF-a) which has a proliferative effect on astrocytes (Selmaj et al., 1990).
1.1.3.3 .Inflammation
Originally, the CNS was considered to be an immune-privileged organ since it was 
suggested that the immunosurveillant lymphocytes which are patrolling elsewhere in the 
organism were excluded from the brain (Barker and Billingham, 1977). It is now clear that 
this is not the case, and that leukocyte can infiltrate the brain under pathophysiological 
circumstances. In MS lesions, macrophages and lymphocytes have been identified in the 
CNS parenchyma, whereas plasma cells and B cells are present in the perivascular space 
(Prineas and Wright, 1978). Most lymphocytes within the lesion are T cells, both CD4+ 
and CD8 + predominantly at the early stage of the lesions. CD4+ lymphocytes, also called 
Helper T-cells, facilitate antibody production by B-cells, and help the expansion of CD8 + 
T lymphocytes, also called cytotoxic T-cells, which are involved in the cytolytic 
destruction of antigen-presenting cells. The distribution of leukocytes within the lesion 
varies according to the type of lesion (Lucchinetti et al., 2000). Although most studies
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indicate that both CD4 and CD8  positive cells are present within lesions, there is still much 
discussion as to which of these T-lymphocyte sub-types prevails during the early stages of 
lesion formation. Transfer of reactivated myelin specific CD4+ T cells induces 
Experimental Autoimmune Encephalomyelitis (EAE) in animal models for MS, 
strengthening the hypothesis that it is the CD4+ subpopulation that initiates the 
autoimmune reaction (Pettinelli and McFarlin, 1981). However, recent data shows an 
important role for CD8 + T cells in the development of neuropathology in MS (Bitsch et al., 
1999; Babbe et al., 2000). Not only is clonal expansion in MS lesions more important in 
the CD8 + population than in CD4+ cells (Babbe et al., 2000), but also the number of 
CD8 + cells within the lesion correlates better with the extent of acute axonal injury than 
the number of CD4+ cells (Bitsch et al., 1999).
Macrophages constitute another type of immune cell which are found in abundance, 
together with T lymphocytes, in MS lesions. They are predominantly present during the 
active phase of the lesion, and participate in myelin degradation and breakdown, as 
indicated by the presence of immunoreactive myelin peptide fragments in their cytoplasm 
(Bruck et al., 1995). Not only do early and late chronic lesions contain lower numbers of 
macrophages, but also the differentiation of those macrophages changes with the lesion 
type, as indicated by a series of markers such as MRP 14, 27E10, 25F9, MRp8 , Ki-MlP 
and Ki-M4P (Bruck et al., 1996); MRP 14 and 27E10 are expressed in early and late active 
lesions, whereas 25F9 is detected throughout all the different lesion type. It has been 
suggested the macrophages are the key cells responsible for myelin degradation through 
the production of macrophage soluble mediators. In vitro, macrophage conditioned 
medium triggered apoptosis in cultured neurons (Flavin et al., 1997). Among the soluble 
factors identified are pro-inflammatory cytokines (such as TNF-a and IFN-y), free radicals, 
glutamate and some proteases such as the matrix metalloproteinases (MMP); all potential 
neurotoxic mediators, as reviewed by Hendriks et al. (2005).
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1.1.3.4. Blood-brain barrier dysfunction
The BBB is certainly compromised in MS and blood vessel damage concomitant with 
leakage of serum proteins into the CNS parenchyma appears to be one of the earliest 
events during the formation of active MS lesions (Gay and Esiri, 1991). The BBB as an 
anatomical structure and biochemical barrier in both physiological conditions and, 
particularly, its malfunction and relevance to MS pathology is described in the following 
section.
1.2 The blood-brain barrier
Goldmann (1913) first introduced the concept of a BBB when he demonstrated that after 
intravenous injection of the trypan blue dye into rats, all organs with the exception of the 
brain stained blue. The cerebro-spinal fluid (CSF) remained free of dye, whereas the 
choroid plexus and the meninges appeared stained. By contrast if the dye was injected 
directly into the CSF, the brain would stain blue.
The BBB is thought to be important in maintaining the homeostasis of the CNS 
parenchyma, as neuronal function is dependent on small fluctuations in the concentration 
of ions and/or molecules such as neurotransmitters. The BBB protects the brain from 
exogenous substances such as drugs, toxins and infectious agents and also from 
endogenous substances such as elevated ion concentrations, blood-borne toxic constituents 
and immunological components. The BBB also eliminates by-products of CNS metabolism, 
such as neurotransmitters, whose high concentrations would be potentially deleterious for 
neuronal function. In addition, the entry of many substances necessary for the normal 
functioning of the CNS is actively regulated at the level of the BBB and these include 
amino acids, glucose, and sodium, potassium and chloride ions (Pardridge, 1984; Hawkins 
and Davis, 2005)
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The three cellular elements of the brain microvasculature are endothelial cells, astrocyte 
end-feet, and pericytes (fig 1.1). Brain endothelial cells, in contrast to endothelial cells 
from the peripheral micro vasculature, form a continuous layer of cells, with no detectable 
fenestrations. Brain endothelial cells are also unique in that they have a reduced pinocytic 
activity (Broadwell, 1989) and form tight molecular junctions (Rubin and Staddon, 1999). 
Astrocytes extend foot-like projections surrounding the capillaries, and play an important 
role in inducing and maintaining the barrier (see section 1.2.2). Less frequent than the 
astrocytes, pericytes and perivascular cells can also be found scattered along the brain 
capillary endothelial cells. Pericytes are thought to be a second defence barrier due to their 
phagocytic properties although their exact role and function remain to be determined.
Tight function
Nurlans I
Fig 1.1: The three main cell types of the brain microvasculature: interactions between 
the brain capillary endothelium, the pericytes, and the astrocyte foot processes are 
crucial for maintaining the BBB. From Miller (1999)
1.2.1. Brain endothelial properties
Microvascular brain endothelial cells are unique in that they present a barrier phenotype. 
These observations were initially made in electron microscopy studies which demonstrated 
that tracers administrated intravenously, such as ionic lanthanum, do not cross the BBB
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and are retained at the level of the vascular endothelium (Donahue, 1964). CNS endothelial 
cells present a physical barrier to the passage of blood-borne substances due to the 
presence of tight junctions between them (Bazzoni and Dejana, 2004). In addition, they 
show functional polarity due to the different distribution of transporters and receptors 
between the luminal and abluminal membranes, enabling regulation of transport. Certain 
transporters and intracellular enzymes function as biochemical barriers to many lipophilic 
substances (table 1.3).
At the electron microscopy level, brain endothelial cells show electron dense contact points 
between them, which represent tight junctions that can physically restrict flux between the 
blood and the brain (Reese and Kamovsky, 1967). The presence of tight junctions restricts 
passage of molecules with a diameter greater than 8-18 A. There are common features 
between endothelial cells and epithelial cells. In epithelial cells, junctions are better 
organized, with tight junctions and adherens junctions following a well-defined spatial 
distribution along the intercellular cleft. Tight junctions are concentrated at the luminal 
side of the rim, while AJ are located below the tight junctions. In contrast, in endothelial 
cells, the junctional architecture is less defined and, along the cleft, adherens junctions are 
intermingled with tight junctions (Simonini et al., 2000). Moreover, epithelial cells also 
form desmosomes, which are absent in the endothelium. The organization of endothelial 
junctions varies along the vascular tree in function of organ-specific requirements 
(Simonini et al., 2000). For instance, in the brain, where a strict control of permeability 
between blood and the nervous system is required, junctions are well developed and rich in 
tight junctions (Wolburg and Lippodt, 2002). In the brain, they are formed by a complex of 
transmembrane proteins, the extracellular part of the protein being in direct interaction 
with its homologous protein on the adjacent cell and are located on the most apical side. 
Some of these proteins have been identified, such as claudin-3 and claudin-5, forming the 
primary seal of the tight junctions (Furuse et al., 1999). Other transmembrane tight 
junctional proteins include occludin, which has been suggested to be a regulatory protein in
terms of the permeability of the BBB (Hirase et al., 1997), and junctional adhesion 
molecules (JAM) which participate in regulating the migration of leukocytes (Martin- 
Padura et al., 1998). In association with transmembrane proteins are cytosolic proteins 
which participate in the maintenance and regulation of the tight junctions, such as zonula- 
occludens (ZO) proteins-1, -2, -3 (Huber et al., 2001) (fig 1.2). Adherens junctions are 
located on the abluminal side in relation to tight junctions. They are found in the 
endothelium of most vascular beds, and are not specific to the BBB. However, they 
participate in the formation of a barrier, as tight junctions cannot develop in the absence of 
adherens junctions. Adherens junctions contain cadherins, specifically VE-cadherin, and a 
submembranous complex of proteins belonging to the catenin family which bind cadherins 
to actin microfilaments.
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Fig 1.2: Proposed interactions of the major proteins associated with tight junctions at 
the blood-brain barrier (BBB). From Huber et al. (2001). (AF6  stands for Afadin 6 )
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As tight junctions prevent the paracellular passage of hydrophilic substances, the 
endothelial cells are responsible for regulating the transcellular movement of substances. 
Transcellular diffusion is possible for small lipophilic substances (<600 Da) and small 
molecules such as O2 and CO2 (Grieb et al., 1985) by penetrating the lipid membrane of 
the endothelial cells. Many lipid soluble substances are substrates of efflux transporters 
and actively pumped out of the brain (Scherrmann, 2002). The function of efflux pumps is 
to protect the brain from various substances. An example of such a transporter is P- 
glycoprotein (P-gp), a membrane-bound ATP-dependent efflux transporter which protects 
the brain against xenobiotics (Fairchild et al., 1987). Another limiting factor of the 
endothelial cells to drug permeability is the presence of several enzyme implicated in drug 
oxidation (Ghersi-Egea et al., 1994). Hydrophilic substances can traverse the BBB via 
specific carrier mediated transport mechanisms, such as for amino acids, glucose and 
nucleosides. For example, glucose, one of the main sources of energy for the brain, is 
transported across the endothelial cells in its D-form via a transporter termed GLUT-1 
(Dobrogowska and Vorbrodt, 1999). Vesicular transport may be receptor-mediated or, 
alternatively, cationic proteins can be taken up via electrostatic interactions with anionic 
sites on the endothelial surface triggering adsorptive endocytosis (absorptive mediated 
transcytosis). Most of these transmembrane proteins are in the luminal or abluminal 
membranes of the endothelial cells and control the uptake of numerous drugs (Scherrmann, 
2002). Table 1.3 summarizes some of the transporters found on the luminal and abluminal 
sides of endothelial cells at the BBB.
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Transporters Substrates Luminal Ablummi
nal
References
INFLUX
TRANSPORTERS
GLUT-1 Glucose + ++++ (Mann et al., 
2003)
System LI Branched chain and 
aromatic neutral amino 
acid
+ + (Mann et al., 
2003)
System B(0>f Neutral and dibasic 
amino acid
- + (Mann et al., 
2003)
Organic anion 
transporters-1
Anionic compounds + - (Mann et al., 
2003)
Organic cation 
transporters
Cationic compounds + - (Mann et al., 
2003)
EFFLUX
TRANSPORTERS
P-gP Cationic or highly 
lipophilic compounds
+ - (Sun et al., 
2003)
Multidrug resistance 
associated protein
Organic anion 
transporters
+ + (Sun et al., 
2003)
Breast cancer resistance 
protein
molecules of either 
negative or positive 
charge, organic anions 
and sulphate conjugates
+ (Cooray et al., 
2002)
RECEPTOR
MEDIATED
TRANSCYTOSIS
Transferrin receptor transferrin + - (Roberts et al., 
1993)
ADSORPTIVE
TRANSCYTOSIS
Acidic glycoproteins Cationic peptides
INTRACELLULAR
ENZYMES
y-Glutamyl
Transpeptidase
Large and neutral 
amino acids
+ + (Cancilla et al, 
1993)
Table 1.3: Transporters found on the luminal and abluminal sides of endothelial cells at the 
BBB.
1.2.2. Role of astrocytes in barrier phenotype induction
As shown in fig 1.1, astrocytic end feet are in close contact with the basement membrane 
surrounding the endothelium. Astrocytes are important for the induction and maintenance 
of a barrier phenotype in brain endothelium. Indeed, astrocytes are thought to produce 
brain endothelial trophic factors. This was demonstrated by a classical in vivo experiment 
in which a piece of CNS tissue was grafted into a non-brain tissue in rat (Svendgaard et al., 
1975). The non-CNS capillaries growing into the grafted CNS tissue developed some
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properties of the BBB, tested by its barrier properties toward L-dopa (Svendgaard et al., 
1975). Astrocytes were confirmed to be the main candidate cell type for this effect since 
cultured rat astrocytes, implanted into the anterior eye chamber, normally with leaky 
vessels, were able to induce tightening of the endothelium (Janzer and Raff, 1987). These 
observations were further reinforced by in vitro studies. Isolated endothelial cells from 
brain tissue lose some of their phenotype, but either co-culture with astrocytes or addition 
of astrocyte conditioned medium (ACM) are able to reinduce some BBB properties. Indeed, 
in the presence of astrocytes, brain endothelial monolayers form tighter junctions with 
higher transendothelial electrical resistance (TEER) and lower rates of paracellular 
permeability (Rubin et al., 1991; Hayashi et al., 1997). Some specific transport systems are 
also up-regulated under these conditions such as GLUT-1 and P-gp (El Hafhy et al., 1997; 
Sobue et al., 1999). However, the ability to acquire a barrier phenotype is not specific to 
brain endothelial cells. In human umbilical vein endothelial cells (HUVEC), the 
immunostaining for tight junction proteins is inherently discontinuous in the absence of 
inducing factors contrary to what is observed with brain endothelial cells but expression of 
these proteins increases dramatically in the presence of ACM (Bums et al., 1997).
1.2.3. Diapedesis across the Blood-brain barrier
Leukocyte migration from the blood, across the vascular endothelium and into a tissue area 
of inflammation has been shown to be highly directed and follows a specific sequence of 
events. The transmigration of the leukocytes themselves has been described as a process 
involving three interdependent steps. The first step involves the transient adhesion of 
leukocytes to the vascular endothelium. In this step, the blood flow causes the leukocytes 
to roll over the endothelial cells and is known as ‘rolling’. The second step consists of the 
activation of leukocytes by chemokines presented on the endothelial surface and their firm 
adhesion to the endothelium. Finally, the last step involves the spreading of the immune 
cell and the migration through the endothelial barrier, a phenomenon also known as
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diapedesis (Ley, 1996; Millan and Ridley, 2005). These three steps are further explained in 
the following sub-sections.
1.2.3.1 .Capture and rolling
The capture and rolling of leukocytes on endothelial cells is a process in which free 
circulating leukocytes in the blood start to interact with the endothelial cells and tether 
towards the site of inflammation. Supported by the blood flow, leukocytes roll along the 
endothelium (Gonzalez-Amaro and Sanchez-Madrid, 1999). Selectins are the proteins 
responsible for this initial weak bond between endothelial cells and leukocytes. Three 
selectins have been identified: P-, E- and L-selectin.
P-selectin is a highly glycosylated 140 kDa protein constitutively expressed by endothelial 
cells. P-selectin is stored in Weibel-Palade bodies, endothelial-specific vesicles that also 
store von Willebrand factor (vWF). Upon stimulation by inflammatory mediators, Weibel- 
Palade bodies fuse with the plasma membrane, which results in the surface expression of 
P-selectin within minutes (Dole et al., 2005). Like P-selectin, E-selectin is expressed by 
endothelial cells (Hooft van Huijsduijnen et al., 1992). The relative molecular weight of 
unglycosylated E-selectin is about 64 kDa but ranges between 107 and 115 kDa depending 
on the level of glycosylation. E-selectin is not constitutively expressed by endothelial cells, 
instead, E-selectin expression is transcriptionally regulated by mediators such as TNF-a 
and IL-1 and its peak expression occurs at 6  h following cytokine stimulation (Wyble et al., 
1997). L-selectin is expressed in most peripheral blood leukocytes, and has been suggested 
to be involved in leukocyte trafficking (Lewinsohn et ah, 1987). The ligands for P- and E- 
selectins include CD24, P-selectin glycoprotein ligand-1 and E-selectin ligand-1 on the 
leukocytes, and the ligands for L-selectin include CD34, mucosal addressin cell adhesion 
molecule- 1 and glycosylation-dependent cell adhesion molecule- 1 on the endothelial cells 
(Millan and Ridley, 2005).
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Fig 1.3: The different stages of leukocyte migration., showing capture and rolling, 
firm adhesion of leukocytes to endothelial cells, and finally transmigration by either 
paracellular or trancellular processes. Adapted from Millan and Ridley (2005).
The duration of selectin-mediated rolling is about 50-500ms and is followed by rapid 
integrin avidity changes in leukocytes induced by chemokines (Alon et al., 1997) known as 
firm adhesion.
\.23.2.Firm adhesion
The proteins responsible for firm adhesion and subsequent arrest of leukocytes on the 
endothelial cells are called integrins. Leukocyte firm adhesion is mediated by activation of 
leukocyte integrins which involve integrin clustering and higher affinity/avidity. These 
changes are initially triggered by the binding of chemokines present on the endothelial 
cells bound to glycosaminoglycans onto chemokine receptors expressed by leukocytes 
(Tanaka et al., 1993; Kitayama et al., 1998) activating heterotrimeric G-protein-dependent
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signalling. Chemokine induced signal transduction results in changes in integrin 
avidity/affinity which then facilitates integrin interactions with their counterpart 
Immunoglobulin-like adhesion molecules on endothelial cells. Among the different 
integrins present on leukocytes, a4p i integrin, which binds Vascular Cell Adhesion 
Molecule (VCAM) present on the endothelial cells, is thought to be important in the early 
stages of the firm adhesion. VCAM-a4pl integrin interactions can up-regulate the avidity 
of aip2 integrin for its ligand InterCellular Adhesion Molecule (ICAM) present on the 
endothelial cells (Chan et al., 2000). The expression of cell adhesion molecules of the 
immunoglobulin superfamily on the endothelial cell surface can be up-regulated by 
cytokines (dos Santos et al., 1996). Effectively, the binding of integrins to adhesion 
molecules triggers downstream signals in both leukocytes and endothelial cells. These 
intracellular signals will subsequently lead to morphological changes which allow the final 
step of transmigration. Leukocytes spread out and consequently are able to squeeze (in 
amoeboid fashion) between the endothelial cells. ICAM-1 cross-linking using antibodies 
mimicking interactions resulting from leukocyte integrin clustering, induces an increase in
^  I
Ca flux in endothelial cells (Etienne-Manneville et al., 2000). An increase in intracellular
94 -  •Ca leads to phosphorylation of myosin light chains and unfolding of myosin II, causing 
the endothelial cells to retract facilitating the passage of leukocytes (Hixenbaugh et al., 
1997). Inhibition of an increase in intracellular Ca2+ in endothelial cells blocks neutrophil 
transmigration (Huang et al., 1993).
1233.Transendothelial migration
Transmigration is a rapid process by which leukocytes crawl between tightly apposed 
endothelial cells. The initial stage involves a leukocyte extending a pseudopod along the 
endothelial cell border. While in non-CNS endothelial cells, most investigators are in 
agreement that the majority of leukocytes enter the sites of inflammation by passing 
between endothelial cells, the route of transmigration of leukocytes across brain
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endothelium is much less clear due to the presence of tight junctions. Two likely 
transmigration routes have been proposed: a paracellular route that involves crawling 
through transiently opened tight junctions, and a transcellular route that involves a 
leukocyte being engulfed by the endothelial cell and being released on the abluminal side 
near the endothelial cell junctional area (fig 1.3) (Millan and Ridley, 2005). Whatever the 
route, leukocyte transmigration requires a rapid disassembly of the cytoskeleton of 
leukocytes on the apical side and a reassembly on the abluminal side of the endothelium 
(Brown, 2001). Similarly to the steps of capture and firm adhesion, transendothelial 
migration requires the interaction of transmembrane proteins between leukocytes and 
endothelial cells, although in this case it involves homophilic interactions. These include 
Platelet endothelial cell adhesion molecule-1 (PECAM-1), CD99, and proteins of the JAM 
family, all of which are located at the cell-cell junction on endothelial cells and are 
strongly expressed by activated leukocytes (Liu et al., 2004). PECAM-1 and JAM are 
members of the immunoglobulin gene superfamily whereas CD99 is a unique heavily 
glycosylated type I transmembrane protein. The role of PECAM-1 in leukocyte 
transmigration is well established as blocking PECAM-1 with a neutralizing antibody 
inhibits diapedesis in vivo (Bogen et al., 1994). CD99 appears to be involved at a later 
stage than PECAM-1 since blocking CD99 arrested monocytes at a point where they had 
partially migrated through the junction of HUVEC (Schenkel et al., 2002). The role of 
JAM is still unclear as they have only recently been identified (Martin-Padura et al., 1998). 
Nevertheless, using neutralizing antibodies, it has been possible to demonstrate the 
importance of JAM in transmigration. Indeed, an antibody against JAM-c blocked 
migration of human polymorphonuclear leucocytes across a HUVEC monolayer in 
response to a CXCL12 chemokine gradient (Martin-Padura et al., 1998).
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1.2.4. The blood-brain barrier in multiple sclerosis
1.2.4.1 Alterations in adhesion molecule expression
As described in section 1.2.3, endothelial cells play an active role in leukocyte recruitment. 
In addition endothelial cell function appears to be altered in MS. Isolated brain 
microvessels from MS patients exhibit a higher adhesion capacity together with an increase 
in ICAM-1 expression (Lou et al., 1997). This up-regulation of ICAM-1 has been 
confirmed in MS brains and was much greater in the MS lesions (Bo et al., 1996). A 
soluble form of ICAM-1, VCAM-1 and L-selectin can also be detected in the blood and in 
the intrathecal fluid of MS patients (Duran et al., 1999). This allows a non-invasive follow 
up of ICAM-1 expression in MS and its correlation with symptoms during MS. The 
concentration of soluble ICAM-1 is higher in both the serum and the CSF in patients with 
acute relapse compared to patients with stable disease (Alves-Leon et al., 2001). 
Furthermore, soluble ICAM-1 production in the CSF correlated with appearance of lesions 
on gadolinium-MRI and immunoglobulin G (IgG) level in the CSF (Acar et al., 2005).
In the CSF, VCAM-1 and E-selectin soluble form are also increased during the duration of 
the disease (Correale and Bassani Molinas Mde, 2003). Soluble PECAM-1 was reported to 
increase in the serum in MS only during the formation of active lesions (Losy et al., 1999). 
No studies on JAM-1 and CD99 in MS have been reported to date. The involvement of 
VLA-4/VCAM-1 interactions in leukocyte entry into the CNS and subsequent disease has 
been demonstrated using a monoclonal antibody against VLA-4 which diminished the 
infiltration of VLA-4-positive cells into the brain of an animal model of MS, EAE, and 
suppressed the clinical and histopathological signs (Soilu-Hanninen et al., 1997). The 
increase in adhesion molecule expression may be the result of activation of endothelial 
cells by cytokines. Indeed, it has been shown that cytokines such as TNF-a and IFN-y
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induce an up-regulation of adhesion molecules by endothelial cells in vitro, and cytokines 
are largely up-regulated in MS, as described in section 1.3.5.1.
12A.2.Changes in blood-brain barrier permeability
In MS, there is also an increase in the permeability of the BBB which can be visualised by 
MRI gadolinium enhancement, showing the opening of the BBB at the tight junctions level 
(Werring et al., 2000). The integrity of the BBB is an important factor in the normal 
function of the brain since it forms a barrier that protects the CNS cells from blood-born 
substances. The integrity of the tight junctions in MS is compromised and discontinuous 
staining of tight junction proteins, such as ZO-1, in MS lesions has been demonstrated, 
most importantly in active lesions, but there is also abnormal ZO-1 staining in inactive 
lesions (Kirk et al., 2003). Interestingly there is also a change in ZO-1 expression in 
normal appearing white matter (NAWM) tissue when compared to tissue from healthy 
controls (Plumb et al., 2002) where a small (around 4%) blood vessel opening can be 
observed (Kirk et al., 2003). Another tight junction protein which has been reported to be 
altered in inflammatory conditions is claudin-3 which is lost in EAE lesions (Wolburg et 
al., 2003).
A variety of factors that can affect the permeability of the BBB are present in MS lesions 
or the serum. Indeed, the serum from MS patients down regulates occludin and VE- 
cadherin expression in cultured brain endothelial cells (Minagar et al., 2003). This effect 
could be the result of cytokine activation, since cytokines are also detected in MS lesions. 
Among some of these cytokines are TNF-a and IFN-y, which have been shown to reduce 
the expression of occludin in vitro in epithelial cells (Mankertz et al., 2000). Other factors 
that can disrupt the organization of tight junctions is vascular endothelial growth factor 
(VEGF), present in chronic and active lesions (Proescholdt et al., 2002), or the MMP, such 
as MMP-9, which is increased in the serum of MS patients (Correale and Bassani Molinas
Mde, 2003) and display a strong immunoreactivity in blood vessel walls in active lesions 
(Lindberg et al., 2001).
Other changes that can contribute to the increased permeability of the BBB in MS patients 
have been reported. These may involve vesicular exchange, as pinocytotic vesicles have 
been shown to be markedly increased in endothelial cells in MS (Brown, 1978).
The pathology of vessels has been proposed previously as possible pathogenic mechanism 
for this disease (Courville, 1968). In this model, vascular damage would result in myelin 
destruction as a result of loss of CNS homeostasis, neurons being particularly sensitive to 
these variations. This hypothesis was reinforced by the detection of antibodies directed 
against proteins of human brain vessels (Souberbielle et al., 1992) but the presence of these 
antibodies could not be correlated with the clinical course of the disease or with abnormal 
MRI activity (Tintore et al., 1996). The time course the alteration of the BBB is still not 
clear, some studies showing an early disruption (Werring et al., 2000) prior to the 
inflammation while others showed that the change of permeability of the BBB occurs in 
parallel with leukocyte infiltration. In addition, it has been demonstrated that monocytes 
use a transcellular migration mechanism without disrupting BBB integrity suggesting that 
leukocyte diapedesis is not always associated with a change in tight junction organisation 
and BBB permeability (Wolburg et al., 2005).
1.3 Chemokines
1.3.1. Structure and function
Chemokines are small molecular weight peptides responsible for adhesion, activation, and 
chemotaxis of leukocytes. Based on genomic studies, it has been estimated that there are as 
many as forty to fifty human chemokines. Many of the genes encoding chemokines have
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been found to cluster at specific loci, mainly grouped at 17ql 1.2-12 and 4ql3 (Oppenheim 
et al., 1991). Chemokines are structurally related, possessing a pattern of conserved 
cysteine residues near the amino-terminal domain (Murphy et al., 2000). It is the position 
of the first and second conserved cysteine residues that determines the basis for the 
classification of chemokines into four families (CC, CXC, CX3C and XC or the a , p, 8  and 
y subfamilies in the old nomenclature, respectively). CC chemokines have no amino acids 
between the two cysteine residues whereas CXC and CX3C chemokines have one and 
three, respectively. XC chemokines only have one cysteine residue (fig 1.4).
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Fig 1.4: Classification of chemokine receptors based on the structural characteristics 
of their relative ligands (stylized beside). The list of chemokines binding each receptor 
is indicated. From Bajetto et al. (2002).
CXC chemokines can be further subdivided into ELR (glutamic acid/leucine/arginine)- 
containing and non-ELR-containing chemokines depending on the presence of an ELR
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motif just prior to the CXC signature. The ELR-containing C-X-C chemokines attract 
neutrophils whereas the non-ELR-containing C-X-C chemokines attract lymphocytes 
(Baggiolini, 1998). It has also been shown that CXC chemokines with an ELR+ motif are 
angiogenic, while chemokines with an ELR- motif are angiostatic with the exception of 
CXCL12 and CXCL2 (Bemardini et al., 2003). The requirement of the ELR motif for the 
angiogenic effect has been demonstrated by site-directed mutagenesis substitution of the 
ELR motif in the sequence of an angiogenic chemokine (i.e. IL-8 /CXCL8 ) with a non-ELR 
motif of the angiostatic molecule (Mig/CXCL9) and vice versa. The shift in angiogenic 
properties of the mutated chemokines to angiostatic in both in vitro and in vivo assays 
strongly supports the importance of the ELR motif as a structural domain for angiogenic 
activity (Strieter et al., 1995).
The second major branch of the CC chemokines are chemoattractants for a wide range of 
cells including monocytes, granulocytes other than neutrophils, various subpopulations of 
lymphocytes including thymocytes, and dendritic cells. The CC subfamily contains the 
largest number of chemokines (Murphy, 2002). The only XC chemokine cloned to date, 
XCL1, has been reported to selectively attract CD8 + T lymphocytes. This chemokine has 
only two cysteines in its primary amino acid sequence (Kelner et al., 1994). Finally, 
CX3CLI also called fraktokine, the only member of the CX3C subfamily, has a unique 
primary amino acid sequence with three intervening amino acids between its first two 
cysteines (Pan et al., 1997). It is an unusual chemokine in that it is a larger protein, with a 
chemokine module positioned at the N-terminus, and contains a transmembrane domain 
and a cytoplasmic tail (Bazan et al., 1997).
1.3.2. Chemokine receptors
Chemokines exert their biological effects on target cells via binding to cell surface 
receptors. Chemokine receptors are classified into CXC, CC, XC and CX3C receptors
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according to the family of chemokines their ligands belong to (fig. 1.4). A remarkable 
feature of the chemokine receptor superfamily, however, is their promiscuity as far as 
ligand binding is concerned (fig 1.4), although binding to a receptor only occurs for 
chemokines from the same sub-group. For example, CCR5 binds to CCL3, CCL4, CCL5 
and CCL8  whereas CXCR3 binds to CXCL9, CXCL10 and CXCL11 (fig 1.4). To date, 
nineteen receptors have been identified among which six receptors bind CXC chemokines 
(CXCR1-CXCR6), eleven receptors bind CC chemokines (CCR1-CCR11), one receptor 
for CX3CLI (CX3CR1) and one receptor for XCL1 (XCR1). D6  and Duffy 
antigen/receptors for chemokines (DARC) are two other chemokine receptors which are 
able to bind promiscuously to both CC and CXC chemokines. These two chemokine 
receptors do not signal, and are thought to be decoy receptors having the role of 
maintaining chemokine gradients (Comerford and Nibbs, 2005).
Chemokine receptors are typically 340-370 amino acids in length with25-80% amino acids 
identical. All chemokine receptors identified to date are G protein-coupled seven 
transmembrane domain receptors (GPCR). A unique feature of these GPCRs is the 
presence of an amino acid sequence (DRYLAIV) in the second intracellular loop domain 
(Murphy, 1994). They all have an extracellular domain which includes the N-terminus and 
three extracellular loops which constitute the binding sites for the chemokine ligands. In 
addition, the N-terminus stalk plays a role in the selectivity and affinity of the ligand 
(Rajagopalan and Rajarathnam, 2004). The intracellular region is composed of three loops 
and the C-terminus domain. The C-terminus is the site where the G protein binds upon 
stimulation by chemokines, leading to G protein phosphorylation and binding of a 
molecule of guanine triphosphate to the a  subunit of the heterotrimeric protein. Indeed, the 
G protein, composed of three sub-units (the a, p and y sub-units), separates into the a  and 
the Py sub-unit, each of them activating other signalling proteins such as adenyl and
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guanylyl cyclases, phosphodiesterases, phospholipase A2 and phospholipase C, leading to 
an increase in second messengers, such as intracellular calcium, important for cytoskeletal 
changes during transmigration. Functional responses induced by most chemokines are 
blocked by Bordatella pertuxin toxin, indicating that intracellular signalling is mediated by 
the Gai sub-unit (Bokoch, 1995). The increase in second messengers and also activation of 
kinases such as phosphoinositide-3-kinase, can in turn, depending on the cell type, 
chemokine ligand and its receptor, activate other downstream proteins such as protein 
kinase A, protein kinase C, the p38 mitogen-activated protein (MAP) kinase, SAPK/JNK 
and p42/44 MAP (also known as erk) kinase pathways. In some cases, some transcription 
factors are activated, such as CREB, c-Jun and c-Fos (Bokoch, 1995; Marinissen and 
Gutkind, 2001).
1.3.3. Physiological functions of chemokines
Chemokines play an important role in orchestrating the immune response, as they activate 
the recruitment of specific subsets of leukocytes (Baggiolini, 1998; Thelen, 2001), 
especially during the step of firm adhesion to the endothelium, already described in section
1.2.3.2. The mechanism by which chemokines control leukocyte function will be further 
described in section 1.3.4.
In addition, chemokines play a role in the formation of blood vessels i.e. angiogenesis, 
especially members of the CXC chemokine family, whose CXCR family receptors are 
expressed by endothelial cells (Bemardini et al., 2003). Within this context, CXCL12 (the 
only CXCR4 ligand) expression has been shown to have a fundamental role during 
vascular development. CXCR4 or CXCL12 gene-deficient mice die prenatally and exhibit 
defects in the formation of gastrointestinal tract arteries, as well as defects in vessel 
development, hematopoiesis, cardiogenesis, and cerebellar development (Nagasawa et al., 
1996; Tachibana et al., 1998). Subsequently, a study on CXCR2 gene-deficient mice has
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shown that this receptor represents the common mediator for the angiogenic activity of 
several chemokines, including CXCL1, CXCL2, CXCL3, CXCL5, CXCL6  and CXCL7, 
and angiogenesis in response to these factors is impaired in the cornea of CXCR2 gene- 
deficient mice (Addison et al., 2000). Conversely, CXCL4, CXCL9, CXCL11, CXCL13 
and CXCL10 inhibit angiogenesis and as such are called angiostatic chemokines 
(Bemardini et al., 2003).
In addition to their role in leukocyte migration and angiogenesis, it has been suggested that 
chemokines are implicated in many autoimmune disorders due to their importance in 
controlling the immune system (Baggiolini, 2001). In addition to MS, other diseases where 
different chemokines have been reported to play an important role in their pathogenesis 
include arteriosclerosis, where CCL2 has been suggested to attract monocytes to the 
atherosclerotic plaque, rheumatoid arthritis, asthma (CCL3) and inflammatory bowel 
disease (Santamaria, 2003; Christopherson and Hromas, 2004).
Finally, certain chemokine receptors have been identified as co-receptors for viral entry 
into cells, in particular that of the human immunodeficiency virus (HIV). Chemokines, as 
natural ligands for these receptors have been shown to block HIV infection. (Cocchi et al.,
1995) showed that CCL3, CCL4 and CCL5 could inhibit infection of macrophages by HIV. 
These three chemokines are ligands for CCR5, which, together with CD4, is the major co­
receptor for HIV R5 subtypes (Deng et al., 1996).
1.3.4. Coordination of the immune system
Chemokines may be involved in homeostastic leukocyte trafficking into tissues, as is the 
case for CXCL12, and in this role they are expressed constitutively by many cell types in a 
tissue-specific manner. Other chemokines are termed inducible and have been shown to be 
expressed only in response to specific inflammatory stimuli. For example, IFN-y, produced
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by T helper cell type 1 (Thl) lymphocytes, triggers the production of CXCL9 and 
CXCL10 (both ligands of CXCR3) which will in turn attract more Thl lymphocytes. This 
is the case in MS lesions where an increase of CXCL10 is correlated with the occurrence 
of CXCR3 positive T cells (Balashov et al., 1999). Interleukin (IL)-4 and IL-13 are 
produced by activated Th2 lymphocytes. These two cytokines induce the production of 
chemokines such as CCL2, CCL11, CCL27, CCL17 and CCL22 which lead to a Th2 
lymphocyte pattern of recruitment (Syrbe et al., 1999).
The specific response of cells from the immune system in inflammation is mediated by the 
distinct expression of chemokine receptors by different subsets of leukocytes (Table 1.3). 
Furthermore, the level of expression of chemokine receptors is dependent on the activation 
state of the cell. Indeed, only activated effector lymphocytes respond to inflammatory 
chemokines, because naive cells do not express the corresponding receptors (Syrbe et al.,
1999).
Cell type Chemokine receptor
Memory T cells CXCR4, CXCR5, CXCR6 , CCR1, CCR2, CCR6 , CX3CR1,
XCR1
Thl T cells CCR1, CCR2, CCR3, CCR4, CCR5, CCR6 , CCR7, CCR10, 
CXCR3, CXCR4, CXCR5, CXCR6 , CX3CR1, XCR1
Th2 T cells CCR1, CCR2, CCR3, CCR4, CCR5, CCR6 , CCR7, CCR8 , 
CCR10, CXCR3, CXCR4, CXCR5, CXCR6 , CX3CRI,
XCR1
oc4[37+ T cells CCR9
CLA+ T cells CCR10
Eosinophils CCR1, CCR3
Basophils CCR1, CCR2, CCR3
Neutrophils CXCR1, CXCR2, CXCR4, CCR2, CX3CRI
Monocytes CXCR1, CXCR2, CCR1, CCR2, CCR5, CXCR4, CX3CRI
Dendritic cells CXCR4, CCR2, CCR5, CCR6 , CCR7, CCR9
Macrophages CXCR1, CXCR2, CXCR4, CCR5, CCR9
NK cells CXCR3, CCR2, CX3CRI
B cells CXCR3, CXCR5, CCR7
Mast cells CXCR1, CXCR2, CCR3
Table 1.4: Functional expression of chemokine receptors in different leukocyte populations. 
Adapted from Olson and Ley (2002)
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1.3.5. Cytokines, chemokines and chemokine receptors in multiple sclerosis
1.3.5.1. Implication o f cytokines in multiple sclerosis
MS is thought to be a Thl lymphocyte-mediated disease. CD4+ T-cells have been 
classified into three sub-types, Thl, Th2 and ThO cells, characterised by their ability to 
produce specific subsets of cytokines. Thl cells produce mainly TNF-a and IFN-y and the 
role of these cytokines has been extensively investigated.
IFN-y has not been shown to be up-regulated in CSF and serum of MS patients (Gallo et 
al., 1991), whereas the elevation of TNF-a is more controversial. A study showed no 
significant increase of TNF-a in the serum and CSF in PP-MS or RR-MS (Rovaris et al., 
1996; Kleine et al., 2003), while others have demonstrated periodic increases of TNF-a in 
CSF and serum of patients with RR-MS (Spuler et al., 1996). However, clinical trials with 
a recombinant TNF receptor p55 immunoglobulin fusion protein which is protective in 
EAE, showed an increased number of exacerbations occurring earlier in MS patients (The 
Lenercept Multiple Sclerosis Study Group and The University of British Columbia 
MS/MRI Analysis Group, 1999). In another study, a different TNF-a-based therapeutic 
regime induced the appearance of new lesions, as indicated by MRI studies when MS 
patients were treated with the monoclonal anti-TNF-a antibody cA2 (van Oosten et al.,
1996). Intravenous injections of recombinant IFN-y worsens MS symptoms (Panitch et al., 
1987a; Panitch et al., 1987b), whereas treatment with anti-IFN-y antibody in SP-MS results 
in significant improvement of symptoms (Skurkovich et al., 2001). However, although 
promising, the latter study by (Skurkovich et al., 2001) was carried out on a small group of 
individuals and within a short period of time, and not all patients responded to anti-IFN-y 
antibody treatment. Overall, the results from clinical MS studies are very different to those 
obtained from EAE studies (section 1.3.6.1).
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In addition to TNF-a and IFN-y, other cytokines may be implicated in MS pathogenesis. 
For example, transforming growth factor (TGF)-pl mRNA levels in peripheral blood 
mononuclear cells have been shown to correlate with MRI disease activity in MS 
(Bertolotto et al., 1999), and serum levels of TGF-pi are elevated in both RR- and SP-MS 
patients (Nicoletti et al., 1998). In active MS lesions, the three forms of TGF-P were 
detected mainly on foamy macrophages and hypertrophic astrocytes (De Groot et al., 
1999). TGF-p2 reduces demyelination, virus antigen expression, and macrophage 
recruitment in a viral model of multiple sclerosis (Drescher et al., 2000). Other cytokines, 
regarded as important in the regulation of T-cell mediated inflammation, such as IL-2 
(Gallo et al., 1991), IL-1 (Rovaris et al., 1996) or IL- 6  (Rovaris et al., 1996) have been 
shown to increase in serum or in CSF of MS patients.
1.3.5.2. Chemokine plasma and cerebrospinal fluid levels in multiple sclerosis 
Alterations in the concentration of chemokines in plasma may reflect the level of activity 
of the immune system during the development of MS. An increase in CXCL8  plasma 
levels during the relapse phase of RR-MS has been reported ( Saruhan-Direskeneli et al., 
2003; Lund et al., 2004; Bartosik-Psujek and Stelmasiak, 2005). However, whether the 
plasma levels of other chemokines such as CXCL10 and CCL2 increase in MS remains 
unclear, with some studies showing similar plasma levels in MS and control patients 
(Saruhan-Direskeneli et al., 2003; Bartosik-Psujek and Stelmasiak, 2005) whereas others 
showed an increase in plasma levels in MS patients (Scarpini et al., 2002).
A more reliable method that should more closely reflect changes in chemokine 
concentrations within the CNS parenchyma is to determine their levels in the CSF obtained 
by lumbar puncture. Another advantage of this method is that levels of different 
chemokines can be correlated with the presence of distinct populations of leukocytes 
within the CSF, which are usually absent in healthy individuals. The concentration of a
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number of chemokines has been shown to be altered in the CSF of MS patients. Among 
them, CSF CXCL10 levels have been shown to increase in MS patients (Mahad et al., 
2002; Scarpini et al., 2002) and this increase has been associated with relapses (Mahad et 
al., 2002). As MS is considered to be a Thl-driven autoimmune disorder, the increase of 
CXCL10 in the CSF (Mahad et al., 2002) correlates with the presence of CXCR3 + T 
lymphocytes in the CFS and with the appearance of lesions on the MRI scans (Sindem et 
al., 2002). In addition, other immune cells such as macrophages and B-cells have been 
detected in the CSF of MS patients (Cepok et al., 2001). Most interestingly the level of 
CCL2, known to attract macrophages, decreases in association with relapses (Sindem et al., 
2001; Mahad et al., 2002; Scarpini et al., 2002; Saruhan-Direskeneli et al., 2003; Bartosik- 
Psujek and Stelmasiak, 2005). Other candidate chemokines, whose elevated CSF levels 
may reflect infiltration of macrophages into the CNS are CCL3 and CCL5. Initially, CCL3 
was shown to moderately increase in the CSF of MS patients (Miyagishi et al., 1995), 
although levels were too low to be accurately determined and this effect was later disputed 
(Mahad et al., 2002). By contrast, increases in CCL5 CSF levels (Bartosik-Psujek et al., 
2004; Bartosik-Psujek and Stelmasiak, 2005) correlate with active Gadolinium-enhancing 
lesions on MRI revealing BBB breakdown (Sindem et al., 2001), as gadolinium does not 
cross the BBB under normal circumstances. Neutrophils are not reported to play an 
important role in MS, as they are not present in the leukocyte infiltrates in MS lesions. 
Nevertheless, CXCL8  which is known to be an important chemoattractant for neutrophils, 
is increased in the CSF of MS patients (Bartosik-Psujek et al., 2004; Bartosik-Psujek and 
Stelmasiak, 2005).
1.3.5.3.Chemokine and chemokine receptor expression in multiple sclerosis lesions 
Because of the poor availability of human tissue material, only a small number of studies 
have compared the expression of chemokines and chemokine receptors between MS 
lesions and NAWM. Interestingly, the changes in the expression of chemokines and
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chemokine receptors observed in MS lesions correlate well with the alterations in 
chemokine levels detected in the CSF, as described in section 1.5.5.2
CXCL10 is not detected in NAWM, but becomes strongly expressed in all MS lesion types, 
in particular in association with reactive astrocytes and T lymphocytes as determined by 
immunohistochemistry (Sorensen et al., 1999; Simpson et al., 2000b; Sorensen et al., 
2002). CXCL10 expression has also been detected in perivascular cuffs of infiltrating 
leukocytes (Sorensen et al., 2002) and in macrophages (Simpson et al., 2000b). Its only 
receptor, CXCR3, is expressed by CD3+ cells, corresponding to T lymphocytes, 
predominantly appearing in early lesions (Sorensen et al., 1999; Simpson et al., 2000b; 
Sorensen et al., 2002; Trebst et al., 2003) and by astrocytes (Simpson et al., 2000b). 
Simpson et al. (2000b) also demonstrated the expression of CXCL9, another ligand for 
CXCR3, with a similar pattern of expression to that observed for CXCL10.
Similarly to CXCL10, CCL2 has been shown to co-localise with astrocytes and 
macrophages in MS lesions (McManus et al., 1998; Simpson et al., 1998). CCL2 staining 
on these cells was more intense when the lesion was active and tended to decrease in 
parallel with the level of active demyelination. Within the active lesion, some staining was 
located on the blood vessels in the centre of the lesion, although the exact cellular origin of 
CCL2 could not be ascertained. According to the authors, perivascular CCL2 expression 
may be the result of CCL2 released by activated astrocytes which would then form a 
gradient resulting in chemotactic leukocyte migration (McManus et al., 1998; Simpson et 
al., 1998). CCR2 expression was detected on macrophages and astrocytes and in the 
perivascular cuff but not in NAWM (Simpson et al., 2000a).
Finally, CCL5 was detected exclusively in MS lesions associated with blood vessels, both 
in the perivascular cuff and on the endothelial cells while there was a diffuse staining of
55
endothelial cells in the control tissue (Simpson et al., 1998). Expression of the receptors 
for CCL5, CCR1 and CCR5, in MS lesions is also cell type-specific. CCR1 is only 
expressed on leukocytes, either lymphocytes or macrophages (Sorensen et al., 1999; Trebst 
et al., 2001; Trebst et al., 2003), while CCR5 is detected on the microglia within the lesion 
only (Sorensen et al., 1999).
1.3.6. Cytokines and chemokines and chemokine receptors in experimental 
autoimmune encephalomyelitis
EAE is not MS, but a model for neuroinflammation and delayed-type hypersensitivity. It 
has nevertheless permitted the study of the cascade of immunological and molecular 
mechanisms of neuroinflammation. In relapsing EAE models, T-cells are activated in the 
peripheral lymphoid tissue by injection of antigenic immunopeptides (Voskuhl, 1998). 
They traffic into the bloodstream, and once in the bloodstream they get into the CNS where 
they may or may not be restimulated. If they are stimulated, T-cells produce inflammatory 
cytokines, chemokines and IFN-y, which induce the accumulation of other mononuclear 
cells. This induces a new wave of CNS inflammation, and T cell accumulation results in 
clinical disease progression (Fife et al, 2001).
1.3.6.1 .Cytokines in experimental autoimmune encephalomyelitis
TNF-a appears to play an important role in the pathogenesis of EAE, the animal model for 
MS, although whether its action is beneficial or detrimental is still debated. In the mouse 
model of transfer EAE, where myelin basic protein-specific T cells are injected into naive 
mice, blocking antibodies directed towards lymphotoxin or towards TNF-a reduced the 
severity of the disease (Ruddle et al., 1990). In addition, treatment with soluble TNF-a 
receptor, in a relapsing-remitting model of EAE, using mice which were injected with 
encephalitogenic PLP peptide, also reduced clinical symptoms, and inhibited elevated CNS 
chemokine levels (Glabinski et al., 2004). By contrast, TNF-a knock-out mice showed a
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much more severe form of EAE than wild type mice, when they were immunized with 
myelin oligodendrocyte glycoprotein (Liu et al., 1998). This exacerbation of symptoms 
could be reversed by TNF-a administration. IFN-y is not crucial for the induction or the 
clinical course of EAE, as IFN-y knockout mice immunized with myelin basic protein, still 
developed the disease (Ferber et al., 1996). Furthermore IFN-y is thought to be important 
for the recovery phase of EAE, as intrathecal injection shortened the recovery phase in 
mice which were EAE induced by injection of myelin oligodendrocyte glycoprotein 
(Furlan et al., 2001).
1.3.6.2. Variations in chemokines in experimental autoimmune encephalomyelitis 
CCL2, CCL3, CCL4, CCL5, CXCL10 and other chemokines are rapidly expressed one or 
two days before onset of clinical symptoms in EAE (Godiska et al., 1995). As the disease 
progresses there is an increase in the expression of chemokines (Glabinski et al., 2003). 
Chemokine expression varies, with CCL3 expression, greater than CCL5 expession which 
is higher than CCL4. CCL2 does not become fully expressed until the relapsing phase of 
disease where its expression in CNS correlates with clinical disease score in EAE 
(Kennedy et a l , 1998). CNS infiltrated T-cells express CCL3, CCL4, CCL5, and CXCL10 
(Glabinski et al., 1997). Monocytes and macrophages that infiltrate the CNS from the 
periphery express CCL3, CCL5 and CCL2 (Miyagishi et al., 1997), whereas resident 
astrocytes express CXCL10, CCL2, CCL5 and CXCL10 in the lesions (Glabinski et al., 
1997; Miyagishi et al., 1997; Glabinski et al., 1999; Nygardas et al., 2000). Anti-CCL3 
antibody inhibits acute EAE development (Kennedy et al., 1998). However the usage of 
knockout mice reveals the complex regulation of chemokines in EAE, as CCL3 knockout 
mice developed equally severe symptoms as normal mice (Tran et al., 2000a). Absence of 
CCL2 in mice leads to decreased local macrophage recruitment and antigen-specific Thl 
immune response in EAE (Izikson et al., 2000; Huang et al., 2001). Results concerning the 
blocking of CXCL10 or CCL3 in EAE gave contradicting results. Administration of
plasmid DNA encoding self CXCL10, leading to production of self-specific antibodies, 
could suppress EAE (Wildbaum et al., 2002). Others demonstrated that neutralization of 
CXCL10 exacerbates EAE (Narumi et al., 2002) or showed that CXCL10 deficient mice 
had a greater number of CNS lesions and a lower threshold for induction of the disease 
(Klein et al., 2004).
1.4 Aims
The general aim of the present work was to investigate the effects of specific chemokines 
on BBB function in terms of both immunological responses (expression of adhesion 
molecules and leukocyte adhesion) and permeability. The specific objectives were:
1) To develop and characterise a method to isolate primary HBEC that are suitable as an in 
vitro human BBB model.
2) To develop an immortalised HBEC line in collaboration with Cochin Institute in Paris, 
to facilitate the investigation of chemokine actions at the BBB.
3) To characterise the basal and cytokine-induced expression of chemokines and 
chemokine receptors by HBEC both in vitro and in situ.
4) To investigate the functional consequences at the in vitro human BBB of specific 
chemokines for which elevated levels of receptors were found to be expressed by HBEC.
58
2. Chapter 2: Chemokine expression by primary human brain
endothelial cells in vitro
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2.1 Introduction
Whether it is activated circulating leukocytes or a local inflammatory reaction that triggers 
the subsequent leukocyte infiltration is still a much debated subject, but a direct correlation 
between chemokine production and demyelination in the CNS of MS patients has been 
established. Chemokines have been suggested to be produced by resident cells such as 
astrocytes and microglia in response to the up-regulation of cytokines in the brain 
parenchyma (Croitoru-Lamoury et al., 2003; Kremlev et al., 2004). MS is mainly 
associated with infiltration of activated Thl T-lymphocytes which express CXCR3 and 
CCR5 receptors (Balashov et al., 1999). The Thl T-lymphocyte subset of T cells is a 
source of IFN-y andIL-2 whereas activated Th2 lymphocytes release IL-4 and IL-10. In 
addition, an increase in IFN-y and TNF-a has been shown to precede relapses in MS 
patients, whereas in chronic stages of the disease, both cytokines are present (Beck et al., 
1988). IFN-y induces the production of CXCL9, CXCL10 and CXCL11, and could further 
lead to the recruitment of activated CXCR3+ lymphocytes. By contrast, TGF-p appears to 
have a suppressive role in MS. Elevated TGF-P levels have been found in the CSF of MS 
patients during remissions (Carrieri et al., 1997) and in the stable phase of MS (Carrieri et 
a l , 1998).
HBEC are the first cells to be in contact with leukocytes when they enter the brain. 
Chemokines bound to the proteoglycans of the luminal surface of endothelial cells are 
presented to circulating leukocytes and trigger their firm adhesion to the endothelium by 
activation of the corresponding chemokine receptor expressed on the surface of the 
leukocytes. CNS resident cells are able to produce chemokines following cytokine 
stimulation and this has been demonstrated both in vivo and in vitro for astrocytes ( Oh et 
al., 1999; Croitoru-Lamoury et al., 2003; Carpentier et al., 2005), and microglia (Lee et al.,
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2002; Kremlev et al., 2004). The release of chemokines by these cells, transported across 
the endothelial cells before being presented at its luminal surface, create a chemical 
gradient guiding leukocyte entry into the CNS (Brown, 2001; Biemacki et al., 2004). 
Another potential source of chemokines is the HBEC constituting the brain microvessels. 
Although a number of studies have shown that HBEC are able to produce chemokines in 
response to a wide range of stimuli (see table 2.1), whether particular cytokines important 
in MS and/or combinations of them act synergistically to induce the expression of several 
chemokines by HBEC remains to be established.
Reference Endothelium 
Cell type
Chemokines Stimulation
(Zidovetzki et al., 
1999)
HBEC CXCL8 (mRNA) Endothelin-1
(Vadeboncoeur et al., 
2003)
HUVEC
HBEC
CXCL8
CCL2
Streptococcus suis
(Lee et al., 2003b) HBEC CXCL8 VEGF
(Omari et al., 2004) HBEC CCL2
CCL5
CD40/CD40L
interactions
(Salmaggi et al., 
2002)
HBEC
HUVEC
CXCL10
(Weiss et a l, 1998) HUVEC
HBEC
CCL2 TNF-a, IFN-y, IL1-P
(Frigerio et a l, 1998) HBEC
HUVEC
CCL2 T N F-a, IFN-y
(Chen et a l, 2001) HBEC CCL2 Endothelin-1, TNF-a, 
ILl-p
(Biemacki et a l, 
2004)
HBEC CXCL8
CXCL10
CCL2
Supernatant of activated 
Thl
(Hofman et a l, 1999) HBEC CXCL8 TNF-a, TGF-P, 
Tat
(Shukaliak and 
Dorovini-Zis, 2000)
HBEC
HUVEC
CCL5 IFN-y, TNF-a, IL-lp, 
LPS
Table 2.1: Chemokine production by HBEC and HUVEC under different stimuli.
61
In this study, the release of chemokines (CCL2, CCL5, CXCL8, and CXCL10) into the 
supernatants of HBEC monolayers in vitro was investigated at the constitutive level, but 
also when stimulated individually by IFN-y, TNF-a and TGF-p, and in combination since 
they have been described as playing a crucial role in the pathogenesis of MS. The 
intracellular distribution of these chemokines and possible location within the storage 
vesicles of HBEC was investigated in vitro.
In order to work on HBEC in vitro, a method to purify HBEC had first to be established. 
The method first used to grow endothelial cells from isolated rat brain capillaries was 
initially developed by Hughes and Lantos (1986) and later adapted by Abbott et al. (1992). 
This method had the advantage that it allowed a good yield of brain endothelial cells. 
However, the presence of other cell types restricted the use of brain endothelial cells in 
vitro to passage 0 or even passage 1. Other methods used to isolate endothelial cells have 
been developed to increase the purity of the endothelial cultures by taking advantage of 
endothelial specific markers. These include the selective binding of the lectin Ulex 
europaeus I  to the surface of endothelial cells (Jackson et al., 1990), or more commonly 
anti-PEC AM-1 (Demeule et al., 2001), both used in combination with magnetic beads for 
isolation of endothelium. Other endothelial-specific isolation methods have employed the 
use of flow cyometric cell sorting (Craig et al., 1998). Both magnetic beads and the FACS 
are cumbersome, require specific equipment, are rather expensive, and result in low yield 
of endothelial cells. Furthermore, its application to isolation of HBEC from human brain 
has the additional disadvantage of further damaging already fragile cells exposed to the 
stressful conditions of the post-mortem environment such as hypoxia and low pH. Since 
the methods described above commonly result in either a low yield of cells or low purity of 
culture, a method recently published by Perriere et al. (2005) designed to generate high 
purity cultures of rat brain endothelium derived from fresh tissue samples was adapted for
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isolation of HBEC from post-mortem tissue. This method relies on the expression of P-gp 
by HBEC (Demeule et al., 2001) and the use of puromycin, which is a substrate of the P- 
gp efflux transporter, toxic to cultured cells. This method was here adapted for use on 
HBEC.
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2.2 Material and methods
2.2.1. Culture medium
For HBEC the endothelial medium was composed of an endothelial basal medium (EBM-2, 
Cambrex, Berkshire, UK) with supplements of: 5 % foetal bovine serum, hydrocortisone, 
VEGF, epidermal growth factor (EGF), insulin-like growth factor I (IGF-1), human 
fibroblastic Growth Factor (FGF), ascorbic acid and Gentamicin Sulfate and 
Amphotericin-B (the concentrations of the supplements included by the supplier were not 
made available). The medium was optimised by cambrex in order to induce endothelial cell 
proliferation.
For astrocytes the culture medium was composed of 45% MEM (minimum essential 
medium)-alpha, 45% F-10, 10% FCS, 1% human serum (for astrocyte proliferation) and 
50U/ml penicillin, 50pg/ml streptomycin, and 50pg/ml fungizone to prevent 
contaminations (Invitrogen, Renfrewshire, UK). The culture medium was made up under 
sterile conditions and stored at 4°C.
For the differentiation medium, ACM was obtained by adding 45% MEM-alpha, 45% F-10, 
50U/ml penicillin, 50pg/ml streptomycin, and 50pg/ml fungizone to confluent astrocytes 
for 24 h. 150mM of 8-(4-chlorophenylthio)adenosine 3’5’cyclic monophosphate sodium 
salt (cAMP) and 17.5pM of RO 20-1724 also named 4-(3-Butoxy-4- 
methoxybenzyl)imidazolidin-2-l was added to ACM and the differentiation medium was 
frozen at -80 °C (I. Romero, personnal communication).
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2.2.2. Preparation of growth surface
HBEC were grown on 25cm2 plastic flasks (Greiner, Gloucestershire, UK) which has been 
previously coated with collagen type 1 from calf skin at the initial concentration of 1 mg/ml 
(Sigma-Aldrich, Dorset, UK). The collagen was diluted by a factor of 1/20 into 5ml of 
Hank's balanced salts solution (HBSS) and left for 1 hour (h) on the surface of the flask. 
The flask was then rinsed with three successive washes of normal HBSS.
The same procedure was followed for the astrocytes but using poly-L-lysine (Sigma- 
Aldridge, Dorset, UK) to coat the plastic flask. Astrocytes were generally grown in 75cm2 
or 175cm2 flasks (Greiner, Gloucestershire, UK). The poly-L-lysine at 0.01% was diluted 
by a factor of 1/100 in HBSS, and left on the flask for 15 minute (min) to 1 h. Excess of 
poly-L-lysine was removed by washing 3 times with HBSS.
2.2.3. Isolation of primary HBEC
Solution A: HBSS containing lOmM HEPES, 50U/ml penicillin, 50pg/ml streptomycin, 
2.5pg/ml fungizone (Invitrogen, Renfrewshire, UK) and 0.4 % bovine serum albumin 
(BSA) (Sigma-Aldrich, Dorset, UK)
Collagenase/disnase solution: 1 mg/ml collagenase/dispase (Roche Diagnostics Ltd, East 
Sussex, UK) containing 10pg/ml DNase I (Roche Diagnostics Ltd, East Sussex, UK) and 
0.147pg/ml A-p-tosyl- L-lysine chloromethyl ketone (Sigma-Aldrich, Dorset, UK)
Primary HBEC were isolated according to the method initially developed by Hughes and 
Lantos (1986), with some changes. Human brain tissue was obtained post-mortem from 
MS patients (table 2.2) fom the MS Tissue Bank, London, UK or from cerebral cortical 
tissue obtained during lobectomies conducted to relieve medically intractable seizures 
carried out at Kings College Hospital, London. The investigation conformed to the
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principles outline in the declaration of Helsinki and following the Open University 
guidelines of the Ethics Committee. Details of patients were kept confidential and the brain 
tissue was in these cases processed 24h after the operation. Human brain tissue was cleared 
of meninges and cut into small pieces with a scalpel blade. Tissue fragments were then 
transferred into 10ml solution A and centrifuged for 5 min at 300g (ALC PK121R from 
Labcare). The pellet was resuspended in 15ml of the collagenase/dispase solution and 
incubated for 1 h at 37 °C. After digestion, microvessels were isolated by density- 
dependent centrifugation on 25% BSA. The myelin floating layer was removed, by gently 
turning the tube at an angle to detach it from the tube, and placed in 25 ml of HBSS. Cells 
within the myelin layer were isolated by centrifuging the myelin for 5 min at 300g. Single 
cells in the myelin consisted mainly of astrocytes and were grown on poly-L-lysine, 75cm2 
coated flasks in 10 ml astrocyte culture medium. The pellet containing microvessel 
fragments underwent a further 2 h enzymatic digestion with 5ml collagenase/dispase 
solution to separate HBEC from other cells associated with capillaries. A percoll gradient 
(50% percoll in HBSS centrifuged for 1 h at 25,000g) was then used to separate 
microvessel fragments from erythrocytes and single cells surrounding vessels. The 
microvessel suspension was placed on 7ml of percoll gradient and centrifuged for 10 min 
at lOOOg. The resulting middle fraction, containing the HBEC, was harvested using a 
Pasteur pipette and after a final centrifugation in 10ml of solution A at lOOg for 5 min, was 
plated on collagen-coated (1/20) 25 cm2 flasks in 5ml EGM-2. They were placed in an 
incubator at a constant temperature of 37°C with an atmosphere of 5%C(>2 and 95% water 
saturated air. For most cultures, the growth medium after 48 h was changed and 0.5p.g/ml 
of puromycin was added to the medium for 5 days with one medium change in between. 
The purity of the culture at passage 2 was confirmed by staining for vWF as an endothelial 
cell marker.
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In order to assess the effect of puromycin on HBEC on morphology and cell purity, 
different concentrations of puromycin were added to cells grown in 24 well plates coated 
with collagen in normal medium. The cells survived and grew in a puromycin 
concentration range of between 0.1pg/ml to 1 jig/ml as well as in control wells in the 
absence of puromycin. The medium was changed every 2-3 days. After 7 days of treatment, 
the cells were passaged on glass coverslip coated with collagen. The cells were left to grow 
without puromycin for 7 further days.
Post-mortem 
tissue from MS 
patient
Time post­
mortem (h)
Age
(years) Gender Cause o f  death
Patient 1 12 92 Male "Old age"
Patient 2 24 70 Female
Aspiration pneumonia, 
sepsis, multiple sclerosis
Patient 3 36 59 Female
Respiratory failure, cardiac 
arrest
Patient 4 36 53 Male
Septicaemia, multiple 
sclerosis
Patient 5 36 59 Female Pneumonia
Patient 6 24 50 Female Multiple sclerosis
Patient 7 24 34 Female Pneumonia
Patient 8 36 44 Female Multiple sclerosis
Patient 9 36 71 Female
bronchopneumonia, multiple 
sclerosis
Patient 10 24 82 Female
Small bowel obstruction, 
Multiple sclerosis
Patient 11 36 63 Male
Metastatic carcinoma of 
prostate, Multiple sclerosis
Table 2.2: MS Donor details.
2.2.4. Maintenance of brain cell cultures
HBEC were passaged onto collagen coated flasks and grown in EGM-2 medium at 37°C 
(Cambrex, Berkshire, UK) until they reached confluence. The medium was changed every 
2-3 days. Confluent cell monolayers were detached from the extracellular matrix by 
washing with HBSS without Ca2+ and Mg2+ for 1 min and incubated with 0.25% w/v 
porcine trypsin- ethylene diamine tetraacetic acid (EDTA) (Invitrogen, Renfrewshire, UK).
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Once the cells were detached, the remaining active trypsin was neutralized by diluting in 
culture medium and the cells were divided 1/3 into another collagen coated flask. The cells 
were passaged as long as they represented a high percentage of HBEC, based on 
morphological appearance. In the present study, cells at passage 2 were routinely used
To evaluate whether there were any preferential side for chemokines release by HBEC, 
cells at passage 2 were seeded on an insert in a Boyden chamber (0.4 pm diameter pore 
used, this size allow the passage of the chemokines in the bottom chamber) (fig 2.1) at a 
concentration of 105 cells/ insert (surface area of 1 cm2). 0.5ml of normal medium was 
added in the upper part of the chamber and 1.5 ml was added to the outer well of the 12 
well plate.
The same procedure was followed to detach astrocytes and to passage the cells. Astrocytes 
in culture could be used until passage 8, but were in general used at passage between 2 and 
passage 5. The purity of the astrocyte culture was confirmed by fluorescence-activated cell 
sorter (FACS) using GFAP (dilution used at 1/100, DakoCytomation Ltd, Cambridgeshire, 
UK) as a marker (data not shown). The protocol used is as described in section 4.2.7.
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Upper (inner) chamber
O X  o Y  o Y  o Y  o Y  o
Bottom (outer) chamber 0.4 pm pore-size tissue
culture insert
Fig 2.1: Illustration of a Boyden chamber.
2.2.5. Capture ELISA
Wash buffer: 0.05% Tween-20 in phosphate buffered saline (PBS)
Elisa Diluent: 0.1% BSA (sigma-Aldrich, Dorset, UK), 0.05% Tween-20 in tris buffered 
saline, pH 7.3
TMB solution: 0.1 mg/ml of tetramethylbenzidine (TMB) (Sigma-Aldrich, Dorset, UK) 
0.03% hydrogen peroxide and 0.0375M citric acid (BDH Chemicals, Dorset, UK) in 0.1 M 
citrate acetate buffer (Sigma-Aldrich, Dorset, UK)
Phosphate Buffered Saline (PBS): 13mM sodium phosphate dibasic, 2mM potassium 
phosphate dibasic, 3mM potassium chloride, 134mM Sodium chloride, pH 7.4.
HBEC (passage 2) were cultured on collagen coated 24 well plates until confluence and
treated for 48 h with 2 pi cytokines at the following final concentrations: TGF-p at
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25ng/ml, TNF-a at 25ng/ml and INF-y at lOOng/ml (R&D Systems, Oxfordshire, UK) in 
lml medium. The concentrations of cytokines selected for this experiment were of the 
same order as those used for other experiments in Hillyer et al. (2003). Culture 
supernatants were then collected and frozen at -20°C until further analysis. For chemokine 
determination in culture medium, capture antibodies (R&D systems, Oxfordshire, UK, 
table 2.3) were diluted in the appropriate concentration (reported in table 2.3) in lOOjal 
PBS and left overnight to allow binding to the surface of 96 well ELISA plates (Nunc 
Maxisorb, scientific laboratory supplies, Nottingham, UK). The plates were washed three 
times with 200pl of wash buffer. Non-specific binding sites were blocked using 1% BSA 
and 5% sucrose for 1 h at room temperature (RT). To ensure chemokine detection was 
within the assay limits, culture supernatants were first diluted at 1/50 (to determine basal 
level) to 1/100 (for the supernatant from stimulated cells) in Elisa Diluent and 100 pi of the 
diluted supernatant was added to each well and incubated for 2 h at RT in duplicate, as 
were the standards, ranging from 0 to 8000pg/ml. After three washes in the wash buffer, a 
biotinylated goat anti-human chemokine detection antibody (R&D systems, table 2.3) was 
added for 2 h in ELISA Diluent. Following three washes in the wash buffer, signal 
amplification was achieved by incubation with lOOpl streptavidin-horseradish peroxidase 
(Amersham Biosciences, Buckinghamshire, UK) diluted at 1:500 in Elisa Diluent solution 
for 1 h. After the final 3 washes, the perodixase reaction was visualised by incubation with 
lOOpl of TMB solution containing substrate of the peroxidase. The reaction was stopped 
with 10% sulphuric acid (BDH Chemicals, Dorset, UK). The optical density of the plate 
was read on a spectrophotometer (Lab systems Mulitskan, Meadow rose Ltd, UK) at a 
wavelength of 450 nm.
The concentration of chemokines in the solution was determined by plotting the
absorbance value against the values given by the standards. The standard curve, when the
concentrations were transformed to logarithmic numbers, gave a sigmoid type of curve (fig
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2.2). The central part of the curve was linear, and the dilutions of the supernatant samples 
were carefully assessed and verified to be located within the linear part of the curve for 
each experiment.
Chemokine Monoclonal capture antibody 
concentration (pg/ml)
Standard 
range (ng/ml)
Polyclonal detection 
antibody concentration 
(ng/ml)
CCL2 1 0.03-8 50
CCL5 4 0.03-8 5
CXCL8 4 0.03-8 20
CXCL10 2 0.03-8 100
Table 2.3: Optimal concentrations of antibodies for capture and detection of chemokines in 
culture supernatants by capture ELISA, and concentration of stantards.
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Fig 2.2: Example of Standard curve
Graphs display typical standard curve for absorbance of CXCL8 at different concentration 
(from 0 to 3600 pg/ml) made up using recombinant CXCL8.
2.2.6. Immunocytochemistry
2.2.6.1 .Immunofluorescence
HBEC were grown on collagen coated Labtek chambered slides (Nunc, Scientific 
laboratory supplies, Nottingham, UK). Cells were fixed with 4% para-formaldehyde (PAF) 
dissolved in PBS on ice for 10 min, and permeabilised for 5 min with 0.1% Triton X-100
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in PBS. For those experiments concerning the effect of puromycin on HBEC culture purity
and vWF staining, cells were fixed with methanol at -20°C for 10 min.
Antigen specificity Host species Concentration Company
Primary
Antibody
vWF Rabbit IgG 1/200 Sigma-Aldrich
Primary
Antibody
PEC AM-1 Mouse 1/50 Serotec
Primary
Antibody
JAM-1 Mouse 1/400 provided by Dr E. 
Dei ana
TRITC-
Phalloidin
conjugated
Actin 1/2000 Sigma-Aldrich
Primary
Antibody
Beta-catenin Mouse IgGl 2pg/ml Santa Cruz 
Biotechnology
Primary
Antibody
Gamma-catenin Mouse IgGl 5pg/ml Transduction
Laboratories
Primary
Antibody
Alpha-catenin Rabbit 1/50 Sigma-Aldrich
Primary
Antibody
Ve-cadherin Goat IgG lOpg/ml Santa Cruz 
Biotechnology
Primary
Antibody
ZO-1 Rabbit 2.5pg/ml Zymed
Primary
Antibody
Occludin Mouse IgGl-
K
lOpg/ml Zymed
Primary
Antibody
Claudin-1 Rabbit lOpg/ml Zymed
Primary
Antibody
Claudin-3 Rabbit lOpg/ml Zymed
Primary
Antibody
Claudin-5 Mouse lOpg/ml Zymed
Primary
Antibody
CXCL10 Rabbit 0.4pg/ml Peprotech
Primary
Antibody
Biotinylated-CXCL 10 Goat lpg/ml R&D
Primary
Antibody
CXCL10 Mouse 5pg/ml R&D
Primary
Antibody
CXCL8 Rabbit lpg/ml Peprotech
Primary
Antibody
CCL2 Mouse lOpg/ml Peprotech
Primary
Antibody
CCL5 Rabbit 0.4pg/ml Peprotech
Secondary
antibody
Rabbit-IgG Goat lOpg/ml Chemicon
Secondary
antibody
mouse-IgG Goat 1 Opg/ml Chemicon
Secondary
antibody
Peroxidase conjugated 
Rabbit-IgG
Swine 1/100 Dako Corporation
Secondary
antibody
Peroxidase conjugated 
mouse-IgG
Rabbit 1/100 Dako Corporation
Table 2.4: List of antibodies used in immunocytochemical analysis. The final 
concentration of the antibody used is given or else the dilution factor is reported for those 
antibodies where no original concentration was available.
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The cells were then blocked in 10% normal goat serum diluted in PBS for 1 h. The primary 
antibodies (see table 2.4) were applied for 1 h at RT. After 3 washes with PBS, the 
corresponding fluorescence-conjugated secondary antibody (table 2.4) was added to the 
cells and incubated for 1 h. A drop of solution containing DAPI (DakoCytomation Ltd, 
Cambridgeshire, UK) was added for 5 mins at RT. After 3 final washes, the slides were 
mounted with a glass coverslip with Dako Fluorescent Mounting Medium 
(DakoCytomation Ltd, Cambridgeshire, UK) and viewed with a fluorescence microscope 
(Olympus BX61).
22 .62 .Intracellular staining for chemokines
Cells were grown on Labtek Chambered slides (Nunc, UK) coated with collagen for one 
week. They were then fixed using 4% PAF for 10 min on ice. In order to block endogenous 
peroxidase as well as to permeabilised the cells, absolute methanol was applied for 2 min 
with 3.5% hydrogen peroxide. After having intensively washed the cells with PBS, a 
blocking bluffer was applied for 1 h (10% rabbit serum or 10% swine serum in PBS for the 
secondary rabbit anti-mouse or the Swine anti-rabbit antibody, respectively). The primary 
antibodies were left overnight on the cells at RT. For negative control, mouse IgG or rabbit 
IgG (10 pg/ml, DakoCytomation Ltd, Cambridgeshire, UK) were used instead of primary 
antibodies. The secondary biotinylated antibody (Dako Corporation, Cambridgeshire, UK), 
rabbit anti-mouse or swine anti-rabbit relative to the species of which the primary antibody 
originated (table 2.4) was used at the dilution of 1/100 and incubated for 1 h. To enhance 
the signal, a further incubation was performed with the VECTASTAIN Elite ABC Kit 
(Vector Laboratories, Peterborough, UK) which contains avidin-biotin complex to which 
the peroxidase associates. After 40 min, the presence of peroxidase was revealed with the 
VIP dye (Vector Laboratories, Peterborough, UK) which is a dye reacting with the 
peroxidase and enables visualization of the immunoreaction product, indicating the
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presence of the chemokines in a pink-purple colour. The VIP agent was applied for 3 min, 
and the reaction was stopped with 2 rinses of distilled water. The slides were then mounted 
with DPX after dehydratation through a series of ascending concentrates of alcohol for 2 
min in each. The staining was viewed with a light microscope (Nikon microphot-FX), and 
the images were acquired using the software Image Pro-plus Image Analysis.
2.2.7. Statistical analysis
Significance was determined by a one way or two way ANOVA, followed by a post hoc 
Tukeys /-test. P<0.05 was considered significant. For the results concerning CXCL8 
production by HBEC, the data were not normally distributed and a Kruskal-Wallis and 
Mann-Whitney test was used.
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2.3 Results
2.3.1. Morphology
Primary HBEC growing out of isolated capillary fragments mainly consisted of elongated 
fusiform-shaped cells (fig 2.3). These cells represented the majority cell type present in the 
culture for the first 10 days. After that time, and depending on the quality of the 
preparation, other cells with different morphology started to grow at a faster rate. 
Contaminating cells based on their fibroblast-like morphological appearance were mainly 
astrocytes although other cell types such as pericytes could not be excluded.
2.3.2. Effect of puromycin treatment on the purity of HBEC cultures
The antibiotic puromycin is a substrate of P-gp, an efflux transporter strongly expressed by 
brain endothelium of the BBB. Therefore it has been proposed recently as a selective agent 
to improve the purity of the rat brain endothelial cell culture (Perriere et al., 2005), as these 
cells should be more resistant to the cytotoxic actions of puromycin than the non-P-gp 
expressing contaminating cells. The effect of different concentrations of puromycin on the 
proliferation of both human astrocytes, which is a possible source of contaminating cells in 
the HBEC culture, and on HBEC was here investigated as well as the purity of the HBEC 
culture (Greenwood, 1992).
Using a pure endothelial batch, the effect of puromycin on HBEC was investigated. The 
growth rate of HBEC incubated in puromycin was unaffected at a concentration of 
0.5pg/ml and lower during the first seven days while the cells grown in lpg/ml did not 
proliferate (fig 2.3). After 16 days, the cells at O.lpg/ml also showed signs of slower 
division rate compared to the control, while the cells grown in 0.5pg/ml were starting to 
detach (fig 2.3).
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From a batch of cells containing contaminant cells in the HBEC culture, the use of 
puromycin to obtain a pure endothelial cells culture was investigated. In 0.5j_ig/ml of 
puromycin, treatment of the culture did not prevent the growth of other contaminant cells 
(fig 2.4) while based on their morphological appearance, 0.5pg/ml and above prevented the 
growth of cells other other HBEC (fig 2.4). The type of contaminant cell was not 
determined.
The cytotoxic effects of 0.75 and lpg/ml of puromycin on cultured astrocytes were 
confirmed on a culture of astrocytes only. Cells grown in 0.1pg/ml proliferate similarly to 
the control cells, whereas the astrocytes grown in 0.5pg/ml and above died after seven 
days (fig 2.5).
These observations were confirmed by staining the cells for vWF (fig 2.6) and DAPI to 
help identify the endothelial cells. In cultures grown in 0.1 and 0.2pg/ml, as many cells had 
grown as in the control culture, but only few were HBEC as shown by vWF staining (fig
2.6). The HBEC appeared to grow in colonies in those cultures. On the contrary, cells that 
grew in concentrations of 0.5pg/ml and above were composed mainly of vWF positive 
cells, with little difference between the three different concentrations used (fig 2.6). In 
conclusion, 0.5pg/ml of puromycin treatment for seven days appeared to be the most 
appropriate to obtain a pure HBEC culture without affecting the growth rate of the cells.
2.3.3. Phenotype of primary HBEC: morphology and expression of endothelial 
markers
The expression of junctional molecules and specific HBEC markers was determined by 
immunocytochemistry. HBEC were largely positive for vWF. However there were some 
differences in staining pattern between different cells within the same culture, as vWF in
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some cells were detected in rod-shape vesicles, corresponding to Weibel-Palade bodies, 
whereas in other cells, the staining was more diffuse throughout the cell cytoplasm (fig
2.7).
Figure 2.8 shows the expression of vWF, and actin organisation as well as junctional 
PEC AM-1 and JAM-1 which are thought to be important for the transmigration of 
leucocytes (Muller et ah, 1993; Johnson-Leger et al., 2002). PECAM-1 and JAM-1 were 
found at the point of cell-cell contact, with a light staining within the cytoplasm around the 
nucleus (fig 2.8). Actin organisation is important for maintaining the tight junction 
structure, as tight junction proteins such as ZO-1 are connected to actin filaments and 
dynamic regulation of perijunctional actin may function as a controlling factor in 
regulating paracellular permeability (Char-Huei et a l, 2005). Actin distribution at the edge 
of the cells is regarded as a sign of low permeability and high electrical resistance, whereas 
appearance of stress fibers is associated with increase of permeability in cultured brain 
endothelium (Lu et al., 2004). In HBEC, actin was located mostly at the junctions of the 
cells although the presence of stress fibres could also be observed unequally distributed 
among different cells. In some cells, many stress fibres were present within the cytoplasm, 
whereas in others, actin was restricted to the junction (fig 2.8).
Figure 2.9 shows the expression by the HBEC of VE-cadherin, a-, y- and p-catenin. The 
three members of the catenin family, a - ,  y- and P-catenin as well as VE-cadherin, all 
constituent proteins of adherens junctions, are all highly expressed by cultured HBEC (fig 
2.9). All four were mainly detected in a linear distribution at the junction between cells. 
There was also a slight positive staining for p -  and y-catenin within the cytoplasm (fig 2.9). 
Every cell expressed a-, P-, y-catenin and VE-cadherin, although some differences were 
observed in the intensity of the staining. Mostly, it appeared that there were colonies of
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cells within the monolayer with higher intensity labelling for the adherens junction proteins, 
as is illustrated with the staining of a-catenin (fig 2.9).
Figure 2.10 shows the distribution of the tight junctional proteins, claudin-3, claudin-5, 
occluding and ZO-1, which are expressed by HBEC but not by endothelial cells of other 
vascular beds. A faint expression of claudin-3, claudin-5 and occludin at the junctional 
areas was observed, some diffuse expression was detected within the cytoplasm. The 
expression of claudin-5 and occludin was mostly patchy, with areas of closely apposed 
cells showing strong staining at the cell-cell junctions. All 3 junctional proteins showed a 
punctuate expression along the cell edges, indicative of immature tight junctions. By 
contrast, claudin-1 was only detected in the cytoplasm as previously reported for HBEC 
(Ishizaki et al., 2003). ZO-1 was expressed by all cells in the monolayer, and the staining 
appeared continuous at the junction. The figures show staining of cells at passage 2. 
Nevertheless, there was no or little variation between passages 1 and 2 for the expression 
of any junctional protein by HBEC in culture (not shown).
2.3.4. Basal and cytokine-induced chemokine release by HBEC
2.3.4.1. Constitutive release o f  CCL2, CCL5 and CXCL10
The level of chemokines constitutively produced by HBEC was measured by harvesting 
culture supernatants from confluent HBEC after 48 h (fig 2.11). No significant difference 
in the release of chemokines was reported between the HBEC that originate from the MS 
donors and from the epileptic donors. They were hence treated as one group. CCL2 was 
produced at basal level (llng/m l ± 3.8ng/ml) whereas CXCL10 and CCL5 were absent in 
the supernatant of unstimulated HBEC, suggesting that there is no release of these two 
chemokines at basal levels in vitro.
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23.4.2.Constitutive release o f CXCL8 by HBEC
CXCL8 released at constitutive level was found to be highly variable among different 
donors ranging from low (3ng/ml) to elevated constitutive release (207ng/ml) (fig 2.11). 
Out of the eight donors, the cells from two of the donors were above 100ng/ml/48h and 
cells from three different donors release around lOng/ml in the supernatant within 48 h. 
The cells from the three other donors were in between (45, 56 and 96ng/ml). Details from 
the MS patients concerning the gender, age and cause of death were available (table 2.5) 
and no correlations between those factors and the release of CXCL8 at basal level could be 
detected. Similarly, there was also a variation in the production of CXCL8 in response to 
TNFa (table 2.5). Also the sample number was too small to draw any conclusions. Details 
from the three epileptic donors were not available, but since the HBEC from the three 
epileptic donors were from the same brain region (the temporal lobe), this indicated that 
the differences could be donor dependent. Indeed, the cells from the epileptic patients also 
display a range of constitutive levels for CXCL8 (45, 56, 142ng/ml).
Basal (ng/ml)
TNF-a (ng/ml) 
(fold increase)
Age
(years) Gender Cause o f  death
Patient 1 96 262 (±2.7) 92 Male "Old age"
Patient 2 207 364 (xl.8) 70 Female
Aspiration 
pneumonia, sepsis, 
multiple sclerosis
Patient 3 3 83 (x25.7) 59 Female
Respiratory failure, 
cardiac arrest
Patient 4 9 411 (x44.4) 53 Male
Septicaemia due to 
UTI, multiple 
sclerosis
Patient 5 17 357 (x20.7) 59 Female Pneumonia
Table 2.5: MS Donor details: cells used in CXCL8 assays.
23 .4 3 .Constitutive release o f CXCL8 and CCL2 by HBEC grown on filters
Chemokines are presented to circulating lymphocytes on the endothelial surface and, after 
rolling, trigger firm adhesion. When endothelial cell cultures are polarized, a greater 
release of chemokines should be observed on the apical side than on the basal side. HBEC
79
were grown on filters to investigate whether there was any preferential side for chemokine 
release. The experiment was conducted with HBEC from two different donors. For both 
CCL2 and CXCL8, a preferential release of the chemokines on the apical side could be 
observed (fig 2.12). For CCL2, 66% of the total was released on the apical side (22±0.55ng 
in the upper chamber, and 12±6.8ng in the lower chamber, n=2 different donors). Similarly, 
three times more CXCL8 was found in the upper chamber at basal level compared to the 
lower chamber of the culture system (31±10.4ng in the upper chamber and 9±6.8ng in the 
lower chamber, n=2). These results suggest that HBEC are polarised on filter, but also that 
there is a low permeability of the HBEC monolayer to small molecular weight proteins 
such as chemokines (table 2.6), hence that tight junctions were formed. There could also be 
an active transport of the chemokines from the basolateral side to the luminal side which 
has already been proposed for CCL2 (Andjelkovic and Pachter, 2000).
Chemokines Molecular weight (kDa)
CXCL8 8.9
CXCL10 8.5
CCL2 8.6
CCL5 7.8
Table 2.6: Molecular weight of CXCL8, CXCL10, CCL2 and CCL5. 
23 A A.Effect oflFN-yon chemokine production by HBEC
When used alone, 100 ng/ml of IFN-y strongly induced the release of CXCL10 by HBEC 
(from Ong/ml to 99±16.5ng/ml, P=0.02, n=8 different donors). By contrast, IFN-y tended 
to reduce the mean secretion for CXCL8 compared to basal levels although this was not 
significant. IFN-y had no significant effect on the basal level of CCL2 secretion 
(10±2.7ng/ml), and induced a small but non-significant increase in CCL5 secretion 
(2±0.8ng/ml) (fig 2.11).
When used in combination with TNF-a, IFN-y-induced release of CXCL10 in the 
supernatant was greater than with IFN-y alone (200±50.9ng/ml versus 99±16.5ng/ml,
P=0.02, n=8 different donors). IFN-y alone failed to induce any significant changes in the 
production of CCL5, but when added in combination with TNF-a CCL5 production was 
greatly increased compared to TNF-a alone (43±2.8ng/ml versus 5±3ng/ml, respectively, 
P=0.0001, n=5 different donors). IFN-y had an inhibitory effect on the production of 
CXCL8 induced by TNF-a, leading to a significant reduction (72±27.2ng/ml versus 
162±31.1 ng/ml, P=0.046, n=8 different donors) whereas no significant difference was 
observed between control and IFN-y-treated HBEC. Finally, IFN-y had no effect on CCL2 
production by HBEC when added to TNF-a (fig 2.11)
23 A.5.Effect o f TNF-a on chemokine production by HBEC
TNF-a (25ng/ml) increased significantly the production of CCL2 and CXCL8 (34±8ng/ml 
versus 12±3.8ng/ml, P=0.04, n=6 different donors; 308±60.5ng/ml versus 72±27.2ng/ml, 
P=0.029, n=8 different donors, respectively) and there was a small but non-significant 
increase in CCL5 production (5±3ng/ml versus Ong/ml). TNF-a alone had no significant 
effect on CXCL10 production, but displayed a synergistic effect when added with IFN-y 
(200±50.9ng/ml versus 99±16.5ng/ml, P=0.023, n=8 different donors) (fig 2.11).
23 A.6.Effect ofTGF-fi on chemokine production by HBEC
TGF-p (25ng/ml) had no effect on the production of any the chemokines tested when used 
at the concentration of 25ng/ml. When used in combination with other cytokines, the only 
significant effects on HBEC observed were an inhibitory effect on the TNF-a-induced 
stimulation of CXCL8 production (134±23.6ng/ml versus 308±60.5ng/ml, P=0.04, n=8) 
and an increase in CCL5 production when used in combination with TNF-a (5±3ng/ml 
versus 22±4.7ng/ml, P=0.00014, n=5) (fig 2.11).
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23  A.I.Effect o f differentiation medium on chemokine production by HBEC 
Increased intracellular cAMP levels and culture medium conditioned by astrocytes has 
been shown to induce a differentiated phenotype in cultured brain endothelium, including 
those of human origin (Rubin et al., 1991). When the cells were grown in differentiation 
medium, CXCL10 release induced by TNF-a and IFN-y was decreased compared to basal 
level (48±0.9ng/ml versus 127±0.6ng/ml, n=T), whereas CXCL8 was increased 
(67±10.9ng/ml versus 29±3ng/ml, n=l). The significance of these results could not be 
assessed as the experiment was only conducted in duplicate on cells coming from one 
donor (fig 2.13)
2.3.5. Intracellular expression and compartmentalisation of chemokines in HBEC
For CCL2 and CCL5, only a faint cytoplasmic staining could be detected in unstimulated 
cells, suggesting the absence of intracellular stores of these chemokines at basal level. 
Stimulation of HBEC with cytokines did not change the pattern of the staining in any of 
the three donors tested (fig 2.14).
CXCL10 labelling in endothelial cells in vitro was conducted with three different 
antibodies from different animal recipients (fig 2.15). A mouse anti-human CXCL10, a 
rabbit anti-human CXCL10 and a goat anti-human CXCL10 were used. The pattern of 
staining in unstimulated cells differed between the three antibodies. The goat anti-human 
CXCL10 antibody did not label unstimulated HBEC whereas the mouse anti-human 
CXCL10 labelled faintly the cytoplasm of HBEC. When the rabbit anti-human CXCL10 
was used, a clear labelling within small vesicles and part of the cytoplasm was observed 
within unstimulated HBEC. When HBEC were stimulated with IFN-y and TNF-a, strong 
positive staining within vesicular structures was observed with all CXCL10 antibodies (fig 
2.15). These vesicles were mainly located around the nucleus, in agreement with a positive
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staining of the Golgi apparatus. A stronger and more diffuse cytoplasm staining was also 
observed with the mouse anti-human CXCL10 antibodies.
Intracellular staining for CXCL8 in HBEC in vitro exhibited a different pattern for each of 
the three donors although one antibody was used (fig 2.16). In unstimulated HBEC, only 
cells from one donor stained positive for CXCL8. In this case, there were some small 
vesicles located around the nucleus positive for CXCL8. Stimulation with IFN-y and TNF- 
a  induced the intracellular expression of CXCL8 in cells from two out of the three donors. 
In one case the cytoplasm was diffusely stained, as well as some vesicles resembling the 
vWF positive Weibel-Palade bodies. In the other case small vesicles around the nucleus 
were stained (fig 2.16).
23.5.1.Effect o f differentiation medium on CXCL10 intracellular expression in HBEC 
In one experiment HEBC grown in differentiation medium for a week, and left 
unstimulated or further stimulated with TNF-a and IFN-y for 48 h, were stained for 
CXCL10. As shown in figure 2.17 differentiation medium decreased the staining of 
CXCL10 in unstimulated cells, but most importantly decreased the number of vesicles 
induced by IFN-y and TNF-a. It should be noted that there was no effect of differentiation 
medium on the change of morphology induced by the cytokine treatment (fig 2.17).
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Fig 2.3: Phase contrast micrographs of cultured HBEC incubated in different 
concentrations of puromycin.
HBEC were seeded on collagen-coated 24 well plates and were treated for one week with 
different concentrations of puromycin (O.lpg/ml, 0.5pg/ml, Ipg/ml) or were left to grow 
in normal medium. Phase contrast images were taken after two days (left column), after 
nine days (middle column) and after sixteen days (right column). Data shown were 
obtained from one experiment, with duplicate wells per treatment. Scale bar = 100pm.
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Fig 2.4: Phase contrast micrographs of cultured HBEC incubated in different 
concentrations of puromycin.
HBEC were seeded on collagen-coated 24 well plates and were treated for one week with 
different concentration of puromycin (O.lpg/ml, 0.5pg/ml, lpg/ml) or were left to grow 
in normal medium. Phase contrast images were taken with a light microscope after 2 days 
(left column), and after 7 days (right column). Results are representative o f four different 
experiments with a single well per treatment. Scale bar = 100 pm.
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Fig 2.5: Phase contrast micrographs of cultured astrocytes incubated in different 
concentrations of puromycin.
Cells were seeded on collagen-coated 24 well plates and were treated for one week with 
different concentrations of puromycin (O.lpg/ml, 0.5pg/ml, lpg/ml) or were left to grow 
in normal medium. Phase contrast images were taken with a light microscope after two 
days (left column) and after seven days (right column). Results are representative of four 
different experiments with a single well per treatment. Scale bar = 100 pm.
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Fig 2.6: Immunocytochemical detection of vWF and the cell nucleus using DAPI 
staining of cells derived from primary HBEC isolation grown in different 
concentrations of puromycin.
HBEC were seeded on collagen-coated 24 wells plate and were treated for one week with 
different concentrations of puromycin (0.1 pm/ml, 0.2pg/ml, 0.5pg/ml, 0.75pg/ml, 
lpg/ml) or were left to grow in normal medium. The cells were then fixed and 
permeabilised with Triton X-100 and processed for detection o f vWF by 
immunocytochemistry and for detection of the nucleus using DAPI staining. Data shown 
were obtained from one experiment, with duplicate wells per treatment. Scale 
bar= 100 pm.
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Fig 2.7: Immunocytochemical detection of vWF on cultured primary HBEC.
HBEC were grown on collagen-coated labtek chamber slides, fixed, permeabilised with 
Triton X-100, and then processed for detection of vWF. In some cells vWF is located in 
Weibel-Palade body like structures (arrows), whereas in some other cells the staining 
appears diffuse within the cytoplasm (star). The bottom images show, cells with different 
pattern of vWF vesicles within the same culture. Data shown were obtained from one 
experiment. Scale bar=50pm.
JAM-1 Actin
PEC AM-1
Fig 2.8: Immunocytochemical detection of JAM-1, actin, PECAM-1 and vWF 
on primary HBEC.
HBEC were grown on collagen-coated Labtek chamber slides, fixed and 
permeabilised with Triton X-100 then processed for detection of JAM-1, actin, 
PECAM-1 and vWF by immunocytochemistry. Results are representative of three 
different experiments for PECAM-1, actin and vWF and show one single experiment 
for JAM-1 with a single well per treatment. Scale bar=100 pm.
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p-catenin y-catenin
a-catenin VE-cadherin
Fig 2.9: Immunocytochemical detection of p, y, a-catenin and VE-cadherin on 
primary HBEC.
HBEC were grown on collagen-coated Labtek chamber slides, fixed and 
permeabilised with Triton X-100 then processed for detection of p, y, a-catenin and 
VE-cadherin by immunocytochemistry. Results are representative of three different 
experiments for p-catenin and show one single experiment for y, a-catenin and VE- 
cadherin with a single well per treatment. Scale bar=100 pm.
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Claudin-1 Claudin-5
Claudin-3 Occludin
Fig 2.10: Immunocytochemical detection of claudin-1, -3, -5, occludin and ZO-1 in 
primary HBEC.
HBEC were grown on collagen-coated Labtek chamber slides, fixed, permeabilised with 
Triton X-100 then processed for detection of claudin-1, -3, -5, occludin and ZO-1 by 
immunocytochemistry. Results are representative of three different experiments with a 
single well per treatment. Scale bar=50 pm.
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Fig 2.11: Chemokine release into culture medium by HBEC following stimulation by 
cytokines for 48 h.
Supernatants from confluent monolayers of HBEC seeded at same density were collected 
after 48 h stimulation with TNF-a (50ng/ml), IFN-y (lOOng/ml) and TGF-p (25ng/ml) or 
a combination of them and assayed by sandwich ELISA for different chemokines. Results 
presented are means ± S.E.M. of eight different experiments for CXCL8  and CXCL10, 
six for CCL2 and five for CCL5 (one well per treatment). Significant differences were 
determined by ANOVA followed by a post hoc t-test for CCL2, CCL5 and CXCL10 and 
by a Kruskal-Wallis and Mann-Whitney test for CXCL8 . * significant difference (P 
<0.05) versus the control; A significant difference (P<0.05) of sample treated with a 
combination of cytokines versus TNF-a treated sample; • significant difference (EO .05) 
of sample treated with a combination of cytokines versus IFN-y treated sample.
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Fig 2.12: Total CXCL8 and CCL2 release into the apical and baso-lateral culture 
medium by HBEC grown on filters after 3 h and 48 h.
Supernatants from confluent monolayers of HBEC grown on filters were collected after 3 
h and 48 h from the apical (white column) and the baso-lateral sides (striped column) and 
assayed by sandwich ELISA for chemokine production. Results presented are means from 
two different experiments with two replicate filters each.
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Fig 2.13: CXCL8 and CXCL10 release by HBEC following stimulation by TNF-a 
and IFN-y for 48 h in nomal medium or in differentiation medium (DF).
Supernatant from confluent monolayers of HBEC were collected after 48 h stimulation 
with TNF-a (50ng/ml) and IFN-y (lOOng/ml) and assayed by sandwich ELISA for 
CXCL8  and CXCL10 production. Results presented are means of duplicate wells from 
one experiment per treatment.
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Fig 2.14: Immunocytochemical detection of CCL2 and CCL5 in HBEC.
HBEC were grown on collagen-coated Labtek chamber slides, fixed, permeabilised with 
Triton X-100, and then processed for detection of CCL2 and CCL5 by 
immunocytochemistry in unstimulated cells (left column) or TNF-a (50ng/ml) and IFN-y 
(lOOng/ml) stimulated cells (right column). Cells labelled with either mouse IgG (Ms 
IgG) or Rabbit IgG (Rb IgG) as negative controls. Results are representative o f three 
different experiments with a single well per treatment. Scale bar = 50pm.
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Fig 2.15: Immunocytochemical detection of CXCL10 in HBEC.
HBEC were grown on collagen-coated Labtek chamber slides , fixed and permeabilised 
with Triton X-100 and then processed for detection of CXCL10 by 
immunocytochemistry using three different antibodies, a mouse anti-human CXCL10, 
and rabbit anti-human CXCL10 and a goat anti-human CXCL10 in unstimulated cells 
(left column) or TNF-a (50ng/ml) and IFN-y (lOOng/ml) stimulated cells (right column). 
Results are representative of three different experiments with a single well per treatment. 
Scale bar = 50pm.
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Fig 2.16: Immunocytochemical detection of CXCL8 in HBEC originating from 
three different donors.
HBEC from three different donors were grown on collagen-coated Labtek chamber 
slides, fixed, permeabilised with Triton X-100 and then processed for detection of 
CXCL8 by immunocytochemistry in unstimulated cells (left column) or TNF-a 
(50ng/ml) and IFN-y (lOOng/ml) stimulated cells (right column). Results show one 
experiment with a single well per treatment. Scale bar=50 pm.
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Fig 2.17: Immunocytochemical detection of CXCL10 in HBEC after stimulation 
with cytokines of cells grown in normal and differentiation medium (DF).
HBEC were grown on collagen-coated Labtek chamber slides, fixed, permeabilised with 
Triton X-100 and then processed for detection of CXCL10 by immunocytochemistry in 
unstimulated cells or TNF-a (50ng/ml) and IFN-y (lOOng/ml) stimulated cells grown in 
normal or differentiation medium. Results show one experiment with one well per 
treatment. Scale bar=50pm.
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2.4 Discussion
Many studies have underlined the importance of a variety of chemokines in MS. In this 
study the contribution that HBEC may make to the overall production of chemokines was 
investigated. The aim was to test the hypothesis that endothelial cells are not only a 
physical barrier that protects the brain from blood-borne substances and/or cells, but also 
that they may play an active role in brain inflammation and in particular, in directing 
leukocyte diapedesis. This was tested by investigating the production of a number of 
chemokines by cultured HBEC both constitutively and following stimulation by cytokines 
known to be up-regulated in MS brains. Here, we have shown that human brain capillary 
endothelial cells are able to produce some of the chemokines which are up-regulated in MS 
brains and/or CSF such as CXCL10, CCL2, CXCL8 and CCL5.
2.4.1. Isolation and purification of primary HBEC.
Isolation and long term culture of brain endothelial cells has often proved a difficult task, 
as the endothelial cells of microvessels are in close contact with fibroblasts, astrocytes, 
smooth muscle cells and pericytes within the vascular unit (Greenwood, 1992). 
Contaminating cells usually overgrow the endothelial cells as they have better proliferative 
capacities under culture conditions. A method recently published by Perriere et al. (2005), 
based on P-gp expression by HBEC (Demeule et al., 2001) and the use of puromycin, one 
of its substrates, was designed to generate high purity cultures of rat brain endothelium 
derived from fresh tissue samples was adapted for isolation of HBEC from post-mortem 
tissue. This method relies and the use of puromycin, which is a substrate of the P-gp efflux 
transporter and is toxic to cultured cells.
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P-gp is an efflux pump belonging to the ATP-binding cassette family of transporters with 
wide specificity for high molecular weight lipophilic substances. Tumour cells have been 
shown to express high levels of this transporter and it has been suggested that its 
overexpression confers resistance of tumour cells to therapeutic levels of cytotoxic drugs 
(Hendrikse et al., 1999). Under physiological conditions, HBEC express high levels of P- 
gp (Jette et al., 1993) and in culture, brain endothelial cells retain the capacity to exclude 
drugs such as the antibiotic puromycin attaining low intracellular levels whereas the 
concentration of puromycin in the cytoplasm of non-P-gp expressing cells is sufficient to 
block the de novo production of proteins and induce cell death. Puromycin causes the 
degradation of polyribosomes and triggers the release of nascent peptides from ribosomes 
(Cundliffe et al., 1974).
Perriere et al. (2005) used puromycin at a concentration of 3 jag/ml for three days from the 
time when the isolated rat brain capillaries are seeded on a collagen matrix. In our system, 
this concentration proved to be extremely cytotoxic for HBEC, and fewer capillaries would 
adhere to the collagen extracellular matrix. The higher sentitivity of HBEC to puromycin 
compared to rat brain endothelial cells is further reinforced by the fact that in their study, 
Perriere et al. (2005) showed that rat brain endothelial cells were treated for 5 weeks with 
0.5pg/ml without any apparent cytotoxic effects. However, the same concentration of 
puromycin induced signs of degradation and apoptosis in HBEC after only 2 weeks. Why 
HBEC are more sensitive to puromycin than rat brain endothelial cells remains to be 
established. It is possible that human brain endothelium expresses lower amounts of P-gp 
(or other unidentified efflux pumps for which puromycin may be a substrate) than rat brain 
endothelium in vivo rendering human cells more sensitive to the cytotoxic actions of drugs. 
Indeed, it has been shown that there are interspecies differences in P-gp activities in 
several marine and freshwater invertebrates which account for the sensitivity of particular 
species to pollution (Smital et al., 2000). It is possible that rat brain endothelial cells
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express P-gp, or an unidentified efflux pump, for which puromycin may be a substrate, at 
higher level than HBEC. Alternatively, HCBE may be more sensitive to culture conditions 
and lose their barrier phenotype more rapidly than rat brain endothelial cells. Nevertheless, 
short treatments with 0.5pg/ml puromycin did not induce any apparent signs of distress in 
HBEC. Hence, when the cells were treated with the lower concentration of 0.5pg/ml and 
for a period of 5 days after the 2 initial days when the cells were allowed to adhere to the 
collagen, the yield of endothelial cells was improved and purity maintained. These 
conditions proved to be the most efficient and the least toxic, based on the cell morphology 
and vWF staining and amount of cells present under these conditions. Astrocytes also 
express P-gp in vitro (Pardridge et al., 1997). Indeed, this could explain why the astrocytes 
did not die immediately following puromycin treatment. The expression of P-gp in vivo by 
astrocytes is more controversial. It has been suggested that expression of P-gp by 
astrocytes is an artefact due to the culture conditions, as no P-gp could be detected by 
immunohistochemistery on brain tissue of normal humain brain (Tatsuta et al., 1992). 
Others have showed that P-gp is weakly expressed by astrocytes in vivo and is up-redulated 
in drug refractory human epileptic tissue (Marchi et al., 2004).
2.4.2. Expression of endothelial junctional proteins by primary HBEC
Primary HBEC displayed many characteristic features of brain endothelium in vivo. These 
include the expression of not only the adherens junction molecules but also the presence of 
a number of tight junction protein types which are specific to brain endothelial cells such 
as claudin-5 (Craig et al., 1998). Some of the junction proteins studied were not uniformly 
expressed in the culture. In some patches of cells, the protein expression was either 
strongly expressed or more linearly distributed whereas in other patches, as with occludin 
and claudin-5, the cells were negative for these proteins at the junctions. This may be 
explained by a difference in the confluence state. The same phenomenon has already been 
reported previously for a BBB associated enzyme, gamma-glutamyl transpeptidase enzyme.
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When a rat brain endothelial cell line was grown in the presence of bovine FGF and on 
collagen, the confluent culture was reported to develop sprouts that extended above the 
monolayer and expressed this enzyme (Roux et al., 1994). The patches of cells that express 
strongly the tight junction proteins were similar in that they were slightly above the other 
cells monolayer.
2.4.3. Constitutive production of chemokines by primary HBEC
Chemokines, known for their chemotactic activities, are mostly functional at 
concentrations between 2 and 200ng/ml. In vitro, the concentration-dependent response of 
leukocytes to chemokines usually follows a “bell shape” curve, that is, a maximal effect is 
achieved at a certain chemokine concentration (Bryan et al., 2002).
Some chemokines are known to be expressed constitutively by certain cell types, whereas 
others are released only upon stimulation with cytokines. Out of the chemokines tested, 
only CCL2 and CXCL8 were found to expressed by HBEC constitutively at concentrations 
above 2ng/ml (CCL2 ~ lOng/ml and CXCL8 ~ 70ng/ml). Our results on CXCL8 and 
CCL2 are similar to those previously described by others showing CXCL8 and CCL2 to be 
secreted into the supernatant of HBEC (Hofman et al., 1999; Biemacki et al., 2004).
Constitutive expression of CCL2 and CXCL8 by cultured HBEC might not reflect 
physiological conditions in vivo. In healthy humans, the concentration of CXCL8 and 
CCL2 in plasma is approximately 20pg/ml and 300pg/ml respectively (Bartosik-Psujek and 
Stelmasiak, 2005), much lower than that found in our cultures. Although it is possible that 
plasma proteases keep circulating levels of chemokines low and that the local 
concentrations within the brain capillaries may be high, it is likely that some factors 
present in the growth medium are stimulatory for CCL2 and CXCL8. HBEC in culture 
express CCL2 abundantly, whereas no CCL2 transcript was present in freshly isolated
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capillaries, or whole brain homogenate (Zach et al., 1997). Furthermore, there is no 
detectable CCL2 expression in the normal rat brain, but CCL2 expression can be induced 
rapidly, within 3 h following ischemia, where there is a predominant staining of CCL2 on 
blood vessels (Chen et al., 2001). It is possible, therefore, that endothelial cells of 
capillaries in post-mortem tissue that have been exposed to ischemia over-express 
chemokines such as CCL2. Alternatively, species differences may determine whether 
endothelial cells express certain chemokines. By contrast with rat brain, CCL2 appears to 
be localised to the endothelial cells in normal human brain sections (Sanders et al., 1998) 
and this may account for the basal expression found in the endothelial cell culture in this 
study. Similarly, CXCL8 expression is also up-regulated by the presence of growth factors 
such as VEGF (Lee et al., 2003b). However, by contrast with CCL2, there is no detectable 
CXCL8 in normal human brain, although CXCL8 has been detected on HBEC of inflamed 
brains such as in HIV encephalitis (Sanders et al., 1998). The culture medium used in this 
study for maintaining endothelial cell cultures contains several growth factors (EGF, FGF, 
VEGF, IGF-1) which may account for the basal in vitro expression not only of CCL2 but 
also CXCL8 which contrasts with the in vivo lack of CXCL8 expression.
2.4.4. Effect of cytokine stimulation on chemokine expression by HBEC.
Following cytokine stimulation, the up-regulation of CCL2 secretion by HBEC, and of 
other chemokines by endothelial cells of peripheral vascular beds, has been well 
documented (Weiss et al., 1998; Frigerio et a l , 1998; Beck et al., 1999; Hofman et al., 
1999; Crane et al., 2000; Chen et al., 2001; Sundstrom et al., 2001; Hillyer et al., 2003). 
However, the regulation of CXCL8, CXCL10 and CCL5 by cytokines in HBEC is less 
clear. In this study, we attempted to make a systematic investigation of the effects of three 
cytokines, TGF-P, TNF-a and IFN-y, alone or in combination, on the expression of these 
four chemokines (CCL2, CCL5, CXCL8 and CXCL10). No cinetique or dose/response 
studies were made due to material restriction, but it would have been of interest.
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2.4.4.1.CCL2
Previous studies have shown that TNF-a and IFN-y induce HBEC to secrete CCL2 
(Frigerio et al., 1998 ; Weiss et al., 1998; Chen et al., 2001). According to Frigerio et al. 
(1998), an up-regulation of CCL2 mRNA induced by TNF-a and INF-y in HBEC only 
occurs in cells originally from MS donor tissue. By contrast, HBEC from non-MS patients 
showed an up-regulation of CCL2 mRNA only following treatment with IFN-y but not 
with TNF-a. In our HBEC culture system, an up-regulation of CCL2 protein to similar 
levels in the supernatant was observed in response to TNF-a in both HBEC from MS and 
non-MS patients (temporal lobe epileptic individuals). Altogether, this data would suggest 
that at least TNF-a may regulate CCL2 production by a post-transcriptional mechanism. In 
addition, CCL2 up-regulation was observed following TNF-a treatment but not IFN-y 
which is in contrast to the observations reported by Weiss et al. (1998) and Chen et al. 
(2001) where both cytokines induced an effect. Furthermore, no synergistic effect of IFN-y 
on the action of TFN-a was observed in the present study. These different results may be 
due to differences in the initial concentration of IFN-y used to stimulate the cells and not to 
individual donor variation as cells from all 6 donors tested responded in a similar manner 
in our study. It would be difficult, however, to relate the concentrations of IFN-y between 
different studies since the concentration of IFN-y previously reported was given in U/ml, 
whereas in this study the solutions were in ng/ml. In another study on endothelial cells 
from other vascular beds, Hillyer et al. (2003) used the same concentration of cytokines 
and observed a marked variability in the response to IFN-y among the different endothelia. 
IFN-y failed to up-regulated CCL2 in HUVEC and liver endothelial cells whereas it 
stimulated CCL2 production in saphenous vein endothelial cells (SVEC), bone marrow 
endothelial cells (BMEC), lung microvascular endothelial cells (LMEC) and dermal 
microvascular endothelial cells (DMEC). A lack of increase of CCL2 by IFN-y was also 
reported in HUVEC and LMEC by Beck et al. (1999), who used concentrations of IFN-y
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as high as 250ng/ml. There was no synergistic effect of IFN-y on the action of TNF-a 
when both cytokines were added together. Hence HBEC appear to respond in a similar 
manner as HUVEC. Retinal microvascular endothelial cells resemble HBEC in that they 
form a tight continuous monolayer with restricted permeability, the so-called blood-retinal 
barrier. Similarly to HBEC, Crane et al. (2000) reported no effect of INF-y on CCL2 
production, although in their case a concentration 5 times lower than in our study was used.
Using immunocytochemical techniques, intracellular CCL2 could not be detected upon 
cytokine stimulation in HBEC (Harkness et al., 2003). In HUVEC cells, CCL2 appears to 
be distributed in small vesicles throughout the cells when stimulated with a combination of 
IFN-y and TNF-a (Oynebraten et al., 2004).
2.4.4.2.CCL5
TNF-a induced CCL5 production by HBEC, whereas IFN-y had no effect. When the two 
chemokines were added together, they displayed an important synergistic effect on CCL5 
production. By contrast, an increase in CCL5 expression by HBEC induced by IFN-y has 
been reported previously (Shukaliak and Dorovini-Zis, 2000). The possibility that IFN-y 
added to the culture medium may be inactive due to either degradation of the recombinant 
protein in the medium or to loss of receptor expression in cultured cells is highly unlikely 
since IFN-y alone induced the expression of other chemokines such as CXCL10. Thus, it is 
possible that other factors such as those mentioned above for CCL2 are responsible for the 
differences in the effect of IFN-y observed by these studies. More surprisingly, the anti­
inflammatory cytokine TGF-p also exerted a synergistic effect together with TNF-a on 
CCL5 production by HBEC. CCL5 staining was not detected when the cells were 
stimulated with cytokines, suggesting that the chemokine is not stored nor re-intemalised 
after 48 h stimulation.
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2AA3.CXCL10
CXCL10 expression is strongly induced by IFN-y in many cell types and this was also the 
case in HBEC. By contrast, TNF-a did not induce a significant increase in CXCL10 
expression. In addition, as demonstrated for CCL5, there was a synergistic effect when 
both TNF-a and IFN-y were combined, where the production of CXCL10 was maximal. 
Endothelial cells from non-CNS vascular beds secrete CXCL10 in response to TNF-a, 
when stimulated under the same conditions and using the same concentration and detection 
methods (Hillyer et al., 2003). These results are also in agreement with those of Salmaggi 
et al. (2002) who have shown that TNF-a at a concentration of 200U/ml was able to 
induce CXCL10 production by HUVEC, but not by HBEC. This effect was further 
increased when IFN-y and TNF-a were combined. This suggests a unique response pattern 
of the HBEC for TNF-a. The intracellular distribution of CXL10 in HBEC was somewhat 
different from other chemokines, in particular when the cells were stimulated with 
cytokines. In the latter case, CXCL10 appeared to be localised mainly within perinuclear 
vesicles. This could be due to either internalisation of CXCL10 produced by the cells and 
degradation by the proteasome system or the presence of de novo protein in the Golgi 
apparatus. Hillyer and Male (2005) have demonstrated that when human recombinant 
CXCL10 was added to HUVEC there was a rapid internalisation of the chemokine and this 
may be the case for CXCL10 secreted by HBEC. However, the pattern of staining looks 
different (Hillyer and Male, 2005) and indicates that the CXCL10 in the present study 
represents an intracellular stock.
2AAA.CXCL8
In HBEC, CXCL8 was up-regulated by TNF-a alone whereas IFN-y tended to decrease the
basal secretion of CXCL8. This effect was more pronounced when IFN-y was applied in
combination with TNF-a, since a significant decrease on the TNF-a effect on CXCL8
expression was observed. The inhibitory effect of IFN-y on the action of TNF-a has been
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previously reported in other cell types including endothelial cells. In fact, this effect 
appears to be cell type specific. In some cell types such as monocytes IFN-y is reported to 
suppress the effect of TNF-a (Schnyder-Candrian et al., 1995), whereas in other cell types 
such as a human gastric cell line, MKN 45, IFN-y enhances TNF-a CXCL8 production 
(Yasumoto et al., 1992). The decrease in CXCL8 by IFN-y in endothelial cells was found 
to be not only at the protein level, but also at the mRNA level (Nyhlen et al., 2004). The 
mechanism which underlines this process remains unclear but it most certainly occurs by 
interference of TNF-a signal transduction pathways that drive CXCL8 expression by IFN- 
y. As reviewed by Hoffmann et al. (2002), CXCL-8 expression is regulated both at the 
transcriptional and post-transcriptional levels. To induce maximal secretion of CXCL8 
there must be an inhibition of nuclear respiratory factor (NRF), a transcription factor that 
acts as a repressor of CXCL8. In addition, both Nuclear Factor Kappa B (NF-kB) and 
activator protein-1 (AP-1) need to be activated for efficient transcription of CXCL8 
whereas the mRNA becomes stabilised through activation of the p38 MAP kinase pathway. 
TNF-a activates NF-kB and AP-1 through a protein kinase C dependant pathway (Kim 
and Rikihisa, 2002). The activation of those two transcription factors by TNF-a is 
inhibited in the presence of IFN-y in endothelial cells, suggesting that NF-kB and AP-1 are 
targets for IFN-y to counterbalance the TNF-a effect (Borgmann et al., 2002). Overall, the 
suppression of CXCL8 production by IFN-y may be considered as a protective effect 
against neutrophil infiltration, since CXCL8 is the major chemoattractant for these cells. 
IFN-y is specific to a Thl mediated response, whereas in general there is poor neutrophil 
infiltration in MS brains. Furthermore, in EAE models such as BALB/c and C57BL/6, 
which are strains of mice that are resistant to EAE when immunised with myelin basic 
protein, the knock-out mice for either IFN-y or its receptor rapidly develop a progressive 
lethal disease, where there is a major infiltration of neutrophils throughout the brain (Tran 
et al., 2000b).
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TGF-p decreased the effect of TNF-a on CXCL8 production, also it represented only a 
partial inhibition. This may be due to the low concentration used of 25ng/ml. There is 
evidence that TGF-p may not exert its inhibitory effects in the presence of high levels of 
pro-inflammatory cytokines (Condos et al., 1998).
2 A A.5.Variation in CXCL8 expression among HBEC cultures from different donors 
By contrast with the other chemokines, there was a high variability in the secretion of 
CXCL8 by HBEC from different donors both at the basal level and in cytokine-stimulated 
cells. This variability in CXCL8 expression by HBEC has been observed by others in 
response to the HIV-1 protein tat (Hofman et al., 1999), and in other endothelial cells types 
in response to cytokines (Hillyer et al., 2003). These differences are not only in the amount 
of chemokine released in the supernatant, but also in the level of CXCL8 localised within 
the cells in vitro. In one case, CXCL8 was located in rod-like shaped vesicles probably 
corresponding to Weibel-Palade bodies, whereas for one other donor CXCL8 was diffuse 
within the cytoplasm. CXCL8 has been identified in Weibel-Palade bodies in HUVEC 
(Utgaard et al., 1998). The method of HBEC isolation is supposed to isolate primarily the 
microvascularfraction of cerebral blood vessels, which are devoided of Weibel-Palade 
bodies (Dorovini-Zis and Huynh, 1992), only present in larger vessels such as arteries or 
venules. However, in some cultures, vWF was located in Weibel-Palade bodies of 
endothelial cells, whereas in others it was located diffusely in the cytoplasm. This suggests 
the presence of HBEC of both microvascular and macrovascular origin in primary cultures. 
Indeed, it has been suggested that pure microvascular cultures are hard to obtain (Pachter 
and Song, 2005), and that when placed in culture, HBEC from larger microvessel 
fragments grow at a faster rate than HBEC from smaller vessels (Spatz et al., 1997). In 
addition, the type of blood vessel where HBEC originate may influence their phenotype. 
While in capillary and postcapillary venules, continuous tight junctions are present, arteries
have endothelial tight junctions containing focal discontinuities and collecting veins 
contain focal leaky regions (Nagy et al., 1984). HBEC from different types of blood 
vessels also have different immunological functions, as leukocyte extravasation has been 
proposed to occur mainly at the level of postcapillary venules (Villringer et al., 1991; 
Battastini et al., 2003). These observations may suggest that phenotypic and functional 
variations are responsible for the differences in staining of CXCL8 observed among 
different batches of HBEC. It is thus possible that CXCL8 is stored in HBEC originating 
from larger vessels, whereas HBEC from capillaries do not express CXCL8 at basal level.
Another factor that might influence intracellular location and/or expression of CXCL8 in 
cultured HBEC is the number of cell divisions since isolation. This type of effect has been 
demonstrated for vWF, for which expression by HBEC tends to decrease as the number of 
passages increases (Craig et al., 1998). In the present study, HBEC at passage 2 were 
routinely used. However, the number of cell divisions since isolation may still be different. 
This is because the yield of capillary fragments and hence the number of dividing cells 
after isolation is dependant on a number of factors (post-mortem time, quantity of tissue, 
cause of death among others).
Another hypothesis underlying differences in CXCL8 intracellular distribution would 
involve inter-individual variation among different donors. Variability of CXCL-8 
production between brain endothelium from different donors cannot be excluded and it 
is possible that the state of activation of endothelial cells at the moment of death may 
influence subsequent chemokine production in culture. The cells producing highest levels 
of CXCL8 at the basal level originated from a donor who died of sepsis. Sepsis results in 
an overwhelming systemic inflammation, which is caused by the excessive release of 
cytokines into the circulation, mainly TNF-a, IL-lp, IL-6 and CXCL8 (Blackwell and 
Christman, 1996). On the other hand, it has also been proposed that endothelial cells store
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CXCL8 in Weibel-Palade bodies, after a prolonged stimulation with inflammatory 
mediators (Wolff et al., 1998), and when cells are subject to a preceding inflammatory 
stimulation, CXCL8 can be released without de novo protein synthesis in HUVEC. This 
could be the case in HBEC isolated from a patient with sepsis in which the high levels of 
CXCL8 release may be due to prior priming with circulating cytokines. However, as the 
cells went through a number of cell divisions, this possibility is unlikely.
Finally, differences in chemokine receptor expression between different batches may 
determine differences in CXCL8 internalization. These may involve CXCL8 specific 
receptors such as CXCR1 or CXCR2 or promiscuous receptors that bind many chemokines 
such as DARC. DARC is a seven-transmembrane-segment receptor which binds several 
chemokines of the CC and CXC families and serves to clear these chemokines from the 
blood. Among the diverse chemokines binding to DARC are CXCL8, CCL5 and CCL2, 
but not CXCL10 (Comerford and Nibbs, 2005). Some individuals lack the expression of 
this receptor on erythrocytes, which confer upon them a resistance to the malarial parasite, 
but these individuals are immunologically normal. The clearance of CXCL8 from the 
blood in these individual is ensured by the presence of the DARC receptor on postcapillary 
venule endothelial cells (Hadley et al., 1994). CXCL8 can be transported across an 
endothelial cell monolayer via DARC (Lee et al., 2003a). Thus it could be hypothesised 
that HBEC, which could arise from different sources (capillaries, venules, arterioles) could 
show a different pattern of CXCL8 expression depending on their level of expression of 
DARC. For example, the endothelial cells that are positive for CXCL8 at basal level could 
originate from venules that express the DARC receptors that would allow then to 
internalize the chemokines secreted by the endothelial cells. This, however, is unlikely 
because of the lack of DARC on brain endothelial cell in situ. Indeed, DARC in the brain 
was located by immunohistochemistry on Purkinje cells in the cerebellum and not on 
endothelial cells (Horuk et al., 1996). Furthermore, the staining for CCL5 and CCL2, also
110
ligands of DARC, was negative indicating the absence of functional DARC on HBEC. It is 
also relevant to consider that the levels of secreted chemokines were relatively different 
among the different chemokines. CXCL8 was detected at very high level in the supernatant 
of unstimulated cells, whereas CCL2 was relatively low. In order to answer this question, it 
would have been of interest to investigate chemokine concentration in the supernatant and 
to correlate this with the intracellular staining in the same cells. Differences in pattern of 
binding of CXCL8 to the vascular bed have also been observed. Rot et al. (1996, 
communicated results but not shown) reported substantial differences in CXCL8 binding 
pattern among organs and also within the same organ in normal pig. For example CXCL8 
binding to endothelial cells was present only in venules of the pericardium, in small veins 
and other blood vessels in the heart muscle but not in the lung (Rot et al., 1996). In 
ischemic brain, there is an important infiltration of neutrophils suggesting that the 
endothelial cells are able to bind CXCL8 under certain circumstances (Garau et al., 2005).
2.4.5. Effect of differentiating factors used to induce BBB phenotype in cultured 
endothelium on chemokine expression
The use of differentiating factors known to induce BBB properties in vitro induced a 
decrease of the intracellular staining of CXCL10 under basal conditions, and of increasing 
the release of CXCL8 in the supernatant when exposed to a combination of the two 
cytokines IFN-y and TNF-a. It would have been of interest to stimulate the endothelial 
cells with ACM alone especially as astrocyte factors have a great influence in the 
inflammatory response capability of the brain. Astrocytic factors have been shown to 
induce ramification of macrophages on hippocampal slices, and reduced their expression of 
MHC class II and LFA (Hailer et al., 1998). This effect was partly inhibited by 
neutralizing antibodies directed toward TGF-P (Hailer et al., 1998). Nevertheless, ACM 
did not induce any changes in the pattern of expression of chemokines by HBEC according 
to Prat et al. (2001). It is much more probable that the decrease in CXCL10 and the
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increase in CXCL8 observed in the present study are directly related to a cAMP mediated 
effect on the signalling pathway of IFN-y. The IFN-y signal transduction pathway involves 
mainly activation of signal transducer and activator of transcription 1 (STAT1) as reviewed 
by Stark et al. (1998) and the cAMP pathway blocks STAT1 (Sengupta et al., 1996). It is 
possible that a similar signalling scenario occurs in HBEC. First, IFN-y would stimulate 
the secretion of CXCL10 via STAT1. An increase in intracellular cAMP would then lead 
to inhibition of STAT1 and hence a decreased expression of CXCL10.
2.4.6. Polarized release of chemokines by HBEC.
Cells in culture form two-dimensional monolayers when grown on plastic substrates and 
therefore are far removed from their natural three-dimensional environment in vivo. In a 
physiological context, it is possible that chemokines may be released either on the luminal 
side into the blood or the abluminal side into the brain parenchyma. HBEC grown on filters 
constitute an in vitro model more closely resembling the in vivo situation and allowing the 
possibility of determining polarized release of chemokines. HBEC release of CCL2 into 
the upper chamber, corresponding to the luminal side, is five-fold higher compared to that 
into the lower chamber when grown on 3 pm diameter pore tissue culture inserts under 
stimulation of TNF-a (Weiss et al., 1998). The results presented here using 0.4 pm pores 
demonstrated that CCL2 release into the apical side at basal level is 50% higher than into 
the basolateral side, whereas three quarters of the total CXCL8 released was found in the 
upper chamber at basal level. These data suggest that chemokines are preferentially 
released onto the luminal side rather than contributing to the brain inflammatory reaction 
within the brain parenchyma. However, the role of luminal released chemokines by HBEC 
in orchestrating leukocyte infiltration is still unclear.
Chemokines released into the circulation would be rapidly degraded by proteases or their
action neutralized by decoy chemokine receptors such as DARC expressed on erythrocytes
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(reviewed by Comerford and Nibbs (2005)). However, it is possible that secreted 
chemokines bind to the endothelial surface either on the secretory cell itself or on 
endothelial cells further along the capillary wall. In order to address this question, the 
localisation of chemokines on/in the endothelial cells by immunocytochemical methods 
was investigated. CCL5 stained negatively on the endothelial cells either at the basal level 
or after cytokine stimulation. CCL2 is released at basal level into the supernatant but no 
chemokine staining was detected at the light microscopy level, neither on the surface of the 
cells nor within the cytoplasm. It is possible that the immunocytochemical methods lack 
sensitivity to detect the chemokines. Yet Hillyer et al (2005) have shown that there is little 
if any binding of recombinant CCL2 on the surface of the different endothelial cells, which 
would be in agreement with our own observations. It is also possible that the cells lose 
their property to bind the chemokines in vitro, as seems to be the case for CXCL8 (Rot et 
al., 1996). As for CXCL10, we used three different antibodies, and two of these antibodies 
showed a negative staining. One antibody showed positive staining for CXCL10 on 
unstimulated cells. There are reasons to hypothesise that this staining might not be specific 
(see chap 4 for explanations).
No papers in the literature report on chemokine staining on HBEC in vitro under basal 
conditions, with the exception of Hofman et al. (1999), who showed a very low staining 
for CXCL8 (less that 3% of the culture). The same group also reported that CXCL8 can be 
up-regulated at the cellular level by endothelin-1, but not on all the cells (50% to 70%) and 
the staining was mainly around the cell membrane (Hofman et al., 1998). CCL2 in a rat 
brain endothelial cells line shows an intracellular localisation (Harkness et al., 2003). 
However there are few studies looking at intracellular chemokines on other endothelial cell 
types for CXCL8, where CXCL8 was detected in the Weibel-Palade bodies at basal level 
in human microvascular endothelial cells from the intestine and nasal polyps endothelial 
cells but not in HUVEC (Utgaard et al., 1998).
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2.4.7. Conclusion
The isolation and purification of HBEC was improved using a technique which has been 
developed to create a pure endothelial cell preparation for rat brain tissue. These cells are 
proven to be more sensitive than rat brain endothelial cells to puromycin treatment. This 
has allowed us to obtain a rather pure brain endothelial preparation, and not to lose any 
cells due to contaminants, and has proven to be a considerable improvement in research on 
primary HBEC. Its use has already helped to obtain a human brain endothelial cell line (see 
chap 4). We further demonstrate that HBEC can produce large amounts of CXCL10 and 
CXCL8, and to a lesser extent CCL2 and CCL5 under cytokine stimulation. Furthermore, a 
possible explanation was provided for the fact that neutrophils are absent from MS lesions 
in that there is regulation of CXCL8 secretion by IFN-y. Interestingly, chemokine 
production in the brain can be influenced by the same factors that can trigger BBB 
properties.
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3. Chapter 3: Chemokine receptor expression by human brain
endothelial cells
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3.1 Introduction
Chemokine receptors, first documented in 1989 (Samanta et al., 1989), have been shown to 
participate in several important functions such as chemotaxis, transport and transcytosis of 
chemokines, clearance of excess chemokines and angiogenesis. Many cells displaying a 
high expression of chemokine receptors are located in the parenchyma of MS brains. 
However, immunohistochemical studies in chemokine receptor expression on human brain 
showing positive reactivity within the neurovascular unit do not differentiate between brain 
endothelial cells and perivascular cells, such as pericytes, or perivascular macrophages or 
even the end feet of parenchymal cells such as astrocytes (Decleves et a l , 2000). Yet the 
expression of chemokine receptors by HBEC could be crucial as they may play a role in 
chemotaxis, transcytosis, clearance of excess chemokines, and angiogenic or angiostatic 
responses.
Previously, in vitro studies have shown that endothelial cells from different vascular beds 
express a variety of chemokine receptors (Berger et al., 1999; Murdoch et al., 1999; 
Hillyer et al., 2003). In addition, chemokine receptor expression may vary from one 
endothelial cell type to another (Hillyer et al., 2003). Nevertheless, few studies have 
reported the expression of chemokine receptors by HBEC, probably due to the difficulties 
encountered when trying to isolate them and limited tissue availability. Berger et al. (1999) 
have shown the expression in vitro of CCR2A, CCR3, CCR4, CCR5 and CXCR1, CXCR3 
and CXCR4 in HBEC in primary culture by immunocytochemistry and by FACS analysis.
In this part of the present study, the expression of chemokine receptors that have been 
previously shown to be up-regulated in lesions such as CCR1, CCR2, CCR5, CXCR2 and 
CXCR3 was investigated (Balashov et al., 1999; Mennicken et al., 1999; Sorensen et al., 
1999; Huang et al., 2000; Jee et al., 2002; Sorensen et al., 2002; Trebst et al., 2003). These
receptors are of particular interest since their chemokine ligands are also expressed by 
endothelial cells such as CCL2, CCL5, CXCL8 and CXCL10. In addition, CXCR1 was 
also investigated since it is the receptor for CXCL8 chemokine together with CXCR2, and 
is strongly expressed by other endothelial cell types (Murdoch et al., 1999; Hillyer et al., 
2003).
In view of the paucity of data concerning CNS endothelium and chemokine receptor 
expression, in this study, attempts were made to characterise the expression of some 
chemokine receptors in vitro, at the transcript level by RT-PCR and at the protein level by 
immunocytochemistry, and in vivo in MS brain, by immunohistochemistry and at the 
electron microscopy level combined with immunogold detection techniques.
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3.2 Material and methods
3.2.1. RT-PCR
RT mix : IX ImProm-II reaction buffer (25mM Tris-HCl, pH 8.3 at 25°C, 37.5mM KC1 
and 5mM DTT), 3mM of MgCh, 0.5mM deoxyribonucleoside triphosphates (dNTPs), 
lU/pl of rRNasin and 2 pi of Improm-II™ Reverse transcriptase (Promega UK, 
Southampton, UK)
PCR mix : IX PCR buffer (50mM KC1, lOmM Tris-HCl, pH 9.0 at 25°C, and 0.1%
Triton® X-100), 1.5mM MgC12, 0.2mM of dNTPs, lpM  of each primer (forward and 
reverse) and 1U of Taq polymerase (Promega UK, Southampton, UK)
Loading Dye : 6X : 0.4% orange G, 0.03% bromophenol blue, 0.03% xylene cyanol FF,
15% Ficoll® 400, lOmM Tris-HCl, pH 7.5, and 50mM EDTA (Promega UK, Southampton, 
UK)
TAE buffer : 40mM tris acetate/lmM EDTA (Sigma-Aldrich, Dorset, UK), PH 8
RNA was isolated from primary HBEC grown to confluence in a F25 cm2 flask coated 
with collagen as described in section 2.2.1, 2.2.2, 2.2.4. Total RNA was extracted using 1 
ml of TRIzol LS (Invitrogen, Renfrewshire, UK) according to the manufacturer’s protocol. 
The cells were scraped off the flask in the 1 ml TRIzol reagent and incubated at RT for 5 
min. 2.6 ml of chloroform (Sigma-Aldrich, Dorset, UK) was added and after a vigorous 
shake, samples were centrifuged (HAWK 15105 from Sanyo) at 12,000g for 15 min at 4°C. 
This centrifugation step allows the separation of protein, DNA and RNA. The RNA is 
located in the colourless upper aqueous phase. The aqueous phase was collected and the 
RNA was precipitated by addition of 0.66 ml isopropyl alcohol (BD chemicals, Dorset, 
UK) for 10 min at RT. The isopropyl supernatant was removed after a centrifugation of 
12,000 g for 10 min at 4°C. The pellet left containing the RNA was washed with 1.33 ml
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of 75% ethanol (B&D chemicals, Dorset, UK). After another centrifugation step, the pellet 
was dried, re-suspended in 30 pi of distilled water and stored at -80°C. A 1 pi aliquot was 
taken and added to 500 pi of distilled water. The concentration of RNA in each sample was 
calculated with the following formula CRNA(hig/ml)=Abs260nmx40, after determining the 
OD at a wave length of 260nm in a UV spectrophotometer (Spectronic Genesys 5, Milton 
Roy, Essex, UK) and correcting the dilution factor.
For the reverse transcription (RT) procedure, the protocol given by the supplier, Promega 
(ImProm-II™ Reverse transcriptase) was followed. 2 pg of RNA was mixed with 1 pg of 
random primer at 70°C for 5 min then annealed on ice. Revese transcription was carried 
out by addition of 40 pi RT mix at 25°C for 5 min followed by 60 min at 40°C. To 
terminate the reaction, the mix was incubated for further 15 min at 70°C. The negative 
control for each sample consisted of RNA samples annealed with random primers with 
Reverse Transcriptase and without the Reverse Transcriptase. The negative control ensures 
that there is no contamination with genomic DNA. The resulting cDNA was either stored 
at -20°C, or taken directly into the PCR amplification procedure.
The PCR amplification steps were performed as advised by Promega which supplies the 
Taq DNA polymerase. 4 pi of cDNA from the RT reaction was added to 20 pi of PCR mix. 
This PCR reaction mix was placed into the PCR machine (Icycler, Bio-Rad Laboratories, 
Hertfordshire, UK) PCR conditions were 5 min at 94C, followed by 40 cycles (94°C, 45 
seconds (sec); Tm, see table 3.1, 45sec, 72°C, 60 sec) finishing with 7 min at 72°C. The 
reaction ended by a final 72°C incubation for 7 min. In addition to the chemokine receptor 
mRNA detection, each sample was run in parallel with cyclophilin primers, acting as a 
positive control.
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The product of the RT-PCR was mixed with a loading Dye and run in a 1.5% agarose gel 
in TAE buffer at the voltage of 5 V/cm. The bands were visualised under UV light with 
Alphalmager 1220 (Alpha Innotech Corporation, distributor GRI, Essex, UK). The 
expected length of the RT-PCR products is listed in table 3.1.
Primers Sequence Tm
(C)
Length
(bp)
Source
CCR1F 
CCR1 R
ACG AAA GCC TAC GAG AGT G 
GGT GAA CAG GAA GTC TTG G
50 240 Designed 
by I. 
Romero
CCR2F
CCR2R
GAT TAC GGT GCT CCC TGT C 
GCC ACA GAC ATA AAC AGA ATC
50 496 Designed 
by I. 
Romero
CCR5F
CCR5R
GCT GAG ACA TCC GTT CCC CTA CA 
GGT GAC CGT CCT GGC TTT TA
58 477 (Lazzarino 
et a l , 
2000)
CXCR1 F 
CXCR1 R
GTG ATG CTG GTC ATC TTA TAC AG 
TTG TTT GGA TGG TAA GCC TGG
52 230 Designed 
by I. 
Romero
CXCR2F
CXCR2R
CGA AGG ACC GTC TAC TCA TC 
AGT GTG CCC TGA AGA AGA GC
53 519 Designed 
by I. 
Romero
CXCR3F 
CXCR3R
GGA GCT GCT CAG AGT AAA TCA C 
GCA CGA GTC ACT CTC GTT TTC
53 200 (Jinquan et 
a l , 2000)
Table 3.1: Sequence of the primers used for RT-PCR with corresponding melting 
temperatures (Tm) and length of expected PCR products (in number of base pairs, bp)
3.2.2. Immunocytochemistry
After seeding, the cells were grown for one week on Lab-Tek™ II Chamber slide (Nunc, 
UK) coated with collagen. They were fixed with 4% paraformaldehyde in PBS for 10 min 
on ice, and the membrane was permeabilised with 0.1% Triton-XlOO in PBS for 5 min. 
After 3 rinses with PBS, the non specific binding sites were blocked using 10% goat serum 
in PBS for 1 h at RT. The primary antibodies for the chemokine receptors were then 
incubated for 1 h at RT. The antibodies, from R&D systems, were fluorescently labelled 
and are listed in table 3.2. To ensure that the cells in primary culture had an endothelial 
phenotype and were not contaminating cells from the isolation procedure, cells were also 
incubated with an antibody specific for vWF as an endothelial cell marker. For double
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labelling, after the excess anti-chemokine receptor antibodies were washed off, the same 
protocol as described in chapter 2, section 2.2.6.1 was followed. Briefly, the second 
primary antibody (vWF, 1/200, Sigma-Aldrich, Dorset, UK) was applied for 1 h at RT. 
After 3 washes with PBS, the goat anti rabbit secondary antibody (1/100, Chemicon, 
Hampshire, UK) conjugated to either phycoerythrin or fluorescein was added to the cells 
and incubated for 1 h. After 3 final washes, the slides were mounted with a glass coverslip 
with Dako Fluorescent Mounting Medium (DakoCytomation Ltd, Cambridgeshire, UK)
and viewed with a fluorescence microscope (Olympus BX61).
Antigen Type Label Supplier
Human CXCR1 Monoclonal mouse 
IgG2A, clone #42705
Phycoerythrin R&D, Oxfordshire, UK
Human CXCR2 Monoclonal mouse 
IgG2A, clone #48311
Phycoerythrin R&D, Oxfordshire, UK
Human CXCR3 Monoclonal mouse 
IgGl, clone #48311
Phycoerythrin R&D, Oxfordshire, UK
Human CCR1 Monoclonal mouse 
IgG2B, clone #53504
Phycoerythrin R&D, Oxfordshire, UK
Human CCR2 Monoclonal mouse 
IgG2B, clone #48607
Phycoerythrin R&D, Oxfordshire, UK
Human CCR3 Monoclonal mouse 
IgG2A, clone #61828
Fluorescein R&D
Human CCR4 Polyclonal rabbit IgG No label Santa Cruz 
Biotechnology
Human CCR5 Monoclonal mouse 
IgG2B, clone #45502
Fluorescein R&D, Oxfordshire, UK
Mouse IgGl Normal mouse IgGl, 
clone #11711
Phycoerythrin / 
Fluorescein
R&D, Oxfordshire, UK
Mouse IgG2A Normal mouse IgG2A, 
clone #20102
Phycoerythrin / 
Fluorescein
R&D, Oxfordshire, UK
Mouse IgG2B Normal mouse IgG2B, 
clone #20116
Phycoerythrin / 
Fluorescein
R&D, Oxfordshire, UK
Table 3.2: List of antibodies for the chemokine receptors used for Immunocytochemical 
analysis.
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3.2.3. Immunohistochemistiy
0.1M Phosphate Buffer (TED: 78mM sodium phosphate dibasic, 23mM sodium phosphate 
monobasic, pH
Mowiol mounting solution: 12 % mowiol in 60mM PB and 30% glycerol
Fresh tissue, from the same origin as the tissue used for the isolation of HBEC (section 
2.2.3), of 1 cm3 was fixed using 2% PAF and 3.75% acrolein in 0.1M PB for 1 h and left 
overnight in 2% PAF only. The sections were cut at 50pm using a Vibratome (Leica 
Microsystems, Buckinghamshire, UK).
In order to characterise the type of lesions, the sections were stained for CD68 and MHC 
class II. As reported in Bo et a l (1989), active lesions are CD68 positive/MHC class II 
positive, chronic active lesions are CD68 positive/MHC class II positive in the edge of the 
lesion and CD68 positive/MHC class II negative in the centre, and chronic inactive lesions 
are CD68 negative/MHC class II negative.
All sections were permeabilized with 0.1% Triton X100 in PBS for 1 h. Non-specific 
binding sites were blocked using 10% normal rabbit serum for 1 h. The primary antibodies 
(CD68, 1/20 from Dako Corporation, Cambridgeshire, UK and MHC class II 1/200 from 
Serotec Ltd, Oxfordshire, UK) were incubated on the slide overnight at RT. After 3 washes 
with PBS, the secondary antibody (rabbit anti-mouse streptavidin conjugated, Dako, 1/100) 
was left to bind for 1 h. The excess of secondary antibody was washed off by 3 times 
rinsing with PBS and the avidin-biotinylated peroxidase (Vectastain ABC Kit, Vector 
Laboratories, Peterborough, UK) was added on the sections for 1 h. 10 mg of 3,3'- 
Diaminobenzidine (DAB), dissolved in 20 ml of PBS with 20 pi of hydrogen peroxide, 
was used to reveal the presence of peroxidase for 3 min. The reaction was stopped by 3
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washes with PBS. Nuclei were stained using Harris’ Hematoxylin for 5 min, the excess 
was washed off under running tap water, and to intensify the staining, the slides were 
plunged in acetic acid (3%) for 10 sec, and further rinsed in running tap water. Thereafter, 
the sections were dehydrated in a series of ethanol baths (50%, the 75%, 90%, 95%, and 
100% ethanol and a final clearing step in 100% xylene) and mounting with DPX (Distrene, 
Plasticiser, Xylene) (B&D chemicals, Dorset, UK).
For sections labelled for vWF/GFAP and CXCR1/CXCR3, an antigen retrieval step was 
included, essentially as described by Shi et al. (1991). Sections were left for 20 min in a 
0.01M citrate buffer, pH 6, at 95°C using a heating block. All sections were then 
permeabilized with 0.1% Triton X I00 in PBS for 1 h. Non-specific binding was blocked 
using 10% normal goat serum for 1 h. Sections were incubated with mouse anti- 
CXCR1/CXCR3 (lOpg/ml, R&D, Oxfordshire, UK) for 1 h and, after 3 washes, the 
secondary goat anti-mouse IgG (1/100, Chemicon, Hampshire, UK) conjugated to the 
fluorochrome cy3 was left for 1 h at RT. Sections were then incubated with a rabbit 
polyclonal anti-human vWF (1/800, Sigma, Dorset, UK) or anti-GFAP (1/100, Chemicon, 
Hampshire, UK) antibodies in PBS overnight at RT. The secondary antibody used was a 
goat anti-rabbit conjugated to FITC (1/200, Chemicon, Hampshire, UK), and was 
incubated for 1 h. Sections were mounted using mowiol and viewed on the fluorescence 
microscope (Olympus, BX61).
3.2.4. Immunogold labelling and electron microscopy
0.1M Phosphate Buffer fPBk 78mM sodium phosphate dibasic, 23mM sodium phosphate 
monobasic, pH 7.4
0.1M Tris-buffered saline (TSk lOOmM Trizma base, 154mM saline, pH 7.6.
Blocking solution: 0.5% BSA in TS
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0.01M Phosphate Buffer Saline fPBS): 7.7mM sodium phosphate dibasic, 2.3mM sodium 
phosphate monobasic, 300mM sodium chloride, pH 7.4.
Crvoprotectant solution: 25% sucrose, 3.5% glycerol in PB, pH 7.4 
Incubation/washing buffer: 0.8%BSA and 0.1%gelatine in PBS
Immunogold labelling was performed essentially as described by Rodriguez et al. (2001). 
For chemokine receptor staining, fresh tissue was fixed using 2% PAF and 3.75% acrolein 
in 0.1M PB for 1 h and left overnight in 2% PAF. The sections were cut at 50pm using a 
Yibratome (Leica Microsystems, Buckinghamshire, UK). The floating sections were then 
treated with 1% sodium borohydride in PB for 30 min and then freeze-thawed to 
permeabilize the tissue For this procedure the sections were incubated in Cryoprotectant 
solution and then rapidly immersed in dichlorofluoromethane (Air Products, 
Warwickshire, UK), followed by liquid nitrogen and then three successive PB washes. 
Blocking solution was added for 30 min, and sections were incubated with primary mouse 
antibody (mouse anti-human CXCR1, 5pg/ml or mouse anti-human CXCR3, 1 pg/ml, 
R&D, Oxfordshire, UK) for 24 h at RT and a further 24 h at 4°C in 0.1%BSA in TS. Non 
specific binding of the secondary antibody was blocked with the incubation/washing buffer 
for 10 min after a rinse with PBS. Sections were then incubated for 2 h with goat anti­
mouse secondary antibody (dilution 1/50) conjugated to colloidal gold (British Biocell 
International, Wales, UK) in the incubation/washing buffer. After a 5 min wash with the 
incubation/washing buffer and three rinses with PBS, bound gold particles were fixed 
using 2% glutaraldehyde in PBS for 10 min followed by a wash in a 0.2M citrate buffer 
solution. The sections were reacted with a silver enhancement solution (British Biocell 
International, Wales, UK). The silver enhancement reaction was stopped by two washes in 
the citrate buffer and three washes with PB. The immunogold stain tissue was post-fixed 
for 1 h in 2% osmium tetroxide in PB for electron microscopy viewing. They were then 
dehydrated in a series of ethanol solutions (concentration 50%, 70%, 80%, 95% for 5 min,
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and twice in 100% for 10 min) and twice in propylene oxide for 10 min before being 
embedded in Epon 812 between sheets of Aclar plastic. Epon polymerisation was carried 
out by incubation at 60°C over 48 h, and a sample of the tissue was mounted on the tips of 
Epon Block. Ultra-thin sections of 70 nm were cut with a diamond knife (Diatone, TAAB, 
Dorset, UK) and collected on copper mesh grids. The ultra thin cutting was made by 
Frances Coyle. The sections on grids were counterstained with uranyl acetate for 20 min 
and lead citrate for 6 min, and examined with a Joel JEM1010 electron microscope 
attached to a Gatan Bioscan digital camera (Joel, Hertfordshire, UK). Micrographs at 
X8000 magnification were taken, and scanned with Epson Perfection 4870 Photo, 
visualised with Photoshop 5.5 programme.
For quantification of the gold particle density (number of gold particles/pm2), the negative 
film of the photograph was scanned and used to count the number of gold particles on the 
blood vessels present in one section and reported on the area of the endothelial cells, that 
was determined on the digital images, using NIH image programme on a Macintosh G4. 
More over, the localisation of the gold particle in the cells was recorded as follows: 
cytoplasmic, luminal or baso-lateral and was reported as a percentage of the total number 
of gold particle.
3.2.5. Statistical analysis
Significance was determined by a one way or two way ANOVA, followed by a post hoc 
Tukeys t-test. P<0.05 was considered significant.
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3,3 Results
3.3.1. Expression of chemokine receptors by HBEC in vitro
Figure 3.1 shows that at the mRNA level, HBEC express CCR1, CCR5, CXCR1, CXCR2 
and CXCR3 but not CCR2 as detected by RT-PCR.
At the protein level CCR3, CCR5 (fig 3.2), and CXCR1, CXCR2 and CXCR3 (fig 3.3) 
were expressed by HBEC as shown by immunocytochemistry. CCR1 or CCR2 (fig 3.2) 
could not be detected, suggesting they are not expressed constitutively in vitro. Chemokine 
receptor staining was compared to the level of fluorescence obtained with isotype-matched 
negative control antibodies conjugated to TRITC or FITC (fig 3.4). The staining for 
CXCR1, CCR3 and CXCR3 was very strong whereas that for CXCR2 and CCR5 was 
much weaker. Chemokine receptors appeared to be localised mainly intracellularly rather 
than on the cell surface, in particular around the nucleus. Their distribution within the cell 
appeared uniform inside the cytoplasm and not specifically within a vesicular compartment. 
The pattern of chemokine receptor expression did not differ between cells originating from 
MS brains and those from epileptic patient brains (data not shown). However, the intensity 
of the staining could not be directly compared as the experiments involving cells from 
different donors were not carried out at the same time. For each chemokine receptor, cells 
were also labelled for vWF to confirm the endothelial cells identity (fig 3.2-4).
3.3.2. Characterisation of MS lesions
All tissue sections were characterised according to the method of Bo et al. (1994). CD68 is 
a marker for microglia and macrophages and according to Bo et al. (1994), only CD-68 
positive inactivated microglia, which are small ramified cells are detected in NAWM
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(normal appearing whitte matter) (fig 3.5). Resting microglia are slightly positive for MHC 
class II antigen in NAWM (fig 3.5).
Generally, the staining for CD68 shows a different pattern in MS lesions (fig 3.5). 
Microglial cells were much more rounded, and with an amoeboid form, representing an 
activated stage of the microglia. In addition, the antibody specific for CD68 also stained 
infiltrated macrophages in lesions.
There were additional distinctive immunohistochemical features that differentiated active 
lesions, chronic active lesions and chronic silent lesions. In the active lesions, all CD68 
positive macrophage/microglia cells were also MHC class II positive. However, in chronic 
active lesions, the centre of the lesion was negative for MHC class II, and the edges were 
still MHC class II positive, suggesting that an active immune response was still occurring. 
By contrast, in chronic silent lesions, staining for amoeboid cells for CD68 was observed 
whereas the staining for MHC class II on these amoeboid cells was absent (not shown).
Using these criteria, a number of chronic active and chronic silent lesions in brain tissue 
from 6 different MS patients were characterised. The description of each individual case, 
including age, gender, disease type, post-mortem time, cause of death and lesion activity is 
shown in table 3.3. In all 6 patients, active lesions were rarely identified. It has been shown 
that active lesions, either chronic or acute, are mostly present at early stages of the disease 
(Sanders et al., 1993). In support of this finding, active lesions were exclusively detected in 
brain tissue from patients that died at an early age (34 and 44 years old) whereas chronic 
active lesions were detected in a 50 year old patient. In the remaining three cases, only 
demyelinated chronic silent lesions, or no lesions at all could be identified. As only a small 
sample of tissue was obtained from the MS Tissue Bank for each individual patient,
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whether the pattern of lesions described above is representative of the whole brain remains 
to be determined.
For the study combining immunogold techniques and transmission electron microscopy, 
only three cases shown in bold in table 3.3 were analyzed corresponding to those with 
chronic active lesions and also with the best preserved ultrastructure of the blood vessels 
which facilitated interpretation of the results. All tissues from the 6 cases were analyzed
for CXCR1/CXCR3 expression by immunofluorescence (sections 3.3.3).
Patient
Age
(years) Gender Post mortem (h) Cause of death lesion activity
1 50 Female 13
Multiple
sclerosis
Chronic active 
lesion
2 34 Female 15 Pneumonia
Active/chronic 
active lesions
3 59 Female 32
Respiratory 
failure, cardiac 
arrest
No demyelinated 
lesions
4 70 Female 21
Aspiration 
pneumonia, 
sepsis, multiple 
sclerosis
Silent chronic 
lesion
5 44 Female 36
Multiple
sclerosis
Active/chronic 
active/chronic 
silent lesions
6 71 Female 36
bronchopneumo 
nia, multiple 
sclerosis
No demyelinated 
lesions
Table 3.3: Case description of brain tissue from the MS patients investigated in this study.
3.3.3. Expression of chemokine receptors by HBEC in situ in normal appearing 
white matter.
CXCR1 and CXCR3 appeared to be expressed at high levels by HBEC in culture. A 
detailed analysis of the expression of these two chemokine receptors was therefore 
performed in situ in MS brain sections.
50pm thickness sections were double labelled with either vWF and CXCR1 or CXCR3 to
determine the cellular location of the receptors. Cells that were positive for vWF appeared
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to also express CXCR1 and CXCR3 (fig 3.6/3.7) but not all. Moreover, the thickness of the 
section does not allow a clear identification co-localisation, as some of the fluorescence 
detected for CXCR1 and CXCR3 could originate from the astrocytes foot processes that 
surround the vessels and are closely juxtapose to endothelial cells, and endothelial cells are 
thin. In addition, other cells within the brain parenchyma were also positively labelled for 
CXCR1 and CXCR3.
Since human astrocytes have been previously shown to express CXCR1 and CXCR3 
(Flynn et al., 2003), double labelling with CXCR1/3 and GFAP, a specific marker for 
astrocytes was carried out. Since astrocytes are bigger cells and easier to identify by 
immonohistochemistry, a clear co-localisation of CXCR1 and CXCR3 and GFAP was 
observed indicating that astrocytes (fig 3.8/3.9) processes and the end-feet surrounding the 
vessels were strongly positive. Cells enclosed within the astrocytic end-feet were also 
positively labelled although the endothelial nature of those cells could not be ascertained.
3.3.4. Expression of chemokine receptors by HBEC in situ in MS lesions.
CXCR1 and CXCR3 were also expressed by many cells in MS lesion (fig 3.6-3.9). The 
positive staining was more diffuse throughout the lesion, probably due to astrogliosis or 
leukocyte infiltration. There did not appear to be any difference in the intensity of the label 
between the edge and the centre in a chronic active lesion (not shown). There were no clear 
results indicating that the staining on the astrocytes or in vessels were stronger for either of 
the two chemokine receptors investigated here. Small rounded cells in the perivascular 
space of infiltrated vessels were strongly positive for CXCR3, which could correspond to 
activated T lymphocytes (fig 3.10).
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3.3.5. infrastructure of MS brain at the electron microscopy level
MS lesions are characterised by the loss of myelin around axons, appearance of gliosis, and 
presence of leukocytes around some but not all the vessels (fig 3.11 A). Some of these cells 
in electron microscopy show electron dense material accumulating in vacuoles, a feature 
that is characteristic of phagocytosis of myelin by macrophages or microglia (fig 3.11 B). 
The centre of the lesions present fewer cell nuclei suggesting a decline in the number of 
cells and axons denuded of myelin (fig 3.11 C). On the edge of lesions, some fibres were 
still myelinated, but the myelin sheet appeared thinner. These observations apply for both 
chronic active and chronic silent lesions. These two types of lesion could not be 
differentiated at the electron microscopical level.
3.3.6. Subcellular localisation of CXCR1 and CXCR3 by immunogold labelling and 
electron microscopy
33.6A.CXCR1
CXCR1 was detected on cells other than HBEC in the vessels. Some polynuclear cells, 
which were highly CXCR1 positive, were located inside the vessel (fig 3.12). It is possible 
that these cells are neutrophils, as they are known to be CXCR1 positive (Ley, 1996), and 
neutrophils are likely to be found in the blood stream as they represent ~ 70% of the 
leukocyte population (Weber-Dabroska et a l , 2002).
33.6.2.CXCR1 in endothelial cells
From each block of tissue, a number of vessels (table 3.4) characterised by the presence of
endothelial cells connected together by electron-dense tight junctions, surrounded by a
basal lamina, and containing a lumen were investigated (fig 3.13). The number of gold
particles present on the luminal or abluminal membranes or within the cytoplasm of
endothelial cells was counted and reported as a percentage of the total number of gold
particles present in the endothelial cells. 87% of the gold particles labelling CXCR1 the
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NAWM were located in the cytoplasm whereas 3 % were found on the abluminal 
membrane and 9% on the luminal membrane (table 3.4).
The preferential location within the cytoplasm was observed for all three donors with a 
similar percentage of gold particles in the cytoplasm on HBEC in NAWM. For the 
localisation on the membrane there was more variability between the three donors (table 
3.4) althought there was a slightly higher distribution on the luminal side versus the 
abluminal side. In the MHC class II positive and the MHC class II negative lesions, there 
were some differences compared with the NAWM, but these differences were not 
consistent, suggesting that CXCR1 expression and localisation is unchanged on brain 
endothelial cells in MS in lesion. There were no changes in the overall number of gold 
particle in the NAWM versus the lesion (fig 3.15).
NAWM
Nb of vessel 
(n=number of total 
particles/vessel)
% of GP in 
cvtoplasm
% of GP on
luminal
membrane
% of GP on
Abluminal
membrane
Case 1 8 (n=11) 87.2 5.7 7.2
Case 2 2 (n=l 1.5) 87.3 12.7 0
Case 3 6 (n=16.16) 87.2 11.6 0
MEAN 87.2 8.9 3.6
MHC class 11+ 
lesion
Case 1 5 (n=1.8) 100 0 0
Case 2 3 (n=8.5) 79.4 13.6 7
Case 3 6 (n=9.3) 83.4 12.8 3.8
MEAN 86.6 9.8 3.6
MHC class n- 
lesion
Case 1 6 (n=3.33) 94.29 2.9 2.9
Case 2 4 (n=8.5) 41.2 52.2 6.6
Case 3 8 (n=19.37) 77.1 13.9 9
MEAN 73.7 19.7 6.6
Table 3.4: Percentage of gold particles (GP) labelling CXCR1 according to membrane or 
intracellular localisation counted on the number of vessels found in one section for each 
lesion type and NAWM per case. Significant differences were determined by ANOVA 
followed by a post hoc t-test.
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33.6.3.CXCR3
Leukocytes within vessels were not as positive for CXCR3 as CXCR1 and some were even 
negative for CXCR3 (fig 3.14 A). All cells with high granule content, probably 
macrophages or neutrophils, were also negative (fig 3.14 B). In the parenchymal space, 
some glial cells, possibly astrocytes according to their morphological appearance, were 
contained a higher gold particle density for CXCR3 (fig 3.14 C).
33.6.4.CXCR3 in endothelial cells
The intracellular distribution of CXCR3 within endothelial cells was different to that of 
CXCR1. 65% of gold particles were located in the cytoplasm in NAWM whereas 14.3% of 
the gold particles were on the luminal membrane, and 20% were on the abluminal 
membrane (table 3.5). The proportion of gold particles in the cytoplasm of HBEC was 
greater than control for MHC class II negative lesions, indicating that CXCR3 may have 
been internalized by HBEC. The proportion of CXCR3 positive gold particles on the 
abluminal surface of HBEC, higher than that observed for CXCR1, was lower in chronic 
active lesions (MHC class II positive) but not in chronic silent lesions (MHC class II 
negative) compared to NAWM. The overall number of gold particles in the MHC class II 
negative lesion also decreased (P=0.013, n=18 for NAWM and n=17 for the MHC class II 
lesion) (fig 3.15).
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NAWM
Nb of vessel 
(n=number of total 
particles/vessel)
% of GP in 
cytoplasm
% of GP on
luminal
membrane
% of GP on
Abluminal
membrane
Case 1 5 (n=5) 67.5 6.8 28.57
Case 2 6 (n=19) 56.7 31.4 11.82
Case 3 8 (n=6.25) 68.2 8.22 23.54
MEAN 64.8 14.3 20.4
MHC class 
11+ lesion
Case 1 5 (n=7.4) 68.7 24.8 0.9
Case 2 6 (n=27) 70.1 10.6 3.1
Case 3 5 (n=6.6) 70.6 18.3 10
MEAN 70.0 17.4 4.5* (P=0.033)
MHC class 
II- lesion
Case 1 4 (n=3.5) 74.3 12.5 18.75
Case 2 8 (n=5) 87.7 3.6 26.3
Case 3 6 (n=5.8) 71.7 22.3 7.1
MEAN 79.0* (P=0.049) 12.3 17.8
Table 3.5: Percentage of gold particles (GP) labelling CXCR3 according to membrane or 
intracellular localisation counted on the number of vessels found in one section for each 
lesion type and NAWM per case. Significant differences were determined by ANOVA 
followed by a post hoc t-test.
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Fig 3.1: Chemokine receptor mRNA expression by HBEC
Chemokine receptor mRNA expression by primary human brain endothelial cells was 
determined by standard semi-quantitative RT-PCR. mRNA for the chemokine receptors 
CCR1, CCR5, CXCR1, CXCR2 and CXCR3 was detected in primary human brain 
endothelial cells (+). Cyclophilin was used as positive control and to ensure equal cDNA 
loading for each sample. Negative controls (-) of samples incubated in the absence of RT 
were included. Data were obtained from 2 experiments.
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Fig 3,2: Immimocytochemical detection of CCR receptors and vWF in HBEC.
HBEC were grown on collagen-coated Labtek chamber slides, fixed, permeabilised with 
Triton X -100 and then processed for detection of CCR receptor by 
immunocytochemistry using specific fluorescent conjugated antibody (left column). 
Cells were then double labelled with an antibody for vWF, an endothelial cell marker 
(right column). Antibody isotype indicated for each receptor. Results are representative 
of three different experiments done with a single well per treatment. Scale bar=50 pm
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Fig 3.3: Immunocytochemical detection of CXCR receptors and vWF in HBEC.
HBEC were grown on collagen-coated Labtek chamber slides, fixed, permeabilised with 
Triton X-100 and then processed for detection of CXCR receptor by 
immunocytochemistry using specific fluorescent conjugated antibody (left column). 
Cells were then double labelled with an antibody for vWF, an endothelial cell marker 
(right column). Antibody isotype indicated for each receptor. Results are representative 
of three different experiments done with a single well per treatment. Scale bar=50 pm
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Fig 3.4: Immunocytochemical detection of isotope matched controls for CCR and 
CXCR receptors and vWF in HBEC.
HBEC were grown on collagen-coated Labtek chamber slides, fixed, permeabilised with 
Triton X-100 and then processed for detection of isotype control by 
immunocytochemistry using specific fluorescent conjugated antibody (left column). Cells 
were then double labelled with an antibody for vWF, an endothelial cell marker (right 
column). Results are representative of three different experiments done with a single well 
per treatment. Scale bar=50 pm.
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Fig 3.5: Immunohistochemical detection of CD68 or MHC class II in NAWM and in 
MS active lesions counter-stained with hematoxylin.
Fixed 50 pm thick sections cut with a vibratome were permeabilised with Triton X-100 
and then processed for detection o f CD68, a marker for microglia (arrows), or MHC 
class II by immunohistochemistry. Sections were then counterstained with haematoxylin 
to visualise cell nuclei in NAWM (left column) and in MS lesions (right column). 
Results are representative of experiments from six donors done in duplicate. Scale 
bar=50 pm
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Fig 3.6: Immunohistochemical detection of CXCR1 and vWF in human NAWM 
and in MS lesions.
Fixed 50 pm thick sections cut with a vibratome were permeabilised with Triton X-100 
and then processed for detection of CXCR1 receptor (in red) and vWF (in green) by 
immunohistochemistry in NAWM (left column) and in MS lesions (right column). 
Merged images show the localisation of CXCR1 within the neurovascular unit. Results 
are representative of experiments from six donors done in duplicate. Scale bar=20 pm
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Fig 3.7: Immunohistochemical detection of CXCR3 and vWF in human NAWM 
and in MS lesions.
Fixed 50 \im thick sections cut with a vibratome were permeabilised with Triton X-100 
and then processed for detection of CXCR3 receptor (in red) and GFAP (in green) by 
immunohistochemistry in NAWM (left column) and in MS lesion (right column). 
Merged images show the localisation of CXCR3 within the neurovascular unit. In the 
NAWM, some vessels were clearly CXCR3 positive (arrow), but for some others it is 
less obvious (star). Results are representative of experiments from six donors done in 
duplicate. Scale ba.r=20 jim
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Fig 3.8: Immunohistochemical detection of CXCR1 and GFAP in human NAWM 
and in MS lesions.
Fixed 50 |im thick sections cut with a vibratome were permeabilised with Triton X-100 
and then processed for detection of CXCR1 receptor (in red) and GFAP (in green) by 
immunohistochemistry in NAWM (left column) and in MS lesions (right column). 
Merged images show the localisation of CXCR1 on astrocytes. Results are representative 
of experiments from six donors done in duplicate. Scale bar=20 p,m
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Fig 3.9: Immunohistochemical detection of CXCR3 and GFAP in human NAWM 
and in MS lesions.
Fixed 50 pm thick sections cut with a vibratome were permeabilised with Triton X-100 
and then processed for detection of CXCR3 receptor (in red) and GFAP (in green) by 
immunohistochemistry in NAWM (left column) and in MS lesions (right column). 
Merged images show the localisation of CXCR3 on astrocytes. Results are representative 
of experiments from six donors done in duplicate. Scale bar=20 pm
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Fig 3.10; Immunohistochemical detection of CXCR3 in human MS chronic active 
lesion.
Fixed 50 |xm thick sections cut with a vibratome were permeabilised with Triton X-100 and 
then processed for detection of CXCR3 receptor by immunohistochemistry in a MS 
chronic active lesion. Results show one experiment (done in duplicate). Scale bar=50 [im
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Fig 3.11: Electron micrographs of a lesion within the brain of a MS patient.
Fixed 50 pm thick sections cut with a vibratome and ultra cut to 70 nm were process to be 
analysed by electron microscopy. Lesions were characterised by the absence of myelin 
surrounding the axons (A) and some blood vessels were surrounded by infiltrated cells 
most probably leukocytes (B). Some of the cells within the brain parenchyma contained 
vesicles (dashed arrow) with myelin degradation products (C). It is possible to distinguish 
nuclei (NU), erythrocyte in capillary (REY) and tight junction (TJ). Scale bar = 5 pm.
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Fig 3.12: Digital electron micrograph of a CXCR1 positive leukocyte inside a vessel from 
a MS patient.
Fixed 50 pm thick sections cut with a vibratome were processed for detection of CXCR1 by 
immunohistochemistry using silver-enhanced gold particles, ultra-thin cut to 70 nm and 
visualised with an electron microscope. Scale bar = 1pm.
Fig 3.13: Electron micrograph of a CXCR3 labelled vessel in a MHC class H negative 
lesion.
Fixed 50 pm thick sections cut with a vibratome were processed for detection of CXCR1 by 
immunohistochemistry using silver-enhanced gold particles, ultra thin cut to 70 nm and 
visualised with an electron microscope. The black arrow indicates a silver-enhanced gold 
particle on the membrane and the grey arrow indicates a gold particle in the cytoplasm of a 
brain endothelial cell in a capillary. It is also possible to distinguish a tight junction (TJ), the 
nucleus of the endothelial cells (NU) and an erythrocyte (ERY) located in the lumen (LU). 
Scale bar = 1 pm
Fig 3.14: Digital electron micrograph of CXCR3 positive cells within MS brain.
Fixed 50 jam thick sections cut with a vibratome were processed for detection of CXCR3 by 
immunohistochemistry using silver-enhanced gold particles, ultra thin cut to 70 nm and 
visualised with an electron microscope. Granulated leukocytes (A) and other types of 
leukocyte (B) were negative for CXCR3. In the parenchyma of the brain, other cell types that 
resembled astrocytes were highly positive for CXCR3 (the arrows indicate gold particles). 
Scale bar= 1 pm
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3.4 Discussion
While the distribution of chemokine receptors in different populations of leukocytes has 
been well documented and reviewed (Olson and Ley, 2002; Kim, 2004), their expression 
on other cell types is still under investigation. Yet, evidence suggests that their role is more 
than just in leukocyte trafficking. For example, CXCR4 is known to be crucial for 
development, as CXCR4 knock-out mice are lethal at embryonic stage presenting 
haematopoietic signs, heart defects, and brain abnormality (Zou et al., 1998).
Several studies have reported chemokine receptor expression on endothelial cells, in 
particular on HUVEC as these cells are relatively easily to obtain and isolate. HUVEC 
express a wide range of CXCR chemokine receptors, whereas fewer CCR chemokine 
receptors are present on these cells (Gupta et al., 1998). Their functional role has been 
suggested to be as regulators of angiogenesis (Luster et al., 1995; Simonini et al., 2000), 
since chemokines modulate endothelial proliferative responses (Li et al., 2003a).
Here, the expression of a number of chemokine receptors in vitro on HBEC at the mRNA 
level by RT-PCR and at the protein level by immunocytochemistry and immunogold 
electron microscopy was studied. This last technique permits the identification of the 
subcellular distribution of the chemokine receptor within the cells. We have focused our 
attention on the chemokine receptors that are shown to be involved in MS namely CXCR1, 
CXCR3 CCR1, CCR2 and CCR5.
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3.4.1. Expression of CXCR chemokine receptors on human brain endothelial cells in 
vitro
In this study the expression of CXCR1, CXCR2 and CXCR3 by HBEC at the mRNA level 
and at the protein level was demonstrated. These receptors appeared to be mainly 
intracellular.
In vitro the environment to which the cells are exposed is very different to that in vivo. 
Most especially the very rich growth factor medium used for HBEC might influence the 
expression of chemokine receptors by these cells. Furthermore other resident cells of the 
brain could modulate the expression of the chemokine receptors in vivo, as it is well known 
for instance that astrocyte factors influence the phenotype of endothelial cells (Rauh et al., 
1992).
The intracellular localisation of the chemokine receptors might reflect the presence of 
chemokines in the culture medium and their binding to the receptor. Indeed, it has been 
shown that high concentrations of CXCL8 when bound to CXCR1 receptor result in its 
internalization and subsequent recycling (Matityahu et al., 2002). As shown in the previous 
chapter, CXCL8 can be released constitutively by HBEC. As for CXCR3, CXCL10 is not 
expressed at basal level, but CXCR3 binds two other ligands, CXCL9 and CXCL11, which 
could be constitutively produce by HBEC. Indeed, CXCL9 has been shown to be released 
by HBEC basally whereas CXCL10 is only released after IFN-y treatment (Salmaggi et al., 
2002).
HBEC were labelled for CXCR3 both at sub-confluence, when they are still dividing, and 
at confluence, when they are at a quiescent stage. In each case, CXCR3 was expressed at a 
similar level. These results are in contrast with the observations by Romagnani et al.
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(2001) who showed that the expression of CXCR3 is dependent on the cell cycle, and 
prominent in the S-phase and G2-M phase in endothelial cells.
Our findings are in agreement with Berger et al. (1999) in terms of CXCR1 and CXCR3 
expression in vitro, but not of CXCR2. A low expression of CXCR2 was detected in 
HBEC, and this expression was supported by RT-PCR analysis. In their study, Berger et al. 
(1999) used a different set of antibodies for CXCR2 which may account for the differences 
from our results. Another possibility is the presence of VEGF in the culture medium. This 
growth factor upregulates the expression of CXCR4 in HUVEC (Salcedo et al., 1999), and 
could have the same effect on CXCR2 on HBEC as both receptors share angiogenic 
properties. Effectively, the present culture medium used in this study contains growth 
factors such as VEGF, IGF, EGF, and FGF, whereas Berger et al. (1999) only used FCS. 
CXCR2 has been reported to be expressed some other endothelial cell types at low levels 
(Salcedo et al., 2000; Hillyer et al., 2003). In addition, Murdoch et al. (1999) detected the 
transcript for CXCR2 but could not detect its protein in HUVEC. CXCR2 expression has 
also been reported on murine brain endothelial cells (Otto et al., 2000).
3.4.2. Expression of CCR chemokine receptors on HBEC in vitro
By contrast with CXCR receptors, there is less evidence for CCR receptor expression on 
endothelial cells in vitro. Berger et al. (1999) showed the expression of CCR2A, CCR3 
and a weak expression of CCR5 on HBEC. Andjelkovic et al. (1999), using freshly 
isolated human brain microvessels, demonstrated the expression of CCR1, CCR2 and 
CCR5 by immunocytochemistry.
In this study, mRNA transcripts for CCR1 and CCR5 were detected in HBEC. The 
expression at the transcriptional level of CCR3 and CCR4 was not investigated. At the
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protein level, CCR3 and CCR5 were shown to be expressed, but CCR1 staining was 
negative.
The presence of mRNA transcript of CCR1 in RNA isolated from HBEC could arise either 
from contaminating cells in the preparation, or from the fact that the expression of CCR1 
protein at basal level is inhibited by post-transcriptional mechanisms. The expression of 
CCR1 is in agreement with Berger et al. (1999), also Andjelkovic et al. (1999) was able to 
show positive staining for CCR1 on microvessels. As the microvessels are freshly isolated, 
it is possible that the culture conditions may regulate the expression of CCR1. 
Alternatively, pericytes and/or perivascular cells but not endothelial cells, may express 
CCR1.
CCR2 was not detected in HBEC at either the transcript or the protein level. Yet it has 
been demonstrated to be expressed on HBEC by other groups (Andjelkovic et al., 1999; 
Berger et al., 1999) and to be functional in endothelial cells, as CCL2, the ligand for CCR2, 
induces an increase in the permeability of an endothelial cell monolayer (Stamatovic et al., 
2005). The antibodies used by the two other groups were different from ours, but that does 
not account for the lack of mRNA detection.
CCR5, which is increased in lesions in MS, is the receptor for CCL3, CCL4 and CCL5. Its 
low expression by HBEC has also been described by others (Berger et al., 1999) as well as 
on others endothelial cell types (Hillyer et al., 2003).
3.4.3. Expression of CXCR1 in situ
CXCR1 is an ELR positive chemokine receptor of the CXCR family. It is expressed on 
neutrophils (Godaly et al., 2000) and has high affinity for the ligands CXCL8 and CXCL6. 
The angiogenic effect of CXCR1 has been well described in vitro, and its expression on
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endothelial cells is well established (Simonini et al., 2000). CXCR1 expression has not yet 
been described in the human brain, but has been shown to be expressed in vitro by some 
resident cells of the brain such as astrocytes and microglia (Flynn et al., 2003). CXCR1 is 
also expressed on cholinergic neurons in vitro and CXCL8 induces a decrease in the Ca2+ 
current in those cells (Puma et al., 2001). In rat brain, mRNA of CXCR1 was widely 
distributed in different regions as determined by in situ hybridization although the cell 
types expressing CXCR1 were not investigated (Danik et al., 2003).
In this study, CXCR1 was shown to be expressed in human brain by a number of cell types, 
such as endothelial cells, or cells that were associated with the microvessels, using 
immunohistochemistry. In addition there were other cell types that were labelled for 
CXCR1. Some of these cells were also labelled by GFAP antibodies, suggesting a CXCR1 
positive population of astrocytes. Despite the fact that no previous studies showed CXCR1 
expression in the brain, our data are supported by previous in vitro work showing the 
expression of CXCR1 by cultured human astrocytes and microglia (Flynn et al., 2003). 
The GFAP negative population of CXCR1 brain-resident cells may consist of microglial 
cells, although co-staining with antibodies specific of microglial markers such as CD68 
may be needed to confirm this.
3.4.4. Expression of CXCR3 in situ
CXCR3 is an ELR negative member of the CXCR receptor family. It is the only known 
receptor for CXCL9, CXCL10 and CXCL11. CXCR3 expression receptor is a hallmark of 
activated T-lymphocytes. It has also been reported to be expressed in situ by CNS resident 
cells, such as a subpopulation of neurons, astrocytes and endothelial cells (Xia et al., 2000; 
Goldberg et al., 2001; Van Der Meer et al., 2001). CXCR3 was also found to be expressed 
on endothelial cells in other organs (Romagnani et al., 2001; Hillyer et al., 2003).
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The present study showing the expression of CXCR3 co-localising with vWF and GFAP,
is in accordance with previous findings (Van Der Meer et al., 2001). However, other
studies did not demonstrate the expression of CXCR3 by astrocytes. Sorensen et al. (2002)
and Kieseier et al. (2002) failed to show the expression of CXCR3 in NAWM of MS
brains, and its expression was exclusively associated with infiltrating lymphocytes in
lesions. The antibodies used in these studies are of different sources. By contrast, Goldberg
et al. (2001), using the same antibody from R&D as in our study, obtained similar results.
Whether different antibodies recognize different domains of the same protein, being more
or less accessible, still remain to be determined. Different patterns of staining using two
different antibodies for CXCR3, the 49801.111 clone (the same used in our study) and the
1C6 clone, has been discussed in the context of human glomerulonephritis (Segerer et al.,
2004). The clone 49801.111 revealed a wider variety of CXCR3 positive cells including
smooth muscle cells compared to the 1C6 clone. The clone 49801.111 was able to
recognize the new variant of CXCR3 receptor called the CXCR3-B (Lasagni et al., 2003),
which differs in its 52 amino acid N-terminal domain from the more classical form, the
CXCR3-A. The CXCR3-B form has been shown to be expressed by non-CNS endothelial
cells in vivo (Lasagni et al., 2003). Recognition of different epitopes by antibodies could
explain the absence of positive labelling for CXCR3 in HBEC and other cell types of
NAWM (Sorensen et al., 2002), in contrast with the present findings. Indeed another group,
using the same CXCR3 antibody as the one used here, detected CXCR3 positive glial cells
in NAWM (Simpson et al., 2000b). However, our results suggest that the variant form of
CXCR3, CXCR3-B, is expressed in the CNS, by the endothelial cells and by astrocytes.
The primers used to detect CXCR3 mRNA recognised both forms of the receptor and
hence could not give further information as to which type of CXCR3 was expressed by
*
HBEC.
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In MS lesions, CXCR3 was expressed by endothelial cells and by astrocytes, as well as on 
rounded cells in the perivascular space, most likely corresponding to infiltrating leukocytes. 
CXCR3 expression in MS lesions was more diffuse compared to NAWM. In response to 
inflammatory conditions, astrocytes in lesions becomes reactive (Holley et al., 2003) 
giving rise to gliosis. It is possible that a hypertrophic astrocytic reaction involving 
CXCR3 positive astrocytes would be responsible for a more diffuse staining for CXCR3 in 
MS lesions.
3.4.5. Subcellular localisation of CXCR1 and CXCR3 by immunogold labelling and 
electon microscopy
No previous studies have reported the localization of CXCR3 and CXCR1 in situ by 
immunogold labelling. An in vitro study Salcedo et al. (2000), as well as our observations 
on brain tissue, indicate that CXCR1 and CXCR3 chemokine receptors are expressed by 
endothelial cells and are partially located intracellularly. The number of gold particles was 
low on the endothelial cells compared to other cell types resembling astrocytes, although 
these results are obtained from post-mortem tissue where cytolytic damage may have 
differentially affected chemokine receptor expression by different cell types.
In this study, there is a trend towards a decrease of CXCR3 expression by HBEC in lesions. 
This decrease is higher in the MHC class II negative lesion than in the MHC class II 
positive. There has been debate about whether or not there is an increase in the number of 
blood vessels in the lesions. Kirk et al. (2004) showed an increase of the number of vessels, 
but it has been argued that this effect could originate from the shrinkage of the tissue 
related to myelin loss. The elevation in MS lesions of VEGF (Proescholdt et al., 2002), an 
important factor in vascularisation, would support the idea of an increase in the density of 
blood vessels in the lesions. As a result, it is possible that when angiogenesis is promoted, 
angiostatic receptors such as CXCR3 could be down-regulated as is the case in MS lesions.
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To answer this question, it would be interesting to study the effect of growth factors on 
CXCR3 expression.
In terms of subcellular localization, there appears to be an increase in the intracellular pool 
of CXCR3, and a decrease in the abluminal membrane localization in MS lesions. The fact 
that CXCL10 induces the internalisation of its receptor might account for the observed 
increase in the intracellular pool of CXCR3 (Campanella et al., 2003) as CXCL10 is 
increased in MS lesions in astrocytes (Sorensen et a l, 2002) and could explain the 
decrease of the receptor on the abluminal side but not on the luminal side. One group has 
suggested that CCR2 acts as a means of transport for its chemokine ligand, CCL2 across 
the BBB (Andjelkovic and Pachter, 2000). It is possible that the same case applies for 
CXCR3 and its ligand, as they are greatly increased in the lesions, mainly in the active 
lesions. However, experiments carried out at the Open University suggest that CXCR3 
does not transport CXCL10, as there is no inhibition by CXCL11 of CXCL10 trancytosis 
across non-brain human endothelial cells (D.Male, personnal communication). Whether 
this is the case for HBEC remains to be determined.
3.4.6. Conclusion
In this study, CCR1, CCR5, CXCR1, CXCR2 and CXCR3 are expressed by HBEC. 
CXCR1 and CXCR3 are strongly expressed in vivo. These two chemokine receptors are 
also present in situ, on endothelial cells but also on other cell types. Both CXCR1 and 
CXCR3 are located on the luminal and abluminal surface of the HBEC, although the 
highest proportion of receptors was located intracellularly.
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4. Chapter 4: Isolation and characterisation of a human brain
endothelial cell line: HCMEC/D3
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4.1 Introduction
The unique features of the BBB that restrict passage of cells and molecules from the blood 
into the brain are mainly associated with the expression of specific proteins, such as those 
at the tight junctions or efflux transporters, by HBEC. The specific pattern of protein 
expression differentiates HBEC from endothelial cells of other vascular beds. In vitro 
reconstruction models of the BBB are crucial for the understanding of the biochemical and 
immunological properties of brain microvascular endothelial cells. Primary cells and 
immortalised cell lines originating from different animal species such as bovine, rat and 
porcine endothelial cells are mostly used (reviewed by Deli et al. (2005)). Studies on 
HBEC are limited by the availability of brain tissue, and also by technical difficulties in the 
isolation method to yield highly pure endothelial cell cultures. Primary HBEC are rapidly 
overgrown by contaminating cells with a higher division rate such as astrocytes. In 
addition, HBEC in culture rapidly de-differentiate, lose their unique barrier phenotype and 
undergo senescence after a small number of passages further limiting their application to in 
vitro studies of the human BBB (Grant et al., 1998).
Immortalisation of a cell type allows unlimited access to material derived from a single cell 
clone. A number of brain endothelial cells from different species have been successfully 
created, such as the GP8 rat brain endothelial cell line (Greenwood et al., 1996) or the t- 
BBEC-117 bovine brain endothelial cell line (Sobue et al., 1999). In both cases, the cells 
were transfected with SV40 large T antigen to promote proliferation and avoid senescence. 
Primary cells in culture have a limited proliferative lifespan before they undergo 
permanent growth arrest, known as replicative senescence. When replicative senescence is 
bypassed by transformation with viral oncogene such as simian virus 40 large T antigen 
(SV40 LT), cells can gain additional lifespan.
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Attempts to immortalise HBEC have proven more difficult and SV40 large T transfection 
is not sufficient for the cells to express a stable phenotype. Stins et al. (1997) described an 
immortalised human brain endothelial cell line, expressing brain endothelial markers such 
as occludin but with an unstable phenotype (Callahan et al., 2004). Gu et al. (2003) 
transfected HBEC with the catalytic component of human telomerase reverse transcriptase 
(hTERT) to prevent telomere shortening following cell division, and obtained a stable cell 
line with a TEER of about 20 ohms.cm2. When adult somatic cells divide, their telomeres 
shorten by 10 to 200 bp per division (Von Zglinicki et al., 2000) because the cells do not 
contain functional telomerase. However, these authors did not investigate the expression of 
junctional molecules characteristic of HBEC.
A new human brain endothelial cell line, named hCMEC/D3, derived through expression 
of hTERT and SV40 large T antigen via a lentiviral vector transduction system was 
obtained from primary HBEC isolated as described in Chapter 2. In this chapter, some 
characteristics and properties of this novel human brain endothelial cell line are described 
and the cells are compared to other isolated cell clones in terms of expression of several 
brain endothelial cells markers, such as junctional proteins. In addition, chemokine and 
chemokine receptor expression by hCMEC/D3 cells are then analysed in order to verify the 
validity of this cell line to study in vitro leukocyte infiltration across the BBB during 
inflammation.
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4.2 Material and methods
4.2.1. Isolation of primaiy HBEC
Primary HBEC were isolated from a temporal lobe resection carried out at King’s College 
Hospital as described in Chapter 2 section 2.2.3. Cells were allowed to grow for 2 weeks at 
which point they were sent to our collaborator’s lab at the Institute Cochin in Paris (Dr. B. 
Weksler and Dr P.-O. Couraud) for immortalisation.
4.2.2. Immortalisation of HBEC
This part of the work was carried out at the Institut Cochin in Paris by Dr. B. Weksler. At 
passage 0, primary HBEC were incubated overnight with a DNA flap lentiviral vector 
encoding human Telomerase Reverse Transcriptase (hTERT) (lOOng p24units/ml) in 
normal growth medium. Following overnight incubation, the cells were washed and left to 
grow in normal growth medium for a further 2 days. Cells were then incubated with a low 
concentration of DNA flap lentiviral vector encoding SV40 large T antigen (20 ng 
p24units/ml) overnight. After washing, cells were grown at 37 °C in normal growth 
medium until sub-confluence. A week following lentiviral transduction with replication- 
defective lentiviral vectors, the absence of viral replication on HBEC was confirmed by 
detection of p24 in culture supernatants by ELISA. Two attempts at immortalising HBEC 
were made. On the second successful attempt, cloning was performed by me during a three 
month period at the Institut Cochin as described below.
4.2.3. Cloning
Individual cell clones were isolated by limiting dilution cloning. Sub-confluent lentivirally 
transduced cells were trypsinised and plated onto a 96 well collagen-coated plate at a 
density of 30 cells/plate to ensure the clonality of cells growing from one well. Each clone
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was initially screened according to their morphological appearance, their growth capacity 
and their inhibition contact properties assessed by observations on the morphological 
appearance of cells at confluence. Approximately 15 clones were selected. The selected 
clones were then further selected according to their stable expression of endothelial cell 
markers such as vWF, PECAM-1, p-catenin and ZO-1. One clone, termed hCMEC/D3, 
met all the above criteria and was selected for further investigation.
4.2.4. Cell culture
Both primary cultures of human brain endothelial cell lines and immortalised cell clones 
were cultured as described in Sections 2.2.1, 2.2.2 and 2.2.4
4.2.5. Transendothelial electrical resistance (TEER)
hCMEC/D3 cells were seeded on collagen-coated clear polyester membrane Transwell® 
filters (0.4 pm pore size, 1 cm2 surface area, Coming Costar Ltd, Buckinghamshire, UK) at 
a density of 105 cells/insert and grown to confluence (1-2 days). The medium was carefully 
aspirated, and replaced by sterile PBS. TEER across the cell monolayer and the insert was 
measured with an Endohm and a measurement chamber (model EVOM, World Precision 
Instruments, Sarasota, USA). The endohm chamber was sterilized with ethanol and rinse 
with PBS. The filter was placed in the steril chamber and a cap was placed aboved. Both 
the cap and the chamber contain each a voltage-sensitive silver/silver chloride pellet in the 
center plus an annular current electrode. The symmetrically apposing circular disc 
electrodes, situated above and beneath the membrane, allow a uniform current to flow 
across the membrane. The electrical resistance of a filter pre-coated with collagen was 
measured and the value obtained was subtracted from the resistance obtained with the 
hCMEC/D3 monolayer on inserts. TEER values are given in H-cm2.
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4.2.6. Paracellular permeability
Permeability buffer: Dulbecco’s Modified Eagle Medium (Invitrogen, Renfrewshire, UK),
1 OmM HEPES and 2% FCS.
hCMEC/D3 cells were seeded on collagen-coated clear polyester membrane Transwell® 
filters (0.4 pm pore size, 1 cm2 surface area, Coming Costar Ltd, Buckinghamshire, UK) at 
a density of 105 cells/insert and grown to confluence (1-2 days). The cells were washed 
once with sterile permeability buffer. The filters were transferred to a 12 well plate 
containing 1.5 ml/well of permeability medium. 0.5ml of 2mg/ml FITC-dextran of 70KDa 
(FD70) (Sigma-Aldrich, Dorset, UK) dissolved in permeability buffer was added in the 
upper chamber. The filters were transferred every 5 min into a fresh well containing 1.5 
ml permeability buffer for 30 min from the beginning of the experiment. The fluorescence 
diffusing to the bottom well was measured at 535nm with a fluorescence reader (model 
Flite, Wallar, USA). The cleared volume (in ml) represents the cumulative volume of 
FD70 solution passing through the cell monolayer. It is calculated as follows 
Cleared volume = (Fs -  Fb)/Fi
whereby Fs is the fluorescence per ml of the well (arbitrary units/ml), Fi is the fluorescence 
of the initial solution (arbitrary units) and Fb corresponds to the background fluorescence 
of the permeability buffer (arbitrary units/ml). The cleared volume was plotted against time. 
The slope of the curve allows calculation of the permeability coefficients (Pe in cm.min'1) 
of the endothelial cell monolayer using the following equation:
1/PS = 1 / me -1 / mf and Pe = PS / S
me and mf are the slopes of the curves corresponding to endothelial cells on filters and to 
filter only, respectively, in ml/min. PS is the permeability-surface area product of the 
endothelial cell monolayer (ml.min'1) and S is the surface area of the filter (1 cm2). Fig 4.1 
shows an example to illustrate how me and mf are calculated.
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Fig 4.1: Typical curve representing cleared volume of FITC-dextran 70KDa (FD70) 
vs time of an hCMEC/D3 monolayer (squares) and a collagen-coated filter (circles).
hCMEC/D3 were grown on Transwell filters until confluence. A FD70 solution was added 
to the upper chamber and the amount of fluorescence crossing the hCMEC/D3 monolayer 
determined every 5 min. The slope of the curves for the filter without cells (mf) and for the 
filter with confluent hCMEC/D3 cells (me) were used to calculate the permeability 
coefficient (Pe).
4.2.7. FACS analysis
Chemokine receptor expression by hCMEC/D3 cells of CCR1-6 and CXCR1-5 was 
determined by flow cytometric analysis under basal conditions and following stimulation 
with a combination of lOng/ml IFN-y and 500ng/ml TNF-a for 24 h. The concentrations 
of cytokines selected for this experiment were of the same order as those used for other 
experiments in Weksler et al. (2005). Cells were first washed with HBSS without Ca2+ and 
Mg2+ for 1 min and then aspirated. 0.25% w/v porcine Trypsin-EDTA was added for 5 min 
at 37 °C. Once the cells were detached from the extracellular matrix, trypsin was 
neutralised by addition of normal culture medium and the cells were spun at 300 g for 5 
min. The cells were fixed by suspending them in a solution of 4% PAF in PBS for 10 min
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on ice, and permeabilized for 1 min in 0.1% triton-XlOO in PBS at RT. Non-specific 
binding of antibodies was blocked by incubating cells with 10% goat serum for 30 min at 
RT. Around 500 000 cells per tube were incubated with a labelled antibody diluted to 1/3 
in 30pl at RT for CCR1-3, CCR5-6 and for CXCR1-CXCR5 using the antibodies listed in 
table 4.1. CCR4 (diluted to 1/100) was an unlabelled antibody thus requiring the addition, 
after the first antibody, of a FITC-conjugated goat anti-rabbit antibody (dilution of 1/200, 
from Chemicon, Hampshire, UK) for 1 h at RT. Between each step, the cells were rinsed 
with PBS and centrifuged at 300g for 5 min. After a final wash, the cells were re­
suspended in 0.5 ml PBS and the labelled fluorescence on the cells was read using 
FACSCalibur with CellQuest™ software (Becton Dickinson, Oxfordshire, UK). The 
median fluorescence of 10,000 cells per sample was read and used for statistical analysis 
after having subtracted the median fluorescence for the isotype controls or for cells 
incubated with secondary antibody alone.
163
Antigen Type Label Supplier
Human CXCR1 Monoclonal mouse 
IgG2A, clone #42705
Phycoerythrin R&D
Human CXCR2 Monoclonal mouse 
IgG2A, clone #48311
Phycoerythrin R&D
Human CXCR3 Monoclonal mouse 
IgGl, clone #48311
Phycoerythrin R&D
Human CXCR4 Monoclonal mouse 
IgG2A, clone #12G5
Phycoerythrin R&D
Human CXCR5 Monoclonal mouse 
IgG2B, clone #51505
Phycoerythrin R&D
Human CCR1 Monoclonal mouse 
IgG2B, clone #53504
Phycoerythrin R&D
Human CCR2 Monoclonal mouse 
IgG2B, clone #48607
Phycoerythrin R&D
Human CCR3 Monoclonal mouse 
IgG2A, clone #61828
Fluorescein R&D
Human CCR4 Polyclonal rabbit IgG No label Santa Cruz 
Biotechnology
Human CCR5 Monoclonal mouse 
IgG2B, clone #45502
Fluorescein R&D
Human CCR6 Monoclonal mouse 
IgG2B, clone #53103
Phycoerythin R&D
Mouse IgGl Normal mouse IgGl, 
clone #11711
Phycoerythrin / 
Fluorescein
R&D
Mouse IgG2A Normal mouse IgG2A, 
clone #20102
Phycoerythrin / 
Fluorescein
R&D
Mouse IgG2B Normal mouse IgG2B, 
clone #20116
Phycoerythrin / 
Fluorescein
R&D
Table 4.1: List of antibodies specific for the chemokine receptors used for FACS and 
immunocytochemistry analysis.
4.2.8. Capture ELISA
Chemokine levels in culture supernatants after 48 h cytokines stimulation were determined 
as described in Section 2.2.5.
4.2.9. Immunocytochemistry
Cells grown to confluence on collagen-coated Permanox Labtek slides were fixed, 
permeabilised and incubated with antibodies listed in Table 4.1 as described in Section 
2 .2 .6.1
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4.2.10. Western blotting
Laemmli’s buffer: 50mM Tris-HCl, 2% SDS, 0.1% bromophenol blue, 40% glycerol, 1 
mM sodium ortho vanadate and 50mM DTT
Running gel: 33% v/v Protogel (30% (w/v) acrylamide, 0.8% (w/v) bisacrylamide) 
(National Diagnostics, North Yorkshire, UK), 0.1% w/v SDS, 0.37M tris/HCl pH 8.8, 
0.03% v/v TEMED and 0.1% w/v APS (Sigma-Aldrich, Dorset, UK).
Stacking gel: 16.7% v/v Protogel (30% (w/v) acrylamide, 0.8% (w/v) bisacrylamide) 
(National Diagnostics, North Yorkshire, UK), 0.03% w/v SDS, 0.12M tris/HCl pH 6.8, 
0.03% v/v TEMED and 0.03% w/v APS (Sigma-Aldrich, Dorset, UK).
Running buffer: 25mM Tris, 192mM glycine, 1%SDS (National Diagnostics, North 
Yorkshire, UK)
Transfer buffer: 25mM Tris, 192mM glycine (National Diagnostics, North Yorkshire, UK), 
20% ethanol
Blocking buffer: PBS, 0.2% tween 20 and 2 % dry milk 
Washing solution: PBS, 0.2% tween 20
hCMEC/D3 cells were grown to confluence in collagen-coated 90 mm diameter Petri 
dishes either in normal medium or in differentiation media. At confluence, cells were 
either left in their respective culture medium or stimulated with 50ng/ml of TNF-a and 
lOOng/ml of IFN-yin normal medium for 48 h (according to what has been used for 
chemokine expression on HBEC). Cells were then washed with ice cold PBS containing 
ImM sodium orthovanadate, lysed in 250pl Laemmli’s buffer and lysed cells were scraped 
into an Eppendorf tube with a sterile scraper (Greiner Laboratories Limited, 
Gloucestershire, UK). In order to inhibit protein degradation induced by the presence of 
released intracellular proteases, the samples were heated at 95 °C for 5 min, a temperature
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at which most protein loses enzymatic activities due to denaturation. The samples were 
then stored at -20°C until further analysis.
On each lane of the stacking gel, a 15 pi sample was loaded and run in parallele with 
molecular weight markers ranging from 14.4 to 97.4 kDa or from 45 to 200 kDa (Bio-rad 
Laboratories, Hertfordshire, UK), at a constant voltage of 50V until the sample arrived at 
the interface between the stacking and the running gels and then at 150V until the visible 
bromophenol blue ran out of the gel. Electrophoresed proteins in the gel were transferred 
onto a Protan® nitrocellulose transfer membrane (Schleicher & Schuell UK Ltd, Greater 
London, UK), using a wet blotting system (Trans-blot cell systems, Bio-Rad Laboratories, 
Hertfordshire, UK) at constant amperage of 15 mAmps over night at 4°C. The membrane 
was quickly washed with Ponceau Red solution (0.1% Ponceau (w/v) in 5%acetic acid 
(v/v), Sigma-aldrich, Dorset, UK) to verify equal loading of samples on each lane.
Nitrocellulose membranes were incubated with blocking buffer for 1 h, followed by 
incubation with the primary antibody (in blocking buffer) for 1 h, at RT (see Table 4.2 for 
details of the primary antibodies used). After 5 consecutive washes with washing solution, 
the secondary antibody was added for 1 h, at RT. The secondary antibody was horseradish 
peroxidase conjugated anti-mouse IgG or anti-rabbit IgG according to the primary used at 
a dilution of 1/5000 or 1/20000 respectively (Pierce Biotechnology, Cheshire, UK ). The 
membrane was washed 5 times with washing buffer followed by a rinse with PBS only for 
10 min and developed using the ECL™ Western blotting detection reagents system 
(Amersham Pharmacia, Buckinghamshire, UK) for 1 min. Membranes were then exposed 
to Hyperfilm (Amersham Pharmacia, Buckinghamshire, UK) and developed in a Kodak X- 
OMAT automated processor (Rochester, USA).
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Antigen
specificity
Host species Concentration Expected size Gel % Company
PECAM-1 Mouse
IgGl
0.4pg/ml 130 kDa 6% Serotec
Beta-
catenin
Mouse IgGl 0.4pg/ml 94 kDa 10% Santa Cruz 
Biotechnology
ZO-1 Rabbit 0.5 jag/ml 225 kDa 6% Zymed
Occludin Mouse IgGl-
K
0.5pg/ml 65 kDa 10% Zymed
Claudin-3 Rabbit 0.5pg/ml 22 kDa 15% Zymed
Claudin-5 Mouse
IgGl
lpg/ml 22-24 kDa 15% Zymed
CXCL10 Rabbit 0.2pg/ml 8.5 kDa 15% Peprotech
CXCL10 Goat O.lpg/ml 8.5 kDa 15% R&D
CXCL8 Rabbit 0.2pg/ml 8.9 kDa 15% R&D
CCL2 Mouse
IgG2B
0.1 pg/ml 8.6 kDa 15% R&D
CCL5 Rabbit O.ljag/ml 7.8 kDa 15% R&D
Table 4.2: List of antibodies used in Westem-Blot. The final concentration of the antibody 
is given when the company gave the initial concentration otherwise the dilution factor is 
reported.
4.2.11. Statistical analysis
Statistical significance was determined by a one way or two way ANOVA, followed by a 
post hoc Tukeys f-test, or a student t-test. P<0.05 was considered significant.
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4.3 Results
4.3.1. Characterisation of initial endothelial clones: morphology and expression of 
junctional proteins
Following immortalisation, around 100 cell clones were obtained by limited dilution 
cloning from which 15 were initially selected based on their non-transformed morphology 
and their contact inhibited properties. Four different clones were further selected based 
upon their morphology which closely resembled those of primary HBEC (section 2.3.1). 
These clones were termed hCMEC/3G, hCMEC/3C8, hCMEC/14Dl and hCMEC/15A2. 
Cells were then screened for the expression of endothelial cell markers including PECAM- 
1, p-catenin, ZO-1 and vWF (figs 4.2 and 4.3). hCMEC/3G cells did not express p-catenin 
and ZO-1 was not located at the cell-cell junctions (fig 4.2). Rare expression of PECAM-1 
and p-catenin was detected located at the cellular junction, whereas no ZO-1 was detected 
for the clone hCMEC/3C8 (fig 4.2). Based on these observations, these two clones were 
not analysed further. Both hCMEC/14Dl and hCMEC/15Al cells expressed PECAM-1, p- 
catenin and ZO-1 at the cell-cell junctions and cells also showed intracellular staining for 
vWF (fig 4.3). Although these two clones appeared suitable as HBEC lines, their limited 
replicative lifespan and lack of stability in terms of expression of immortalising genes such 
as hTERT prevented their further use. Indeed, large polynucleated cells appeared in culture 
from passage 11, indicative of the presence of cells undergoing senescence (not shown). 
The number of cells displaying this phenotype in culture increased with passage, while 
their growth rate considerably decreased and their morphology became more 
heterogeneous.
The hCMEC/15A2 cell clone was further transduced with hTERT and sub-cloned by 
limited dilution cloning in order to obtain a more phenotypically stable cell line. A new
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clone, termed hCMEC/D3, showed a morphology reminiscent of both the parental 
hCMEC/15A2 clone and primary cells (fig 4.4) and was stable for at least 15 further 
passages (from passage 20 to 35). Similarly to hCMEC/15A2 cells, hCMEC/D3 cells 
expressed PECAM-1, p-catenin and ZO-1 at the cell-cell junctions (fig 4.5) as did the 
primary HBEC (section 2.3.2). The expression of these junctional proteins remained stable 
over several passages (fig 4.6). Claudin-5 could also be faintly detected at the cell borders 
while claudin-3 was distributed diffusely within the cytoplasm (fig 4.5).
4.3.2. TEER and paracellular permeability to FD70 of hCMEC/D3 monolayers
hCMEC/D3 monolayers grown to confluence on Transwell filters were tested for their 
permeability to FD70. The permeability coefficient of control hCMEC/D3 monolayers was 
on average of 2.67 10'5 ± 1.20 10'5 cm/min (table 4.3). This permeability coefficient was of 
the same magnitude as the values obtained with primary HBEC (table 4.3). TEER was on 
the contrary low, close to 10 ohms.cm2, reflecting a high ionic permeability, compared to 
HBEC. These results indicate that hCMEC/D3 constitutes an in vitro BBB model which is 
potentially suitable for the study of paracellular permeability, especially for molecules of 
high molecular weight.
Cells Permeability Coefficient to 
FD70 (cm/min)
TEER (ohms-cm2)
hCMEC/D3 2.67x1 O'05 (±2.09 10 9.66±3.33
HBEC (passage 2) 4.58x10™ 23.5 ±3.53
Table 4.3: Permeability coefficient and TEER for hCMEC/D3 cells and HBEC. Results 
presented are the mean ± S.E.M. of three different experiments for hCMEC/D3 and two 
different experiments for HBEC.
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4.3.3. Effect of BBB promoting factors on TEER and expression of junctional 
proteins by hCMEC/D3 cells
The influence of BBB promoting factors on the barrier phenotype of hCMEC/D3 cells was 
investigated. The expression of junctional proteins such as p-catenin, PECAM-1, ZO-1, 
occludin, claudin-3 and claudin-5 was determined by immunocytochemistry and Western 
blotting on hCMEC/D3 cells grown in differentiation medium and compared to control 
conditions. In the presence of differentiation medium, a change in the morphology of 
hCMEC/D3 cells was observed by phase contrast microscopy. The cells in normal medium 
were more elongated, whereas the cells in differentiation medium were more of a 
cobblestone shape (fig 4.7). Furthermore, a more regular and continuous cortical 
distribution was observed for p-catenin and ZO-1 in cells in differentiation medium 
compared to cells grown under basal conditions (fig 4.7). Differentiation medium did not 
induce redistribution of tight junctional proteins such as occludin and claudin-3 from the 
cytosol to the cell junctions. Nevertheless, all tight junction proteins investigated were 
expressed by hCMEC/D3 cells as shown by immunoblotting. Both occludin and claudin-3 
were up-regulated by treatment with differentiation medium whereas the expression of 
other tight junction proteins already present at the cell-cell junction such as p-catenin and 
ZO-1 and claudin-5 remained unchanged (fig 4.8). In parallel studies, hCMEC/D3 cells 
were grown to confluence on Transwell filters and the TEER hCMEC/D3 monolayers was 
determined. There was a slight but significant (P=0.001, n=3) increase in TEER when cells 
were grown with Differentiation medium compared to control cells (fig 4.9). Altogether, 
these data suggest that, as with HBEC (Torok et al., 2003), factors such as astrocytic- 
conditioned media and elevated intracellular cAMP levels are able to induce a tighter 
barrier phenotype in hCMEC/D3 cells.
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4.3.4. Cytokine-regulation of adhesion molecule expression by hCMEC/D3 cells.
ICAM-1, VCAM-1 and PECAM-1 are known to be expressed by endothelial cells either 
under basal conditions or following stimulation by cytokines (dos Santos et al., 1996). 
Flow cytometric analysis was used to determine the expression of these three adhesion 
molecules by hCMEC/D3 cells both constitutively and following incubation with 25ng/ml 
TNF-a for 48 h. ICAM-1 and PECAM-1 were strongly expressed at the basal level, while 
only a faint expression of VCAM-1 was detected (fig 4.10). When stimulated with TNF-a, 
there was a seven-fold increase in ICAM-1 (P=0.001, n=4) expression and a nine-fold 
increase in VCAM-1 (P=0.044, n=4) expression. By contrast TNF-a induced significant 
decrease in PECAM-1 expression (P=0.038, n=4) by 30 % compared to control cells (fig
4.11). Weksler et al. (2005) also demonstrated the expression of ICAM-2, CD40, CD44 
and MHC class II by hCMEC/D3 which followed a similar pattern of expression to that by 
primary HBEC (Bo et al., 1996; Omari and Dorovini-Zis, 2003), reinforcing the potential 
of hCMEC/D3 as a cell line suitable for immunological studies.
4.3.5. Constitutive and cytokine-induced chemokine production by hCMEC/D3 cells
Constitutive levels of CCL2, CCL5, CXCL8 and CXCL10 were measured in culture 
supernatants of confluent hCMEC/D3 cells for 48 h (fig 4.12). None of the chemokines 
determined were within the lower detection limit in the culture medium of control cells 
(~0.5ng/ml). Following treatment with IFN-y for 48 h, the release of CXCL10 into the 
supernatant was induced to 38+/-10.8ng/ml and a small, but non significant increase in 
CCL2 was detected (2.4+/-1.3ng/ml), although CXCL8 and CCL5 levels remained below 
the detection limit of the assay. By contrast, TNF-a induced the production of all 
chemokines tested, CCL2, CXCL8, (P=0.0001, P=0.003, n=3) CCL5, and CXCL10 (no 
statistical analysis due to the low number of experiments), to different concentrations (fig
4.12).
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The combination of IFN-y and TNF-a triggered a synergistic effect rather that an additive 
one for CCL5 and CXCL10. For example, stimulation with INF-y or TNF-a alone led to 
culture supernatant levels of 38ng/ml and 60ng/ml, respectively, but when the two 
cytokines were combined, the CXCL10 level rose to 231ng/ml (fig 4.12). By contrast, 
IFN-y had an inhibitory effect on CXCL8 production induced by TNF-a, leading to an 
almost two-fold decrease. Finally, IFN-y did not have any effect on the production of 
CCL2 when added to TNF-a (fig 4.12).
TGF-p alone (25ng/ml) had no effect on the chemokine production by hCMEC/D3 cells. 
When used in combination with other cytokines, TGF-p induced an inhibitory effect on 
TNF-a stimulation of CXCL8 (P=0.027, n=3) and CCL5 production by hCMEC/D3 cells 
leading to a four-fold and a 1.50-fold decrease respectively (fig 4.12).
4.3.6. Intracellular expression and compartmentalisation of chemokines in 
hCMEC/D3
CCL2, CCL5 and CXCL8 staining in the cytoplasm of hCMEC/D3 cells was negative, 
suggesting no intracellular stock of these chemokines at the basal level. Stimulation of 
cells with cytokines did not induce any changes in the pattern of chemokine staining (fig
4.13).
CXCL10 labelling in endothelial cells in vitro was conducted with three different 
antibodies originating from different species (fig 4.14). A mouse anti-human CXCL10, a 
rabbit anti-human CXCL10 and a goat anti-human CXCL10 were used. Similarly to the 
pattern of staining for primary HBEC, the three antibodies gave different patterns of 
staining. While untreated cells were faintly stained with the rabbit anti-human CXCL10, 
cells were not stained by the two other antibodies. When hCMEC/D3 cells were stimulated
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with the cytokines, there was a strong staining around the nucleus for the three antibodies. 
In addition small vesicles could be observed with both the mouse and the rabbit anti­
human CXCL10. The Westem-blot analysis, using both the rabbit anti-human CXCL10 
and the biotinylated goat anti-human CXCL10, revealed no band of the correct size 
(8.5kDa) for unstimulated cells, whereas a strong band appeared when the cells were 
stimulated with cytokines (fig 4.15). A number of bands of different molecular weight than 
the expected one of CXCL10 were also visible within the immunoblot (fig 4.15), 
suggesting that the antibody, in addition to CXCL10, binds non-specifically to a number of 
other proteins. This might explain why there was positive staining for CXCL10 by 
immunocytochemistry on unstimulated hCMEC/D3 cells. It is also possible that a band 
above that corresponding to CXCL10 could be the pro-peptide form of CXCL10 of a 
higher molecular size (about 14.5 kDa) and that this antibody, as opposed to the two others 
can recognise both CXCL10 forms.
4.3.7. Constitutive and cytokine-induced chemokine receptor expression
Chemokine receptors are important in inflammatory conditions and play a role in 
angiogenesis. In order to confirm that chemokine receptor expression by hCMEC/D3 cells 
was unchanged by lentiviral transduction of immortalising genes, the expression of CCR1- 
6 and CXCR1-5 was investigated by flow cytometric analysis under basal conditions and 
following stimulation with a combination of lOng/ml IFN-y and 500ng/ml TNF-a for 24 
h. The concentrations of cytokines selected for this experiment were of the same order as 
those used for other experiments in Weksler et al. (2005). hCMEC/D3 cells expressed all 
CXCR receptors tested, with a high expression of CXCR1 and CXCR3 and a lower 
expression of CXCR2, CXCR4 and CXCR5 (fig 4.16). There was a small but significant 
(P=0.023, n=3) up-regulation in CXCR3 expression following cytokine treatment (fig 
4.18). As for the CCR receptors, the expression of CCR3, CCR4, CCR5 and CCR6 could 
be detected while hCMEC/D3 cells were negative for CCR1 and CCR2 (fig 4.17).
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Following stimulation by cytokines, CCR1, CCR3 and CCR4 were slightly, but 
significantly up-regulated (P=0.044, P=0.038, P=0.002, n=3) (fig 4.18).
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hCMEC/3G hCMEC/3C8
P-catenin
PECAM-1
Fig 4.2: Immunocytochemical detection of P-catenin, ZO-1 and PECAM-1 in 
hCMEC/3G and hCMEC/3C8 clones.
hCMEC/D3 were grown on collagen-coated Labtek chamber slides, fixed, permeabilised 
with Triton X-100 and then processed for detection of p-catenin, ZO-1 and PECAM-1 
by immunocytochemistry. The immunocytochemical detection of PECAM-1 for the 
hCMEC/3G clone was not performed. Results are from one single experiment with 
single well. Scale bar=50pm.
175
hCM EC/14Dl hCMEC/15A2
P-catenin 
and vWF
ZO-1
PEC AM-1
Fig 4.3: Immunocytochemical detection of p-catenin, vWF, ZO-1 and PECAM-1 on 
hCMEC/3G and hCMEC/3C8 clones.
hCMEC/D3 were grown on collagen-coated Labtek chamber slides, fixed, permeabilised 
with Triton X-100 and then processed for detection of P-catenin, ZO-1 and PECAM-1 
by immunocytochemistry. The cells were co-labelled with vWF located in the cytoplasm 
and p-catenin located at the cell-cell junctions. Results are from one single experiment 
with a single well. Scale bar=50pm.
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Fig 4.4: Phase contrast micrographs of cultured hCMEC/D3.
hCMEC/D3 were grown on collagen-coated flasks until confluence. Phase contrast 
images were taken with a light microscope with a x 1 0  objective (left image) and a x 2 0  
objective (right image) showing monolayers of contact-inhibited closely apposed 
fusiform cells. Scale bar = 100 pm.
p-Catenin PECAM-1
ZO-1 Claudin-5
Claudin-3
Fig 4.5: Immunocytochemical detection of p-catenin, PECAM-1, ZO-1, Claudin-5 
and Claudin-3 labelling in hCMEC/D3
hCMEC/D3 were grown on collagen-coated Labtek chamber slides, fixed, permeabilised 
with Triton X-100 then processed for detection of p-catenin, PECAM-1, ZO-1, Claudin-5 
and Claudin-3 by immunocytochemistry. Results are representative o f three different 
experiments with a single well. Scale bar=50pm.
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Passage 20 Passage 27
P-Catenin
PECAM-1
Fig 4.6: Immunocytochemical detection P-catenin, ZO-1 and PECAM-1 in 
hCMEC/D3 at passage 20 (left) and passage 27 (right).
hCMEC/D3 were grown on collagen-coated Labtek chamber slides, fixed, permeabilised 
with Triton X-100 then processed for detection of p-catenin, ZO-1 and PECAM-1 by 
immunocytochemistry. Results are from one experiment. Scale bar=50pm.
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Normal medium Differentiation medium
P-catenin
ZO-1
Occludin
Claudin-3
Fig 4.7: Immunocytochemical detection P-catenin, ZO-1, Occludin and claudin-3 on 
hCMEC/D3 cells grown in normal medium (left) and in differentiation medium 
(right).
hCMEC/D3 were grown on collagen-coated Labtek chamber slides, fixed, permeabilised 
with Triton X-100 then processed for detection of P-catenin, ZO-1, occludin and claudin- 
3 by immunocytochemistry. Results are representative of three different experiments 
done with a single well. Scale bar=50pm.
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P -c a te n in  '
PECAM -1 i
Claudin-3
Claudin-5
Fig 4.8: Immunoblotting of P-catenin, PECAM-1, ZO-1, Occludin, Claudin-3 and 
Claudin-5 in hCMEC3 cells grown in normal medium (left) or in differentiation 
medium (right).
hCMEC/D3 cells were grown to confluence in normal medium or in differentiation 
medium on collagen-coated Petri dishes. Cells were lysed in Leammli’s buffer and lysates 
were subjected to electrophoresis on a 6 %, 10% or 15% polyacrylamide gel. 
Electrophoresed proteins were then transferred onto nitrocellulose membrane. Equal 
loading was checked using Ponceau red. The blots were probed with an anti P-catenin, 
PECAM-1, ZO-1, occludin, claudin-3 or claudin-5 antibody and an appropriate HRP- 
conjugated secondary antibody. The signal was then revealed by chemiluminescence. The 
blots are representative of experiments repeated twice.
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Basal Differentiation medium
Fig 4.9: Effect of BBB promoting factors on the TEER of hCMEC/D3 monolayers.
hCMEC3 cells were grown on collagen-coated Transwell filters and the electrical 
resistance was measured once the cells reached confluence (1-2 days). The TEER of cells 
grown in differentiation medium was significantly higher than control monolayer 
(P<0.05). Significance was tested by /-test. Results presented are the mean ± S.E.M. of 
three different experiments from single insert.
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Fig 4.10: Basal and TNF-a-induced ICAM-1, VCAM-1 and PECAM-1 expression in 
hCMEC/D3 cells by FACScan analysis.
hCMEC/D3 cells were fixed with 4% PAF, permeabilised with TritonX-100, labelled 
with antibodies specific for ICAM-1, VCAM-1 and PECAM-1, and analysed by FAScan. 
Representative FACScan histograms show the expression of unstimulated hCMEC/D3 
cells (black line) and hCMEC/D3 cells stimulated with 25 ng/ml TNF-a for 48 h (grey 
line). Cells not labelled with primary antibodies served as negative controls and are 
represented as grey filled histograms. The histograms are representative of experiments 
repeated four time.
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Fig 4.11: Basal and TNF-a-induced ICAM-1, VCAM-1 and PECAM-1 expression in 
hCMEC/D3 cells by FACScan analysis.
hCMEC/D3 cells were fixed with 4% PAF, permeabilised with TritonX-100, labelled 
with antibodies specific for ICAM-1, VCAM-1 and PECAM-1, and analysed by FAScan. 
Results are expressed as the median fluorescence for ICAM-1, VC AM- and PECAM-1 
expression by unstimulated hCMEC/D3 cells and hCMEC/D3 cells stimulated with 25 
ng/ml TNF-a for 48 h. Significance was tested on normalised values with a t-test 
(*=P<0.05). Results presented are the mean ± S.E.M. of four different experiments.
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Fig 4.12: Chemokine release into culture medium by hCMEC/D3 cells following 
stimulation by cytokines for 48 h.
Supernatants from confluent hCMEC/D3 monolayers were collected after 48 h 
stimulation with TNF-a (50ng/ml), IFN-y (lOOng/ml) and TGF-p (25ng/ml) or a 
combination of them and assayed by sandwich ELISA for chemokine production. Results 
presented are the mean ± S.D. of three different experiments for CXCL8  and CCL2, two 
for CXCL10 and CCL5 (one well per treatment). Significance was tested by ANOVA 
followed by a post hoc t-test for CXCL8  and CCL2, no statistic analysis could be 
performed for CXCL10 and CCL5 as the number of experiment was too small. * 
significant difference (P <0.05) versus the control; A significant difference (PO.OS) of 
sample treated with a combination of cytokines versus TNF-a treated sample.
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Fig 4.13: Immunocytochemical detection of CXCL8, CCL2 and CCL5 in 
hCMEC/D3 cells.
hCMEC/D3 cells were grown on collagen-coated Labtek chamber slides, fixed, 
permeabilised with Triton X-100 and then processed for detection of CXCL8 , CCL2 and 
CCL5 by immunocytochemistry in unstimulated cells (left column) or TNF-a (50ng/ml) 
and IFN-y (lOOng/ml) stimulated cells (right column). Results are representative of three 
different experiments. Scale bar = 50pm.
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Fig 4.14: Immunocytochemical detection of CXCL10 in hCMEC/D3 cells
hCMEC/D3 cells were grown on collagen-coated Labtek chamber slides, fixed, 
permeabilised with Triton X-100 and then processed for detection of CXCL10 by 
immunocytochemistry using three different antibodies, a mouse anti-human CXCL10, 
and rabbit anti-human CXCL10 and a goat anti-human CXCL10 in unstimulated cells 
(left column) or TNF-a (50ng/ml) and IFN-y (lOOng/ml) stimulated cells (right column). 
Results are representative of three different experiments. Scale bar = 50pm.
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Fig 4.15: Immunoblotting of CXCL10, CXCL8, CCL2 and CCL5 in hCMEC/D3 
cells at basal level and following stimulation with IFN-y and TNF-a.
hCMEC/D3 cells were grown to confluence on collagen-coated Petri dishes then 
stimulated for 48 h with lOOng/ml IFN-y and 50 ng/ml TNF-a or left unstimulated. Cells 
were lysed in Laemmli’s buffer and lysates were subjected to electrophoresis on a 15% 
polyacrylamide gel. Electrophoresed proteins were then transferred onto nitrocellulose 
membranes. The blots were probed with anti-CXCLlO, CXCL8, CCL2 and CCL5 
antibodies and appropriate HRP-conjugated secondary antibodies. The signal was then 
revealed by chemiluminescence. The blots are representative of experiments repeated 
twice.
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Fig 4.16: Basal and TNF-a and IFN-y-induced chemokine receptor expression in 
hCMEC3 cells by FACScan analysis.
hCMEC3 cells were fixed with 4% PAF, permeabilised with TritonX-100, labelled with 
FITC- or PE- labelled antibodies specific for CXCR1-5, and analysed by FAScan. 
Representative FACScan histograms show the expression of unstimulated hCMEC/D3 
cells (black line) and hCMEC/D3 cells stimulated with 500 ng/ml TNF-a and lOng/ml 
IFN-y for 24 h (grey line). Cells labelled with FITC- or PE- labelled isotope-matched 
antibodies are represented as grey filled histograms. The histograms are representative of 
experiments repeated three times.
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Fig 4.17: Basal and TNF-a and IFN-y-induced chemokine receptor expression in 
hCMEC3 cells by FACScan analysis.
hCMEC3 cells were fixed with 4% PAF, permeabilised with TritonX-100, labelled with 
FITC- or PE- labelled antibodies specific for CCR1-6, and analysed by FAScan. 
Representative FACScan histograms show the expression of unstimulated hCMEC/D3 
cells (black line) and hCMEC/D3 cells stimulated with 500 ng/ml TNF-a and lOng/ml 
IFN-y for 24 h (grey line). Cells labelled with FITC- or PE- labelled isotope-matched 
antibodies are represented as grey filled histograms. The histograms are representative of 
experiments repeated three times.
189
*□  B asa l
□  IFN+TNF
120 -
100
©  fc- 
3  C3 
—  i*
^  'Sa  1q 60 -
© -<3
CXCR1 CXCR2 CXCR3 CXCR4 CXCR5 CCR1 CCR2 CCR3 CCR4 CCR5 CCR6
Fig 4.18: Summary of chemokine receptor in hCMEC3 at constitutive level and 
when stimulated with TNF-a and IFN-y for 24 h.
Results are expressed as the mean fluorescence for CXCR1-5 and CCR1-6 expression by 
unstimulated hCMEC/D3 cells (white filling) and hCMEC/D3 cells stimulated with 500 
ng/ml TNF-a and lOng/ml IFN-y (grey filling) for 24 h. Significance was tested on 
normalised values by ANOVA with a post hoc t-test (*=P<0.05). Results presented are 
the mean ± S.E.M. of three different experiments.
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4,4 Discussion
In this study, the hCMEC/D3 cell line, a stable human brain endothelial cell line, was 
obtained by transduction of hTERT to prolong stable lifespan and of SV40 large T antigen 
to foster proliferation, using a new generation of lentiviral vectors that are efficient on 
slowly proliferating cells such as HBEC. This cell line was characterised, in the first 
instance for its properties to create a low permeability barrier, indicating functional 
retention of the physiological properties of the BBB. The expression of junctional proteins, 
such as p-catenin, PECAM-1, ZO-1, claudin-5 and claudin-3 was demonstrated by 
immunocytochemistry. The expression of junctional proteins, despite being slightly lower 
than in HBEC, appeared stable for a high number of passages. The expression of some 
junctional proteins such as occludin and claudin-3 was up-regulated in the presence of 
ACM and cAMP elevating agents, known to have barrier-phenotype promoting effects on 
brain primary endothelial cells (Rubin et al., 1991). Furthermore, on a functional level, 
hCMEC/D3 cells showed low paracellular permeability to FD70, of the same magnitude as 
primary HBEC. However, hCMEC/D3 cells showed a low value of TEER.
Endothelial cells from different organs display different patterns of expression of 
inflammatory molecules such as adhesion molecules, chemokines and chemokine receptors 
(Hillyer et al., 2003). The hCMEC/D3 cell line was therefore further characterised for its 
level of adhesion molecule expression, chemokines and chemokine receptors as well as for 
its response to cytokines such as IFN-y, TNF-a and TGF-p. Constitutive and cytokine- 
induced expression of adhesion molecules by hCMEC/D3 cells follow a similar pattern to 
that observed in HBEC. CXCL8, CCL2, CCL5 and CXCL10 levels of expression was 
within the same range as that of primary HBEC both at the basal level and when stimulated 
with cytokines alone or with a combination of cytokines, with the exception of CXCL10
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which, in contrast to primary endothelium, was induced by TNF-a. Expression of 
chemokine receptors by hCMEC/D3 cells was also similar to primary brain endothelium, 
although there was little increase in chemokine receptor expression following pro- 
inflammatory cytokine treatment.
4.4.1. Expression of endothelial junctional proteins by hCMEC/D3 cells in normal 
medium and in differentiation medium.
Confluent monolayers of hCMEC/D3 cells showed a subcellular localisation of BBB 
endothelial junction-associated molecules similar to primary HBEC. Nevertheless, the 
level of expression of junctional proteins appeared generally lower, and the junctional 
staining was neither as strong nor as continuous (section 2.3.3). In general, cultured HBEC 
lose their capacity to express certain tight junctional proteins over a number of passages, as 
shown by the results from section 2.3.3, where occludin and claudin-5 were not uniformly 
expressed by all cells, and junctional localisation of claudin-3 was rare. In cryofracture 
studies, the plasma membrane cleaves between the acyl tails of membrane phospholipids, 
leaving a monolayer on each half of the specimen. The E-face is the inner face of the outer 
lipid monolayer. The P-face is the inner lamella viewed from outside the cell. Claudin-3 
forms tight junctions associated with the P-face (Furuse et al., 1999). BBB endothelial 
cells in vivo reveal a P-face/E-face ratio of about 55/45 (Kniesel et al., 1996). 
Microvascular brain endothelial cells cultured in vitro form tight junctions, which are 
associated with the E-face (Wolburg et al., 1994). This effect was shown to be associated 
with a lower expression of claudin-3 (Liebner et al., 2000), which at the time the authors 
considered to be claudin-1. However, it was later demonstrated that the claudin-1 antibody 
used cross-reacted with claudin-3 (Wolburg et al., 2003). In non-blood-brain barrier 
endothelial cells such as pulmonary vessels, tight junctions are almost completely 
associated with the E-face (Schneeberger, 1982). Therefore it appears as if  brain 
endothelial cells in culture dedifferentiate towards a non-CNS endothelial phenotype. This
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phenomenon reinforces the idea that either the absence of factors present within the brain 
extracellular milieu or the culture conditions in vitro induce dedifferentiation of brain 
endothelial cells.
A number of factors present in the growth medium could be responsible for 
dedifferentiating endothelial cells in vitro such as IGF-1 known to enhance 
dedifferentiation in human neuroblastomas (Weber et al., 2003) or EGF that induce 
dedifferentiation in renal epithelial cells (Zhuang et al., 2005). FCS and serum-derived 
factors such lysophosphatidic acid and VEGF have been shown to alter the characteristics 
of brain endothelium (Nitz et al., 2003). Indeed, TEER values of porcine brain endothelial 
cells grown in serum were lower than those of cells cultured without serum (Nitz et al., 
2003). Furthermore, ZO-1, occludin and claudin-5 staining in these cells were redistributed 
from the cell periphery to the perinuclear cytoplasm in the presence of serum (Nitz et al.,
2003). In our study, hCMEC/D3 cells were cultured for much longer periods than primary 
cells in the presence of serum, which could account for the lower levels of junctional 
proteins when compared to primary HBEC.
Brain-derived factors absent in the culture medium may include those secreted by 
surrounding astrocytes that induce an increase in intracellular cAMP of endothelial cells. 
The combination of ACM and agents such as forskolin which activates adenylate cyclase 
and thus elevates levels of intracellular cAMP has been shown to be most effective in the 
improvement of barrier properties in cultured endothelial cells as it induced lower 
paracellular permeability and higher expression of tight junctional proteins (Rubin et al., 
1991; Wolburg et al., 1994; Rist et al., 1997). Wolburg et al. (1994) showed that bovine 
brain endothelial cells grown in ACM and cAMP expressed higher amounts of occludin 
and claudin-3 despite their failure to induce a more junctional localisation of these proteins. 
This is one indication that the ability to respond to astrocyte-derived factors and rise in
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intracellular cAMP is retained by transformed cell lines such as hCMEC/D3 cells. This is 
in agreement with Hamm et al. (2004) who showed no differences in the subcellular 
localisation of occludin, claudin-3 and claudin-5 between bovine brain endothelial cells in 
co-culture with rat astrocytes and cells which were first grown in the presence of rat 
astrocytes, but then the astrocytes were removed for 1 to 4 days. Astrocytes may be crucial 
for inducing the formation of tight junction but not for maintaining them in their proper 
subcellular localisation, as removal of astrocytes with 3-chloropropanediol in vivo in rats 
induced only a transient loss of junctional proteins such as ZO-1 and claudin-5 (Willis et 
al., 2004). Co-culture with rat astrocytes induced no differences in ZO-1 and p-catenin 
localisation in bovine brain endothelial cells (Hamm et al., 2004). However, in this study 
ZO-1 and p-catenin staining was more continuous when cells were grown in the presence 
of ACM and cAMP elevating agents.
Increased intracellular cAMP may therefore be one of the important contributing factors 
maintaining tight junction structure. Indeed there is a slight increase in ZO-1 expression at 
the junction in porcine brain endothelial cells when grown in ACM, but the elevation is 
markedly higher in the presence of both ACM and cAMP (Torok et al., 2003). 
Furthermore, increase in cAMPi has been shown to increase the gene expression of 
claudin-5 in porcine brain endothelial cells (Ishizaki et al., 2003). Alternatively, the up- 
regulation in tight junctional protein expression in response to cAMP might not be 
associated with an increase in TEER and a lower permeability. Indeed, improved electrical 
resistance levels are readily reversible since resistance decreases rapidly when cAMP 
levels return to normal (Rubin et al., 1991). Thus, the effects of cAMP on TEER are likely 
to be independent of gene transcription (Rubin et al., 1991). It is possible that cAMP 
regulates reorganisation of the cell cytoskeleton as untreated endothelial cell cultures 
contain actin stress fibers throughout their cytoplasm, but after cAMP treatment stress 
fibers become less abundant and the belt of filamentous actin at sites of cell junctions
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becomes more apparent (Rist et al., 1997). Other cells from the CNS might be important 
for inducing barrier properties, such as neurones (Tontsch and Bauer, 1991) or pericytes 
(Hayashi et al., 2004). In addition, pericytes have been reported to support survival of 
endothelial cells and to promote angiogenesis by secreting VEGF (Darland et al., 2003; 
Erber et al., 2004).
4.4.2. TEER and paracellular permeability to FITC-dextran 70kDa of hCMEC/D3 
monolayers
As mentioned previously in this Chapter and in Chapter 2, cerebral endothelial cells, when 
cultured, lose their characteristics and resemble peripheral endothelial cells. Furthermore, 
immortalisation of a cell type is often associated with dedifferentiation. hCMEC/D3 is a 
cell line that retains expression of tight junctional molecules such as occludin and claudin- 
5 despite their not being consistently detected at cell-cell contacts. In order to evaluate the 
tightness of the junctions of the hCMEC/D3 cell line, the permeability of a confluent 
hCMEC/D3 monolayer to FD70 was investigated as well as the resistance reflecting the 
ionic permeability. The permeability to FD70 obtained with hCMEC/D3 monolayers 
showed that despite the fact that the expression of occludin, claudin-5 and claudin-3 was 
not continuous at the cell-cell junctions, hCMEC/D3 showed lower permeability 
characteristics than a non brain endothelium monolayer such as HUVEC (Weksler et al., 
2005) or than a brain endothelial cell line from other species such as the rat line GPNT 
(Romero et al., 2003). The expression of other tight junctional proteins at the junction such 
as JAM-1 which also participates in permeability regulation (Martin-Padura et al., 1998) 
may have contributed to the lower paracellular permeability of hCMEC/D3 cells compared 
to other cell lines.
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The hCMEC/D3 cell line shows low TEER values which are not in agreement with the low 
permeability to paracellular marker observed. In this study, the low junctional localisation 
of the claudins and occludin probably results in the low resistance values given by 
hCMEC/D3 monolayers. Indeed, electrical resistance across cell monolayers reflect their 
ionic permeability. In epithelial cells of mice carrying a null mutation for occludin, 
alteration of occludin expression did not affect the transepithelial resistance (Saitou et al., 
2000). Occludin has been suggested to have a more important role in regulating 
paracellular permeability rather than in establishing the tight junction structure and 
properties (Baida et al., 2000). By contrast, localisation of claudins at the junctions is 
considered to be directly related to electrical resistance. Epithelial cells treated with 
clostridium perfringens enterotoxin which binds to claudin-3 and claudin-4 show low 
electrical resistance values (Sonoda et al., 1999). Claudins have been suggested to seal 
paracellular diffusion of tracers across the tight junction (Matter and Baida, 2003). This is 
further supported by the slightly higher resistance obtained with HBEC when treated with 
BBB promoting factors, in which there is an increased expression of occludin and claudin- 
3. In conclusion, hCMEC/D3 monolayers possess functional intercellular junctions which 
result in low permeability especially to hydrophilic proteins with a molecular mass higher 
than 4 KDa (Weksler et al., 2005), whereas the hCMEC/D3 cell line is a less valuable 
BBB model for small hydrophilic molecules and ions.
4.4.3. Expression of adhesion molecules by hCMEC/D3 cells
ICAM-1 is a major protein in the regulation of leukocyte adhesion to endothelial cells, and 
blocking ICAM-1 results in an inhibition of leukocyte infiltration (Alter et al., 2003). 
ICAM-1 has been reported to be expressed on brain endothelial cells and to be up- 
regulated by stimulation with cytokines in vitro (Fabry et al., 1992; Wong and Dorovini- 
Zis, 1992) as well as in vivo (Henninger et al., 1997; Komatsu et al., 1997). hCMEC/D3
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cells, similarly to primary HBEC, express high constitutive levels of ICAM-1 which are 
up-regulated by TNF-a stimulation.
VCAM-1 is expressed under basal conditions at very low levels by hCMEC/D3 cells. In 
primary HBEC, it has been shown that VCAM-1 is expressed at a low level (Stins et al.,
1997) similarly to primary rat brain endothelial cells (dos Santos et al., 1996). VCAM-1 
expression by hCMEC/D3 cells was induced by TNF-a after 48 h stimulation at a 
concentration of 25ng/ml. TNF-a has been shown to have a transient effect on VCAM-1 
expression by primary rat brain endothelial cells, with a maximum increase between 12 
and 24 h and a subsequent decline to basal levels (dos Santos et al., 1996). The rapid 
increase in VCAM-1 expression in response to TNF-a has been also described in human 
endothelium after 4 h (Stins et al., 1997). Thus it is possible that the small effect of TNF-a 
in up-regulating VCAM-1 is associated with either the low concentration used (25ng/ml) 
or the time of investigation (48 h). Larger effects on VCAM-1 expression was observed on 
hCMEC/D3 cells after 24 h cytokine stimulation and when the concentrations of cytokines 
used were higher (Weksler et al., 2005).
After 48 h of stimulation with TNF-a, there was a small decrease in the expression of 
PECAM-1. PECAM-1 is a junctional protein, and TNF-a increases the permeability of the 
BBB (section 5.3.2) (Deli et al., 1995). Hence, it is possible that cytoskeletal 
reorganization following increases in endothelial permeability by TNF-a results in 
decreased PECAM-1 expression despite its possible importance in transmigration. This 
observation has been previously reported on HUVEC (Shaw et al., 2001). Another protein, 
which acts both as an adhesion molecule important in transmigration as well as a junctional 
protein is JAM-1, and its expression is also decreased following stimulation with cytokines 
(Shaw et al., 2001).
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4.4.4. Chemokine expression by hCMEC/D3 cells
hCMEC/D3 cells showed overall little difference in the release of CXCL8, CXCL10, 
CCL2 and CCL5 into cell culture supernatants compared with primary HBEC using the 
same conditions as described in section 2.3.4.
CCL2 was detected in the supernatants of primary HBEC albeit at low levels, but is not 
released by hCMEC/D3 cells. This difference between primary and immortalised cells may 
be a direct consequence of promoting proliferation by introducing immortalising genes into 
cells. Effectively transformed BMEC also expressed little if any CCL2 at basal levels 
(Vanderkerken et al., 2002; Hillyer et al., 2003), whereas primary BMEC have been shown 
to express low levels of CCL2 in the culture medium (Pellegrino et al., 2005). It is 
therefore possible that the rate of cellular proliferation could affect chemokine production, 
with rapidly dividing cells producing less CCL2. However, Harkness et al. (2003) showed 
that addition of dexamethasone, a brain endothelial cell differentiating agent that decreases 
proliferation rate, to the culture medium decreased basal CCL2 production by an 
immortalised rat brain endothelial cell line (Harkness et al., 2003). In this study chemokine 
production was assessed in confluent monolayers of contact-inhibited cells and the same 
culture medium and growth factors were used for both primary and immortalised 
endothelial cells, hence it is highly unlikely that proliferation rate has influenced CCL2 
production. Moreover, no CCL2 was detected intracellularly, and this was confirmed by 
Western-blotting which is a more sensitive method. Alternatively, differences in CCL2 
production between primary and immortalised cells may be the result of the clonal nature 
of cell lines, whereas primary cultures consist of a heterogeneous population of cells.
As described in section 2.3.4, there are variations in CXCL8 production by primary HBEC 
isolated from different donors. CXCL8 production by hCMEC/D3 cells is well within the
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observed range for primary cells both at basal and stimulated levels i.e. no CXCL8 is 
present at basal level whereas low levels are detected when stimulated with cytokines. 
Similarly to some batches of primary HBEC, no CXCL8 was detected by 
immunocytochemistry either at basal level or when the cells were stimulated with 
cytokines for 48 h whereas a faint band for CXCL8 was detected in lysates of cytokine 
stimulated cells by western-blotting, suggesting low levels of intracellular CXCL8.
CCL5 and CXCL10 are both inducible chemokines and are not expressed at the basal level 
in primary HBEC. This is also the case for hCMEC/D3 cells. Cytokine stimulation induced 
a similar response in CCL5 secretion in both primary cells and hCMEC/D3 cells, whereas 
hCMEC/D3 cells, but not primary cells, released CXCL10 into the culture medium in 
response to TNF-a. It has been previously shown that most other endothelial cell types 
such as BMEC, SVEC, DMVEC, HUVEC and LMVEC (Briones et al., 2001; Hillyer et al.,
2003) also produced CXCL10 in response to TNF-a stimulation. The absence of an 
inductive effect by TNF-a in HBEC might constitute a specific property of brain 
endothelium that differentiates it from other vascular beds. However, as discussed earlier, 
the hCMEC/D3 cell line may represent an intermediate phenotype between brain and non­
brain endothelium, thus it is possible that TNF-a-induced CXCL10 production ensues as a 
result of brain endothelial cell dedifferentiation.
4.4.5. Chemokine receptor expression by hCMEC/D3 cells
The expression of chemokine receptors on primary HBEC was difficult to quantify by
techniques such as FACS analysis due to the low numbers of cells produced by the
isolation method. Hence it was not possible to compare their expression between
hCMEC/D3 cells and primary HBEC. Nevertheless the pattern of chemokine receptor
expression was similar for both primary and immortalised cells. Similarly to primary cells,
CCR1 and CCR2 were not detected at the protein level in hCMEC/D3 cells, whereas
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CCR3 and CCR5 were both present at low levels. By immunocytochemistry, CCR4 could 
not be detected on primary HBEC, whereas FACS analysis showed a low expression of 
CCR4 in hCMEC/D3 cells (table 4.4). CCR4 has been reported to be expressed by primary 
HBEC at low level by immunocytochemistry (Berger et al., 1999). It is possible that in our 
case, the antibody was not sensitive enough to detect CCR4 by immunocytochemistry, 
while FACS analysis was a more sensitive technique. In the CCR receptor family CCR6 
was also detected on hCMEC/D3. This is the first report of CCR6 expression by brain 
endothelial cells. CCR4 and CCR6 expression has been previously reported on DMVEC, 
LMVEC and SVEC, but not HUVEC (Hillyer et a l , 2003). Only CCR1 and CCR3 
expression increased when stimulated with 500ng/ml of TNF-a and lOng/ml of IFN-y after 
24 h. Transcript levels of CCR1 and CCR3 are increased in neutrophils when stimulated 
with IFN-y (Bonecchi et al., 1999). CCR2, as demonstrated for HBEC was absent and its 
expression could not be induced by cytokine simulation. CCR5 expression was unaffected 
by cytokine stimulation. This shows a special regulation of chemokine receptor expression 
by endothelial cells. Indeed in the case of leukocytes, CCR5 has been shown to be up- 
regulated in response to lOng/ml IFN-y and TNF-a on T cells (Juffermans et al., 2000).
CXCR1, CXCR2 and CXCR3 are expressed in a similar pattern by both primary human 
brain endothelial cell lines and hCMEC/D3 cells (table 4.4). CXCR4 was also expressed 
by hCMEC/D3 cells but only at low levels in primary cells. CXCR4 has been reported on 
primary HBEC (Berger et al., 1999; Mukhtar et al., 2002; Mukhtar et al., 2005), and is of 
particular interest as a co-receptor for HIV virus, and thus could be participating in the 
entry mechanism of the virus into the brain. Interestingly, CXCR5 was also detected by 
FACS analysis. This chemokine receptor is important in the development of normal 
lymphoid tissue and is mainly located on B cells and some T cells. This is the first time 
that CXCR5 was described on HBEC in vitro. In vivo, CXCR5 expression has been 
previously reported to be associated with blood vessels in primary CNS lymphoma (Smith
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et al., 2003). In this study, the authors demonstrate that CXCL13, the only known ligand of 
CXCR5, is produced within the tumour. It is possible that CXCL13 activation of CXCR5 
on brain endothelial cells may induce vascularisation of the tumour. However, it is unlikely 
as CXCL13 has been previously shown to have the opposite effect and to inhibit the 
angiogenic action of growth factors such as FGF-2 on HUVEC (Spinetti et al., 2001) and 
there is no evidence supporting an angiogenic effect for CXCL13. When compared among 
cells originating from different vascular beds, CXCR5 expression is variable, which may 
determine the nature of the response to CXCL13. CXCR5 expression has been 
demonstrated on SVEC, while little if any CXCR5 was present on HUVEC and none on 
BMEC, DMEC and LMVEC (Hillyer et al., 2003).
4.4.6. Conclusion
In this study we have obtained a stable human brain endothelial cell line, termed 
hCMEC/D3, by transduction of hTERT and SV40 large T antigen using highly efficient 
lentiviral vectors. A comprehensive characterisation of this cell line showed that cells 
retained expression of junctional proteins, specific to HBEC, which contribute to low 
permeability of large hydrophilic molecules. This cell line also represents an interesting 
model to study the role of HBEC in inflammation and infiltration of leukocytes into the 
CNS, as the expression of adhesion molecules, chemokines and chemokine receptors 
closely resembles the expression pattern of primary HBEC (table 4.4).
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HBEC HCMEC3
Junctional Proteins
PEC AM-1 + + + +
(3-Catenin + + + +
ZO-1 + + +
Claudin-5 + ±
Claudin-3 - -
Occludin ± -
Permeability Coefficient to 
FD70 (cm/min)
4.58x10'U5 
(±1.51 10'05)
2.61x10^ 
(±2.09 10*05)
TEER fohms.cm2') 23.5 ±3.53 9.66±3.33
Chemokime released(ng/ml)
CXCL8 basal 72(±27.2) 0
IFN-y 42(±12.5) 0
TNF-a 308(±60.5) 38(±15.2)
TGF-p 30(±13.1) 1(±0.9)
IFN-Y+ TNF-a 162(±31.1) 20(±2.2)
IFN-Y+ TGF-p 5 3 (±23.7) 1(±0.5)
TGF-P+ TNF-a 134(±23.5) 11 (±3.2)
CXCL10 basal 0 0
IFN-y 100(±16.5) 39
TNF-a 8(±2) 60
TGF-p 0 3
IFN-Y+ TNF-a 200(±50.9) 27
IFN-Y+ TGF-p 115(±26.8) 6
TGF-P+TNF-a 12(±4) 32
CCL2 basal 12(±3.8) 0
IFN-y 10(±2.7) 2(±0.8)
TNF-a 34(±8) 23 (±5.4)
TGF-p 15 (±4.6) 3 (±2.4)
IFN-Y+ TNF-a 36(±7.2) 27(±7.5)
IFN-Y+ TGF-P 16(±4.5) 6(±4.5)
TGF-P+ TNF-a 34(±6.9) 32(±13.2)
CCL5 basal 0 0
IFN-y 0 0
TNF-a 5(±3) 6
TGF-P 0 01
IFN-Y+ TNF-a 43 (±2.8) 37
IFN-Y+ TGF-p 2(±0.9) 2
TGF-P+ TNF-a 22(±4.7) 15
Chemokine exnression
Basal ± CXCL8 -
IFN-Y+ TNF-oc ± CXCL8/CXCL10 CXCL10
Chemokine receptor 
exnression
CCR receptor CCR3/CCR5 CCR3/CCR4/CCR5
CXCR receptor CXCR1 /CXCR2/CXCR3 CXCR 1 /CXCR2/CXCR3
Table 4.4: Summary of junction protein expression, permeability to FD70, TEER, 
chemokine release chemokine expression and chemokine receptor expression of HBEC 
andhCEMC3.
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5. Chapter 5: Effect of CXCL10 on the immunological and 
barrier function of human brain endothelial cells and astrocytes
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5.1 Introduction
CXCL10, because of its chemotactic effect on T lymphocytes, which are themselves 
involved in many autoimmune disorders, is of particular interest in MS. Indeed, CXCL10 
is found to be up-regulated in CSF (Mahad et al., 2002; Scarpini et al., 2002), and induced 
in MS lesions (Sorensen et al., 1999; Simpson et al., 2000b; Sorensen et al., 2002). 
Furthermore, HBEC, the first cells to be contacted by leukocytes in the transmigration 
process, express high levels of CXCR3, the only receptor for CXCL10 (Berger et al., 
1999).
The gene for CXCR3, unlike those for all other chemokine receptors, is located on the 
human chromosome Xql3 (Loetscher et al., 1998). CXCR3 has three ligands, CXCL9, 
CXCL10 and CXCL11, the latter binding CXCR3 with the highest affinity (Cole et al.,
1998). The three ligands have different binding sites on the extracellular loop of the 
receptor, allowing different responses. The N-terminus and the first extracellular loop 
mediate CXCL10 and CXCL11 responses, while the third extracellular loop is important 
for CXCL10 and CXCL9-induced chemotaxis (Xanthou et al., 2003). Similarly, specific 
intracellular domains are involved in response to different ligands. For instance, CXCL9 
and CXCL10 induced-CXCR3 internalisation is mediated by the C-terminus and P- 
arrestinl binding, while the third intracellular loop is required by CXCL11 (Colvin et al.,
2004). The C-terminus and a DRY sequence in the third trans-membrane domain are 
important for the chemotactic response induced by the three chemokines (Colvin et al.,
2004).
CXCR3 is a 364 amino acid G-protein coupled receptor with seven transmembrane 
domains (Lasagni et al., 2003). In addition, two alternative variants of CXCR3 have 
recently been identified (Lasagni et al., 2003; Ehlert et al., 2004). The CXCR3-B variant is
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a 416 amino acid receptor containing a longer N-terminus on the extracellular side, and 
differs from the original CXCR3, currently named CXCR3-A, in its first 52 amino acid 
residues. CXCR3-B is a receptor for CXCL4 as well as for the other three known ligands, 
CXCL9, CXCL10 and CXCL11. The other variant is the result of alternative splicing via 
exon skipping (Ehlert et al., 2004). This variant, termed CXCR3-alt, only has a predicted 
four or five transmembrane domain and an altered C-terminal domain (Ehlert et al., 2004). 
Cells transfected with CXCR3-alt displayed a chemotactic response towards CXCL11 only, 
and higher concentrations of the chemokine were needed to generate a response in 
comparison to the normal receptor variant (Ehlert et al., 2004).
Binding of a ligand leads to the activation of a range of signalling pathways. Binding of 
CXCL11, which is the most potent agonist, activates p42/p44 MAP kinase and 
Akt/phosphatidylinositol 3 kinase (Smit et al., 2003). The pathway responsible for the 
migration towards CXCL11 is mediated by Gai and a phospholipase C-dependant pathway 
(Smit et al., 2003). In human glomerular mesangial cells and pericytes, CXCR3 activation 
induces chemotactic properties, and also induces proliferation (Romagnani et al., 1999; 
Bonacchi et al., 2001). In these cells, the MAP kinase pathway induces these two effects, 
as PD98059, an inhibitor of p42/p44 MAP kinase partially inhibits the migration and 
completely inhibits the proliferative effect of CXCL10 on pericytes (Bonacchi et al., 2001). 
By contrast, CXCL10 has an anti-proliferative effect on endothelial cells in agreement with 
its angiostatic role (Luster et al., 1995). In endothelial cells, there is no increase in the 
calcium influx in response to CXCL10 (Salcedo et al., 2000). Lasagni et al. (2003) 
hypothesised that the different proliferative responses to CXCL10 between endothelial 
cells and non-endothelial cells may be the result of the exclusive expression of a different 
variant receptor by endothelial cells, specifically CXCR3-B which signals though a 
different pathway than the typical Gai pathway induced by CXCR3-A. Indeed, CXCR3-B 
transfected cells when stimulated with CXCL10, decreased their proliferation activity, and
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this effect was not blocked by Bordatella pertussis toxin, but was linked to an increase in 
the intracellular cAMP (Lasagni et al., 2003).
In this study, the role of CXCR3, strongly expressed by hCMEC/D3 cells (fig 4.16) on the 
endothelial barrier function and infiltration of leukocytes into the brain, was investigated 
following CXCL10 stimulation. The paracellular permeability of hCMEC3/D3 monolayers 
in response to CXCL10 was assessed, as well as the adhesion of a monocytic cell line, 
THP1, on endothelium activated by CXCL10. Furthermore, the functional expression of 
CXCR3 was confirmed by investigating the activation of signalling pathways in 
hCMEC/D3 cells in response to CXCL10.
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5 .2  Material and methods
5.2.1. Westem-blot
Stripping buffer: lOOmM p-mercapto-ethanol (Sigma Aldridge, Dorset, UK), 2%w/v SDS, 
62.5mM Tris/HCL pH 6.8.
hCMEC/D3 cells were grown to confluence on sterile 90 cm2 petri-dishes (Greiner 
Laboratories Limited, Gloucestershire, UK) and rested in serum-free medium for 48 h prior 
to stimulation. CXCL10 (lOOng/ml) was used to stimulate the cells at 0, 2, 5, 15, 30 and 60 
min.. Following stimulation, cells were lysed in Laemmli’s buffer and processed as 
described in section 4.2.9. The antibodies used are reported in table 5.1.
Following blotting with antibodies specific for the phosphorylated form of the signalling 
proteins, each nitrocellulose membrane was stripped and incubated with the antibody 
against the non-phosphorylated form of the protein in order to verify equal loading of 
samples on different lanes. This was achieved by washing the blot for 15 min in PBS 
followed by immersion in stripping buffer for 30 min at 50°C. After a final wash in PBS, 
the membrane was blocked and re-probed as previously described in section 4.2.9.
207
Antigen
specificity
Host
species
Concentration Expected
size
Company
Primary
antibody
Phospho-P42/44 
MAP kinase 
(pY1007pY1008)
Rabbit O.lpg/ml 42 and 44 
kDa
Biosource
International
Primary
antibody
P42 MAP kinase Mouse
IgG2a
lpg/ml 42 kDa Upstate
Biotechnology
Primary
antibody
Phospho-p38 
MAP kinase 
(Thrl80/Tyrl82)
Rabbit 1/1000 43 kDa Cell Signaling 
Technology
Primary
antibody
p38 MAP kinase Rabbit 1/1000 43 kDa Cell Signaling 
Technology
Primary
antibody
Phospho-
SAPK/JNK
(Thrl83/Tyrl85)
Mouse
IgGl
1/2000 46 and 54 
kDa
Cell Signaling 
Technology
Primary
antibody
SAPK/JNK Rabbit 1/1000 46 and 54 
kDa
Cell Signaling 
Technology
Table 5.1: List of antibodies used for Western-blotting. The final concentration of the 
antibody is given where the company gave the initial concentration, otherwise the dilution 
factor is reported.
5.2.2. TEER measurement
TEER was measured from confluent hCMEC/D3 monoloyers as explained in Section 4.2.4.
5.2.3. Paracellular permeability
Paracellular permeability to FD70 of a confluent hCMEC/D3 monolayer in response to 
CXCL10 stimulation (lOOng/ml for 48h) was proceded as in section 4.2.5. The 
concentration of CXCL10 was chosen according to the amount of CXCL10 secreted by 
HBEC (section 2.3.4.4).
5.2.4. FACS analysis
Adhesion molecule expression in response to CXCL10 was assessed by FACS analysis as 
in section 4.2.6.
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5.2.5. Adhesion of THP1 cells to hCMEC/D3 monolayers
5.2.5.1.Culture conditions and maintenance ofTHPl cells
THP1 medium was composed of RPMI medium, 20% Foetal calf serum, 50U/ml penicillin 
and 50pg/ml fungizone (Invitrogen, Renfrewshire, UK). THP1 cells were grown in 
suspension and after reaching a cell density of 106cells/ml, cells were split 1:2.
5.2.5.2.Cell adhesion assay
hCMEC/D3 cells were seeded onto 96 well plates at a density of 2xl05 cells per well 
(Greiner, Gloucestershire, UK) and grown to confluence. hCMEC/D3 cells were 
stimulated with lOOng/ml CXCL10 for 6, 24 and 48 h and with 25ng/ml TNF-a for 48 h, 
in a serum and growth factor free medium. The concentrations of TNF-a selected for this 
experiment were of the same order as those used for other experiments in Che et al., (2002). 
The concentration of CXCL10 was chosen according to the amount of CXCL10 secreted 
by HBEC (section 2.3.4.4). THP1 cells were labelled with radioactive chromium-51 (51Cr) 
administered from an aqueous sodium chromate stock solution (37 MBq, lmCi, Amersham 
Biosciences, Buckinghamshire, UK). Briefly. 106 THP1 cells were incubated in 100 pi of 
RPMI medium (Invitrogen, Renfrewshire, UK) with 100 pCi of 51Cr at 37°C for 1 h. The 
excess of 51CR was removed by 2 consecutive washes with RPMI medium by spinning the 
cells at 300xg for 5 min. hCMEC/D3 cells were then washed four times with warm 
medium and 2xl05 51Cr-labelled THP1 cells were added in 200 pi per well. After 1 h 
incubation at 37°C, loosely adherent or unattached THP1 were washed 4 times with warm 
medium, and the hCMEC/D3 monolayer plus the adherent THP1 cells were lysed in 150pl 
of 1% Triton X-100 for 10 sec. The cell lysates were transferred into Eppendorf tubes and 
the radioactivity was read on a 1470 automatic y-counter Wallac (Perkin Elmer 
Lifesciences, Cambridgeshire, UK). The percentage of adherent THP1 in each sample was 
calculated from the radioactivity of a control sample using the following formula:
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(cpm in the binding lymphocyte lysate / total cpm in input lymphocyte lysate) x 100.
5.2.6. Capture ELISA
Detection of CCL2, CCL5 and CXCL8 release in response to CXCL10 stimulation was 
determined using capture ELISA as described in section 2.2.5.
5.2.7. Statistical analysis
Significance was determined by a one way or two way ANOVA, followed by a post hoc 
Tukeys t-test. P<0.05 was considered significant.
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5.3 Results
5.3.1. Signal transduction pathways activated by CXCR3 in hCMEC/D3 cells
In order to assess whether CXCR3 expression on hCMEC/D3 cells was functional and 
whether CXCL10 could trigger the activation of signalling pathways in hCMEC/D3 cells, 
levels of phosphorylation of p42/44 MAP kinase, JNK kinase and p38 MAP kinase was 
analysed by western-blotting. Phosphorylation of the three kinases was observed when 
hCMEC/D3 cells were stimulated with lOOng/ml CXCL10 (fig 5.8). The level of p42/44 
and p38 MAP kinase phosphorylation was stronger than JNK kinase phosphorylation. 
Phosphorylation of p42/44 MAP kinase was observed after 5 min and reached a maximun 
at 15 min, whilst p38 kinase phosphorylation occurred slightly earlier, with a maximum 
phosphorylation at 5 min. JNK phosphorylation increased after 5 min and this level of 
phosphorylation was maintained at 15 min. At 30 min the level of phosphorylation of JNK 
was back to basal level (fig 5.1). In conclusion, CXCL10 stimulation of hCMEC induced 
activation of several signalling pathways including the three MAP kinases, p42/44 MAP 
kinase, p38 MAP kinase and JNK kinase.
5.3.2. Effect of CXCL10 on the permeability of hCMEC/D3 monolayers
CXCLlO-induced effects in the permeability to FD70 of hCMEC/D3 monolayers were 
determined in order to assess the role of this chemokine in the inflammatory-induced 
changes in barrier function observed in MS. The permeability of hCMEC/D3 monolayers 
was assessed following 3 h and 48 h stimulation with CXCL10 (lOOng/ml). As a positive 
control TNF-a-induced permeability changes were recorded in parallel (fig 5.2 & 5.3). 
Cleared volume versus time in response to CXCL10 stimulation for 3 h and 48 h or TNF- 
a  for 3 h was not significantly different to that of control cells (fig 5.2). As a result, there 
were no significant differences in the permeability coefficient of the endothelial monolayer
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(Pe) (fig 5.3). Stimulation of hCMEC/D3 monolayers with 25ng/ml TNF-a for 48 h 
resulted in a ten fold increase in the permeability coefficient of the hCMEC3 monolayer to 
FD70 (P=0.007, n=3)(fig 5.3). The TEER values of hCMEC/D3 cells also showed an 
decrease when the cells were treated with TNF-a for 48 h but not for 3 h, whereas no 
changes in TEER were observed for CXCL10 at either 3 or 48 h (fig 5.4).
5.3.3. Effect of CXCL10 on the adhesion of THP1 monocytic cells to hCMEC/D3 
monolayers: in vitro adhesion assays and adhesion molecule expression
In order to determine whether CXCL10 could modulate the adhesion of leukocytes to 
endothelial cells by direct activation of the endothelial cells, hCMEC/D3 were stimulated 
with CXCL10 for 3 h, 24 h and 48 h, prior to addition of THP1 cells and the percentage of 
cells adhering to the hCMEC/D3 monolayer was counted. As a positive control, the cells 
were stimulated for 48 h with TNF-a (25ng/ml) in the same way. The percentage of 
adherent THP1 cells to unstimulated hCMEC/D3 monolayer was 5.98±0.99% (n=3). 
CXCL10 did not increase the adhesion of THP1 cells to hCMEC/D3 monolayers following 
3, 24 and 48 h treatment, whereas 150% greater THP1 adherence to the TNF-a stimulated 
hCMEC/D3 monolayer was observed (P=0.007, n=3)(fig 5.5).
Expression of adhesion molecules on hCMEC/D3 cells were measured by FACS analysis 
after 3 h and 48 h stimulation with CXCL10 (lOOng/ml). In direct relation to the adhesion 
assay results, ICAM-1, VCAM-1 and PEC AM-1 were expressed at variable levels by 
hCMEC/D3 (fig 5.6), and were unaffected by CXCL10 stimulation for 3 h (fig 5.7) or for 
48 h (fig 5.8). Taken together, these data suggest that CXCLlO-induced adhesion of 
leukocytes to the endothelium is not a result of the direct activation of CXCR3 by 
CXCL10 on endothelial cells.
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5.3.4. CXCLlO-induced chemokine production by hCMEC/D3 cells
Release of CXCL8, CCL2 and CCL5 into the culture medium in response to CXCL10 
(lOOng/ml) stimulation for 48 h was quantified by sandwich ELISA. Basal production of 
CXCL8 and CCL2 was extremely low, whilst CCL5 was not detected. CXCL10 
stimulation did not induce up-regulation of these three chemokines (table 5.1). In 
conclusion, lOOng/ml CXCL10 did not modulate the production of CXCL8, CCL2 and 
CCL5 in hCMEC/D3 after 48 h.
Chemokines Basal chemokine production 
(ng/ml)
CXCL10 stimulated 
(lOOng/ml for 48 h) chemokine 
production (ng/ml)
CXCL8 0.17 ±0.07 0.23 ±0.1
CCL2 0.39 ±0.06 0.31 ±0.03
CCL5 Under limit detection (60pg/ml) Under limit of detection 
(60pg/ml)
Table 5.2: CCL2, CC15 and CXCL8 production at basal levels and in response to CXCL10 
stimulation (lOOng/ml) for 48 h on hCMEC/D3 monolayer.
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Fig 5.1: Time course of p42/44 MAP kinase, p38 MAP kinase and JNK 
phosphorylation induced by CXCL10 in hCMEC/D3 cells.
Confluent hCMEC/D3 cells were stimulated with 100 ng/ml CXCL10 for 1, 5, 15, 30 
and 60 min or unstimulated. For all phosphorylated proteins the nitrocellulose filters 
were dehybridised and reprobed with an antibody recognising the non-phosphorylated 
form of the protein to ensure equal loading. The Western blots shown here are 
representative of 2 (for p42/44 MAP kinase and p38 MAP kinase) and show one for 
SAPK/JNK.
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Fig 5.2: Clearance of FD70 through hCMEC/D3 monolayers stimulated with 
CXCL10 or TNF-a.
hCMEC/D3 cells were grown on Transwell filters until confluence. (A) Cells were 
stimulated with 100 ng/ml CXCL10 for 3 h (pink line) or 48 h (green line) before the 
permeability to FITC-dextran was determined. (B) Cells were stimulated with 25 ng/ml 
of TNF-a for 3h (pink line) or 48 h (green line) before the permeability to FD70 was 
determined. The cleared volume was calculated every five minutes for 30 minutes and 
was plotted against time to obtain clearance of FITC-dextran through the endothelial 
monolayer. Data are the means of duplicates from one representative experiment.
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Fig 5.3: Permeability coefficient of hCMEC/D3 monolayers to FD70 stimulated 
with CXCL10 or TNF-a.
hCMEC/D3 cells were grown on Transwell filters until confluence. Cells were 
stimulated with 100 ng/ml CXCL10 or 25ng/ml of TNF-a for 3 h or 48 h before the 
permeability to FD70 was determined. Significance was tested on normalised values by 
ANOVA with a post hoc t-test (*=P<0.05). Results presented are the mean ± S.E.M. o f 
three different experiments with duplicate wells.
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Fig 5.4: Effect of CXCL10 or TNF-a on the TEER of hCMEC/D3 monolayers.
hCMEC/D3 cells were grown on Transwell filters until confluence. Cells were 
stimulated with 100 ng/ml CXCL10 or 25ng/ml of TNF-a for 3 h or 48 h before the 
TEER was determined. Results presented are the means of two different experiments 
with duplicate wells.
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Fig 5.5: Effect of CXCL10 stimulation of hCMEC/D3 monolayers on the adhesion 
of ThPl cells.
hCMEC/D3 cells were grown on 96 well plates until confluence. hCMEC/D3 cells were 
stimulated with CXCL10 (100 ng/ml) for 3, 24 or 48 h, or TNF-a (25ng/ml) for 48 h and 
the adhesion of 51Cr labelled ThPl was determined. Significance was tested by 
ANOVA with a post hoc t-test (*=P<0.05). Results are from one representative 
experiment of three ± S.E.M. of triplicate wells.
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Fig 5.6: Basal and CXCLlO-induced ICAM-1, VCAM-1 and PECAM-1
expression by hCMEC/D3 cells by FACScan analysis.
hCMEC/D3 cells were fixed with 4% PAF, permeabilsed with TritonX-100, labelled 
with antibodies specific for ICAM-1, VCAM-1 and PECAM-1, and analysed by 
FAScan. Representative FACScan histograms show the expression of unstimulated 
hCMEC/D3 cells (black line) and hCMEC/D3 cells stimulated (grey line) with 100 
ng/ml CXCL10 for 3 h (left) or 48 h (right). Cells not labelled with primary antibodies 
served as negative controls and are represented as grey filled histograms. The histograms 
are representative of experiments repeated three times.
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Fig 5.7: Basal and CXCLlO-induced ICAM-1, VCAM-1 and PECAM-1 expression 
by hCMEC/D3 cells by FACScan analysis.
Results are expressed as the median fluorescence for ICAM-1, VC AM- and PECAM-1 
expression by unstimulated hCMEC/D3 cells and hCMEC/D3 cells stimulated with 100 
ng/ml CXCL10 for 3 h. Significance was tested on normalised values by ANOVA with 
a post hoc t-test (*=P<0.05). Results presented are the mean ± S.E.M. of three different 
experiments.
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Fig 5.8: Basal and CXCLlO-induced ICAM-1, VCAM-1 and PECAM-1 expression 
by hCMEC/D3 cells by FACScan analysis.
Results are expressed as the median fluorescence for ICAM-1, VC AM- and PECAM-1 
expression by unstimulated hCMEC/D3 cells and hCMEC/D3 cells stimulated with 100 
ng/ml CXCL10 for 48 h. Significance was tested on normalised values by ANOVA 
with a post hoc t-test (*=P<0.05). Results presented are the mean ± S.E.M. of three 
different experiments.
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5.4 Discussion
In this chapter, the role of CXCL10, one of the ligands of CXCR3 that is highly expressed 
by both primary HBEC and hCMEC/D3 cells was investigated. CXCL10 facilitates the 
infiltration of leukocytes into the brain by acting on the permeability properties and the 
immunological properties of the endothelial cells. Brain endothelial cells, the main 
component of the BBB, form a physical barrier protecting the brain and restricting the 
infiltration of immune cells. Furthermore, they express lower levels of adhesion molecules, 
such as VCAM-1 at resting levels (dos Santos et al., 1996), therefore, we hypothesized that 
CXCL10, present in the MS brain at high levels, would modulate the immunological and 
permeability characteristics of the brain endothelium.
CXCR3 was first confirmed to be an active receptor on hCMEC/D3 since phosphorylation 
of three different MAP kinase pathways; p42/44 MAP kinase, p38 MAP kinase and 
SAPK/JNK, at different time points, was observed following stimulation with CXCL10 
when stimulated with CXCL10. As p38 and/or p42/44 MAP kinase and/or SAPK/JNK are 
involved in physiological responses of endothelial cells that have been shown to promote 
the infiltration of leukocytes such as release of chemokines (Hashimoto et al., 1999; Marin 
et al., 2001), adhesion molecules expression (Pietersma et al., 1997; De Cesaris et al.,
1999) and increase in permeability (Nwariaku et al., 2003), changes of permeability, 
chemokine release or adhesion molecule expression by hCMEC/D3 in response to 
CXCL10 was investigated.
CXCL10, at a concentration of lOOng/ml had no effect on the permeability to FD70 of an
hCMEC/D3 monolayer, and did not induce any changes in the TEER, which could imply
that the opening of the BBB in MS is not directly correlated with CXCL10 expression in
MS lesion. In contrast, TNF-a, which has previously been reported to affect the integrity
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of the BBB by translocation of junctional proteins (Ozaki et al., 1999), is here confirmed to 
increase the permeability and decrease TEER of hCMEC/D3 monolayer at a concentration 
of 25ng/ml for 48 h.
hCMEC/D3 adhesive properties toward THP1 cells also remained unchanged in response 
to CXCL10 treatment, and the level of adhesion molecules, ICAM-1, VCAM-1 and 
PECAM-1 was not altered. Furthermore, there was no apparent up-regulation, induced by 
CXCL10, of the release of three different chemokines that can be expressed by HBEC as 
determined previously (section 2.3.4).
5.4.1. Signal transduction pathways induced by CXCL10 stimulation in hCMEC/D3 
cells
Stimulation of hCMEC/D3 cells with CXCL10 at lOOng/ml induced phosphorylation of 3 
different types of MAP kinases, p42/44 MAP kinase, p38 MAP kinase and SAPK/JNK. 
The activation of these kinases was short lived; about 10 min for p38 MAP kinase and 
SAPK/JNK, and a longer activation for p42/44 MAP kinase. This suggests that CXCR3, 
the only receptor for CXCL10 which is expressed on hCMEC/D3 cells, is coupled to a 
signalling pathway and may induce a physiological response. In these cells, the p42/44 
MAP kinase phosphorylation response to CXCL10 has already been described in other cell 
types such as pericytes (Bonacchi et al., 2001) starting 15 min after stimulation and is 
maximal at 60 min, in astrocytes (personal communication, S. Maru) with the same pattern 
of stimulation as the one observed with hCMEC/D3, as well as in neurons after 15 min 
stimulation (Xia et al., 2000). p42/44 MAP kinase activation is generally associated with 
proliferation, but also regulates cell differentiation, migration and survival, amongst other 
processes, as reviewed by Ebisuya et al. (2005). Cell proliferation in response to CXCL10 
has been reported in several cell types such as pericytes (Bonacchi et al., 2001) and 
astrocytes (personal communication, S. Maru) however not for endothelial cells, on which
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it could exert an angiostatic effect and to inhibit the angiogenic effect of growth factors 
such as bovine FGF (Angiolillo et al., 1995). It would have been interesting to confirm this 
effect on hCMEC/D3. In fact, the duration and magnitude of the p42/44 MAP kinase 
activity has been suggested to regulate physiological responses. For example, a strong 
activation of p42/44 MAP kinase activity causes cell-cycle arrest (Roovers and Assoian,
2000), as it stimulates the cyclin dependent kinase inhibitor p21, causing a decrease in the 
activity of cyclin dependent kinase, and in turn, the arrest of the cell in G1 of the cell cycle 
(Sewing et al., 1997). The transient activation of p42/44 MAP kinase in brain endothelial 
cells might be too small to induce any proliferative responses. However added to VEGF, 
which has been already shown to induce a strong p42/44 MAP kinase activation (Wong 
and Jin, 2005), CXCL10 might enhance the level of phosphorylation of p42/44 MAP 
kinase enough to stimulate the cyclin dependent kinase inhibitor p21, hence inhibiting the 
VEGF proliferative effect.
p38 MAP kinase and SAPK/JNK phosphorylation in response to CXC10 stimulation has 
not been reported before. The p38 MAPK signalling pathway plays an important role in 
inflammation and other physiological processes. The p38 MAP kinase pathway is activated 
in response to TNF-a stimulation of endothelial cells (Hashimoto et al., 1999). In the case 
of TNF-a, p38 MAP kinase activation leads to an increase in the permeability of HUVEC 
monolayer via formation of stress fibres (Kiemer et al., 2002), causes the up-regulation of 
CXCL8 (Hashimoto et al., 1999), and increases the surface expression of VCAM-1 but not 
ICAM-1 (Pietersma et al., 1997). Inhibitors of p38 MAP kinase such as the diaryl 
imidazoles (for example SB203580 or SB202190) were proven to be anti-inflammatory in 
animal models such as those for rheumatoid arthritis (Kumar et al., 2003). A major 
function of the p38 MAP kinase pathway is post-transcriptional control of inflammatory 
gene expression. Many of the mRNAs are unstable (or untranslatable) because of AU-rich 
elements in the 3'untranslated region. Signalling in the p38 pathway counteracts these and
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stabilizes the mRNAs by preventing their otherwise rapid de-adenylation, as is the case for 
CXCL8 (Rot et al., 1996). Nevertheless, p38 MAP kinase phosphorylation, in response to 
CXCL10, does not induce the same response in endothelial cells, as we have demonstrated 
that there were no changes in permeability, CXCL8 or VCAM-1 expression. p38 MAP 
kinase activation has been implicated in other cell functions such as cell differentiation, in 
senescence, in apoptosis and in G1 and G2/M phases of the cell cycle, as reviewed by 
Zarubin and Han (2005). CXCL10 could play a role in some of these functions in 
endothelial cells, and this would need to be further investigated.
5.4.2. Effect of CXCL10 on the permeability of hCMEC/D3 monolayers
Permeability assays of hCMEC/D3 cells, grown on filters, to FD70 demonstrated no effect 
of CXCL10. IFN-y has been shown to induce a decrease in TEER and increase in 
permeability of non-brain endothelial cell monolayers such as HUVEC (Huynh and 
Dorovini-Zis, 1993; Dewi et al., 2004) with a time lag suggesting that the IFN-y effect is 
not direct but dependant on an additional inflammatory mediator affecting endothelial 
permeability. Some of these factors have been identified, such as NO or MMP (Lou et al., 
1999; Wong et al., 2004). IFN-y also induces the production of CXCL10, and both primary 
HBEC and hCMEC/D3 cells express high levels of CXCR3, the unique receptor for 
CXCL10. In this study, CXCL10 did not appear to have any effect on the permeability of 
hCMEC/D3 cells. CCL2, another chemokine, has been showed to increase the permeability 
of mouse brain microvascular endothelial cells rapidly within 2 h (Stamatovic et al., 2005). 
The increase in permeability is suggested to be due to the delocalisation of tight junction 
proteins from the membrane into the cytoplasm, and the formation of stress fibres 
(Stamatovic et al., 2003). After 20 h, CCL2 also decreases the expression of both occludin 
and ZO-1 in mouse brain endothelial cells (Song and Pachter, 2004). The increase in 
permeability of endothelial cell monolayers in response to CCL2 has been associated with 
its angiogenic properties. CXCL10 is an angiostatic chemokine, inhibiting proliferation of
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HUVEC in vitro (Luster et al., 1995). However the angiostatic effect of CXCL10 was not 
observed by all (Angiolillo et al., 1995)(personal communication, P. Hillyer). The 
angiogenic properties of chemokines such as CCL2 and CXCL8 include the capacity of the 
endothelial cells to detach from their actual location, proliferate and migrate into the tissue 
to form new vessels. CCL2 and CXCL8 regulate production of proteins that affect 
permeability, such as MMP-1 (Galvez et al., 2005). Other chemokines such as CCL2, 
CCL3, and CX3CL1 were also shown to increase MMP-9 secretion by primary isolated rat 
brain microglia in vitro (Cross and Woodroofe, 1999). In summary, CXCL10 alone does 
not appear to induce an increase in permeability of brain endothelial cell monolayers. This 
effect may be cell specific as ligand stimulation of CXCR3 in multiple myeloma cell lines 
increases MMP-2 and MMP-9 activity in the culture medium, but not in bone marrow 
plasma cells (Pellegrino et al., 2004). It is possible that CXCL10 acts on the circulating 
leukocytes expressing CXCR3, which can, once activated by CXCL10 or any other ligand 
of CXCR3, induce the opening of the BBB. Indeed, it has been demonstrated that the 
binding of reactive leukocytes increases the permeability in non-brain endothelial cell 
monolayers (Damle and Doyle, 1990).
Furthermore, CXCL10 is not able to induce significant transendothelial migration of 
unstimulated T lymphocytes in contrast to other chemokines such as CCL5 or CCL3 (Roth 
et al., 1995). This would further suggest the lack of a direct effect of CXCL10 on the 
endothelial cells. Only FITC-dextran of a molecular size of 70kDa was tested but 
hantavirus infection of LMEC, which induces production of CXCL10, failed to increase 
the permeability of the LMEC monolayer to FITC-dextran of 3, 10, 40 and 70 kDa 
(Sundstrom et al., 2001). If the response of hCMEC/D3 to CXCL10 is similar to LMEC, it 
is possible that CXCL10 has no effect on paracellular permeability. Nevertheless, the 
permeability of endothelial cells can be regulated at many different levels, such as the 
transcellular activity, which is not reflected using FITC-dextran, and could also be
224
modified with CXCL10. Before reaching a conclusion it would be important to investigate 
whether CXCL10 induces any changes in pinocytic activity.
5.4.3. Adhesion of THP1 cells to hCMEC/D3 monolayers in response to CXCL10 
stimulation
The percentage of adhesion of THP1 cells to hCMEC/D3 monolayers at basal levels is 6 % 
after 1 h and is increased three-fold by TNF-a treatment of the endothelial cells. In order to 
avoid a masking effect of the serum in the medium, endothelial and THP1 cells were in 
medium both serum and growth factor free medium at the time of the stimulation, and at 
the time of the experiment. This could explain the low percentage of adhesion obtained 
compared to others who obtained an adhesion of 28% of monocytes to HUVEC (Zhang 
and Issekutz, 2002) and 28% activated lymphocytes have been shown to adhere to HUVEC 
(Taub et al., 1993), also this is not directly comparable with the results of this study as 
monocytes were used, and activated lymphocytes could show different adhesion properties 
to hCMEMC/D3 monolayer. Other studies have also reported a low 5 % adhesion of 
another monocyte cell line, the U937, onto endothelial cells (Cavender et al., 1991). Serum 
is known to contain factors that promote the expression of adhesion molecules on 
endothelial cells (Lozada et al., 1995) but this effect is not apparent with heat-inactivated 
serum. Nevertheless, the absence of serum in the medium did not affect the response of the 
endothelial cells, as the adhesion of THP1 to TNF-a treated hCMEC/D3 increased 
compared to unstimulated monolayers, as has been previously reported (Che et al., 2002). 
Another factor is the low expression of VCAM-1 on the brain endothelial cells compared 
to the other vascular endothelial cells (dos Santos et al., 1996), and also monocyte 
adhesion is dependent on VCAM-1. Indeed Floris et al. (2002) demonstrated that blocking 
VCAM-1 effectively blocked the adhesion of monocytes, and conversely, that the 
transfection of HUVEC with VCAM-1 could enhance the adhesion of monocytes by 
100 % (Gerszten et al., 1998). CXCL10 did not upregulate VCAM-1 expression on brain
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endothelial cells which adds further evidence for the absence of a direct modulating effect 
of CXCL10 on the adhesive properties of brain endothelial cells.
Subcutaneous administration of human CXCL10 in immune deficient mice, and the 
intraperitoneal injection of human peripheral blood lymphocytes were used to demonstrate 
the recruitment of monocytes and lymphocytes in response to CXCL10 in vivo (Taub et al.,
1996). There is an important physiological component, as the migration response towards 
chemokines differs in vitro and in vivo. T lymphocytes migrated towards CXCR3 ligands 
in vitro but showed little chemotaxis in response to CCR5 ligands, such as CCL5 (Stanford 
and Issekutz, 2003). In vivo, using subcutaneous chemokine injections, lymphocytes were 
recruited in large numbers in response to CXCL10 and CCL5 but to a lesser extent to 
CXCL9 and CXCL11 (Stanford and Issekutz, 2003). In addition, in vitro data showed that 
CXCL10 induced migration of monocytes and activated lymphocytes (Taub et al., 1993) 
and that anti-CXCLlO antibodies partly blocked the transendothelial chemotactic 
migration of IL-2 activated peripheral blood lymphocytes across an IFN-y stimulated 
HUVEC monolayer (Salmaggi et al., 2002). In the present study, CXCL10 prestimulation 
of endothelial cells at different time points had no effect on the adhesion of THP1 on the 
hCMEC/D3. This suggests that the increased adhesion of monocytes to endothelial cells in 
the presence of CXCL10 originates from the activation of monocytes only. CXCL10 has 
been shown to induce T cell adhesion to purified ICAM-1 and VCAM-1 via an increase in 
the p-land P-2 integrins avidity (Lloyd et al., 1996), and in the case of migration assays 
this might be sufficient to increase leukocyte infiltration. Indeed, this increase in integrin 
avidity would mean an increase in ICAM-1 and VCAM-1 cross linking on the endothelial 
cells, which has been shown to result in cytoskeleton changes (Adamson et al., 1999), and 
an increase in permeability in the case of VCAM-1 cross-linking (van Buul et al., 2002), 
thereby facilitating the transmigration of the leukocytes across the barrier formed by the 
closely apposed brain endothelial cells.
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In vivo, endothelial cells present the chemokines, bound onto the proteoglycans, to the 
passing leukocytes. There is no increase of adhesion of THP1 even after 3 h of CXCL10, 
which suggests that the chemokines are not retained at the surface of the endothelial cells 
in this period of time. This is in agreement with the results of Hillyer and Male (2005) 
showing that chemokines such as CCL5 and CCL3, bound to the surface of the 
endothelium, are removed within 150 min, and furthermore, that CXCL10 binding is low 
and only present on DMVEC and LMVEC, while non existent on HUVEC. The study by 
Luster et al. (1995) is the only report describing binding of CXCL10 on proteoglycans of 
endothelial cells. It would have been interesting to include an earlier time point to 
determine whether the bound CXCL10 on the surface of the endothelial cells would have 
had an effect on adhesion of THP1, and whether the bound CXCL10 would be sufficient to 
modify the adhesion of monocytic cells to the endothelium.
5.4.4. Regulation of chemokines production by CXCL10 in hCMEC/D3 cells
The leukocyte infiltrate in MS lesions is composed mainly of T cells and monocytes. No 
neutrophils are reported to be present. Moreover, cytokines up-regulated in MS, such as 
TNF-a or IL-l-a, trigger the production of CXCL8 in endothelial cells (Kaplanski et al., 
1994; Kaplanski, 1995) (section 2.3.4). CXCL8 is a chemoattractant for neutrophils. 
Furthermore, there is a temporal variation in the type of infiltrating cells. The hypothesis 
tested here is that one chemokine such as CXCL10 which attracts activated lymphocytes 
(cells that are present in the early stage of the lesions) could in turn induce the secretion of 
other chemokines such as CCL2 or CCL5 in endothelial cells, both monocyte 
chemoattractants. In this part of the study, CXCL10 was investigated for its possible role 
as a modulator for the production of other chemokines. The regulatory effect of one 
chemokine on another has been previously demonstrated in murine astrocytes, since, when 
stimulated with CCL5, they can induce the production of CCL2 (Luo et al., 2002). CCL5
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as well as CCL11, up-regulates the transcript expression of the CXCL8 analogue in mice, 
as well as CCL2, CCL3 and the cytokine TNF-oc (Luo et al., 2002). There was no effect of 
CXCL10 on the production of CXCL8, CCL2 or CCL5 by hCMEC/D3 cells. It is possible 
that a regulatory loop exits between chemokines and cytokines. For instance, cells 
incubated in the presence of CCL3 showed enhanced IFN-y production, (Karpus et al.,
1997) and CCL2 enhanced production of IL-4 (Lukacs et al., 1997). In astrocytes a 
positive feedback seems to occur between CCL5 and TNF-oc, which in turn up-regulates 
CCL2 expression. Indeed, when murine astrocytes are stimulated with CCL5, TNF-oc is 
up-regulated after 12 h while CCL2 up-regulation occurs at 25 h (Luo et al., 2002). This 
effect in endothelial cells is unlikely to be via INF-y, which is the principal stimulatory 
cytokine for CXCL10, as INF-y is not expressed by endothelial cells under basal 
conditions or when stimulated with cytokines such as TNF-oc or IL-ip (Nilsen et al., 1998). 
Nevertheless, in hCMEC/D3 cells, in contrast to HBEC, TNF-oc also induced CXCL10 
production. But in hCMEC/D3 cells, CXCL10 does not appear to have any feedback action 
on TNF-oc expression in endothelial cells as CXCL8 and CCL2, which are up-regulated by 
TNF-oc, were unchanged by CXCL10 stimulation at the time of 48 h. Also this would need 
to be confirmed by measuring TNF-oc, as the release of the cytokine could be insufficient 
to induce CCL2 and CXCL8 release in the supernatant, or that the time point we should 
have looked at is different from 48 h.
5.4.5. Conclusion
In this study, CXCL10 was demonstrated to play no major role in regulating some 
properties of the brain endothelial cells, such as in the permeability and adhesion properties. 
There is no inter-regulation of CXCL10 on CXCL8, CCL2 and CCL5 chemokines. 
CXCL10 stimulation of hCMEC/D3 cells induces the activation of specific signalling 
pathways suggesting that CXCR3 is a functional receptor. It is possible that the activation
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of these pathways is correlated with its already known angiostatic properties on 
endothelium and it would have been interesting to investigate this hypothesis.
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6. Chapter 6: General discussion
230
The aim of this study was to investigate the expression of chemokines and chemokine 
receptors on HBEC. Because of the limited number of endothelial cells obtained from 
brain tissue, a method of isolation for highly pure HBEC was set up and an immortalised 
human brain endothelial cell line was developed. After having established that CXCL10 
was produced at high levels in response to cytokine stimulation and that its unique receptor, 
CXCR3, was expressed by HBEC, both in vitro and in vivo, the effect of CXCL10 on 
HBEC and its consequences on leukocyte infiltration was investigated.
A method to isolate purer primary rat brain endothelial cells (Perriere et al., 2005), relying 
on the expression of efflux pumps, was adapted to isolate HBEC. Using this method, 
sufficient HBEC were obtained, with a low number, if any, of other cell types, that under 
normal conditions outgrow HBEC, as a result of their lower proliferative rate. Nevertheless, 
the use of puromyin could contribute to a change in protein expression. For example, cells 
treated with puromycin showed an increase in P-gp expression (Perriere et al., 2005) which 
is already an artefact of the culture system, as P-gp expression on endothelial cells in vitro 
is lower than P-gp expression on freshly isolated vessels whilst multidrug resistance 
protein is increased in vitro (Seetharaman et al., 1998). This is an important factor to take 
into account when this method of isolation is used especially to study drug transport using 
an in vitro BBB model when compared to other isolation methods. The first investigations 
in this thesis were on cells obtained that had been untreated with puromycin and no 
differences were reported for chemokine production in response to cytokines, so in this 
study, a method of isolation using puromycin was appropriate. Another consequence of 
using puromycin is the lack of heterogeneity in the HBEC. Indeed, it has been shown that 
there are different phenotypes of endothelial cells within the same cell culture (Rupnick et 
al., 1988), some being a cobblestone shape and others were fusiform that could reflect the 
presence of cells from different vascular bed such as arteriolar or venular endothelial cells. 
These two types of cells could be found in our cell cultures with a predominance of the
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fusiform shaped cells. When using a marker such as PEC AM-1 to select the endothelial 
cells during the isolation procedure, the cells appeared more homogeneous (personal 
communication, A. Mabondzo). The significance of the appearance of different cell types 
in culture would need to be determined, in order to determine whether these cells are from 
different parts of the cerebral vasculature. HBEC heterogeneity could also explain the 
differences observed in CXCL8 secretion at basal levels.
Four chemokines, CCL2, CCL5, CXCL8 and CXCL10, and their receptors were studied 
for their implication in MS pathology. These chemokines were all expressed by primary 
HBEC when stimulated with TNF-a, with the exception of CXCL10 which was induced 
by IFN-y. The specificity of CXCL10 induction by IFN-y and not TNF-a confirmed the 
absence or the extremely low level of contaminating astrocytes in the culture as astrocytes 
produce CXCL10 in response to TNF-a (Oh et al., 1999). Another interesting finding with 
respect to chemokine production is their regulation by cytokines. TGF-J3 is an anti­
inflammatory cytokine, but could up-regulate certain chemokines when used in 
combination with IFN-y or TNF-a. IFN-y, generally referred to as a pro-inflammatory 
cytokine, decreases the level of CXCL8 release by the endothelial cells in response to 
TNF-a. The role of TNF-a in MS is controversial. While it has been established that in 
EAE, the animal model used for MS, TNF-a suppression is beneficial (Glabinski et al., 
2004), this has not been the case for MS (Skurkovich et al., 2001). The lack of neutrophil 
infiltration in MS, despite the increase of CXCL8 in the CSF of MS patients, also suggests 
that there is a means of down-regulating the expression of a CXCL8 chemotactic gradient 
that could be induced by TNF-a. The presence of IFN-y could explain this phenomenon. 
IFN-y does not play an important role in EAE (Ferber et al., 1996), but anti-IFN-y has a 
greater effect than anti-TNF-a in treating MS (Skurkovich et al., 2001). However,
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complete suppression of IFN-y could lead to an infiltration of neutrophils as is the case in 
knock-out mice or IFN-y used for EAE model (Tran et al., 2000b).
Immortalisation of HBEC by transduction of a highly efficient lentiviral vector system 
containing hTERT and the SV40 large T antigen, resulted in a stable human brain 
endothelial cell line, named hCMEC/D3. This cell line was characterized for its properties 
of HBEC, as well as for the expression of chemokines and chemokine receptors. Overall, 
whether from primary human brain or from the hCMEC/D3, brain endothelial cells 
produced significant amounts of the chemokines which are involved in MS in response to 
cytokines, also up-regulated in MS. It is interesting that the first cell type which comes into 
contact with leukocytes itself produces such high quantities of chemokines, as the classical 
view is that CNS resident cells, such as astrocytes and microglia produce chemokines that 
are transported across the endothelial cells to be presented on the luminal side to 
leukocytes. The role of chemokines, secreted from endothelial cells, would be interesting 
to study. They could participate in early recruitment of certain types of leukocytes. For 
instance, T cells are present early on in the lesion in MS (Lucchinetti et al., 2000) which 
could be related to the high level of CXCL10 released by the endothelium. More striking is 
the case where neutrophils can be recruited within 3 h into the brain and this correlates 
with the rapid release of CCL2 and CCL3 (Kim et al., 1995), again highly produced by the 
endothelium. Endothelial cells could also contribute to the gradient of chemokines to 
attract leukocytes into the brain, as a part of its release is from the basolateral side. 
Altemativly, the chemokines released by HBEC could prevent the formation of a gradient 
promoting the entry of leukocytes into the brain. Indeed, HBEC grown on filters released 
more chemokines on the apical side than on the baso-lateral side. The non-bound 
chemokines so released by the endothelium could bind to the leukocyte chemokine 
receptors leading the internalisation of the receptor, and hence the disensitivation of the 
response of the leukocyte to the chemotactic gradient.
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Amongst the four chemokines investigated for their production, CXCL8 and CXCL10 
were released in higher quantities compared to CCL2 and CCL5. Interestingly, the receptor 
for CXCL10, CXCR3, and the receptors for CXCL8, CXCR1 and CXCR2 were highly 
expressed by the brain endothelial cells. On the other hand, CCL2 and CCL5 release into 
the culture supernatant of endothelial cells, in response to cytokines, was smaller when 
compared to the two CXCR chemokines, as were the expression level of the receptors for 
these two chemokines, either expressed at a very low level, or absent for CCL2. The 
correlation between chemokine production and chemokine receptor expression could 
indicate the possibility of an autocrine action of the chemokines on the endothelial cells or 
it could participate in the regulatory mechanism of chemokine production. Chemokine 
receptors are quickly internalised upon chemokine binding. This mechanism maintains the 
gradient of chemokines and limits the action of the chemokines. It is in general the DARC 
receptor that is responsible for this function, but CXCL10 does not bind to this receptor. 
The organism must hence have developed other mechanisms to degrade chemokines such 
as CXCL10. A known mechanism of chemokine degradation and regulation are by the 
MMPs (Van den Steen et al., 2003 a,b). Another possibility is that the receptor present on 
the endothelial cells could fulfill this function. The high presence of the receptor in the 
cytoplasm in situ could suggest that this could be the case, as a high turnover of the 
receptor would be observed if the chemokines were present (Venkatesan et al., 2003). 
Furthermore, association of these chemokines with endothelial cells has also been observed 
in vivo (personal communication, P. Rezaie). Moreover, primary data suggests that the 
internalisation of CXCL10 by non-brain endothelial cells is not CXCR3-mediated 
(personal communication, D. Male).
hCMEC/D3 will prove to be a useful cell line and a more appropriate model to study the 
BBB in vitro compared to HUVEC, than most studies used in the past. hCMEC/D3 has the
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advantage of retaining a number of phenotype characteristics intrinsic to HBEC, such as 
the expression of tight junction proteins and a low permeability to macromolecules above 4 
kDa, as well as the ability to respond to BBB-promoting factors such as ACM and high 
intracellular cAMP levels. Nevertheless, it does not represent a perfect BBB model as not 
all of the junctional proteins are located at the cell-cell junction in cells forming a 
confluent monolayer as they are in primary HBEC. Furthermore, the chemokine expression 
pattern is overall similar, but presents small differences. Indeed, CXCL10, which is not 
induced by TNF-a in primary HBEC, is released by hCMEC/D3, when the cells are 
stimulated in the same conditions. This is interesting as most peripheral endothelia release 
CXCL10 in response to TNF-a (Hillyer et al., 2003). It suggests a regulation in response 
to TNF-a in primary HBEC, which is different in hCMEC/D3 cells. This could suggest a 
negative regulation in response to TNF-a stimulation in the primary HBEC, and 
hCMEC/D3 cells as a result of immortalisation, have lost this characteristic or a positive 
regulatory mechanism acquired by immortalisation. They could provide a useful tool to 
study the fine regulation that differentiates brain endothelial cells from peripheral 
endothelial cells in their chemokine production. CCL2 and CXCL8, which were released 
by primary HBEC in vitro at basal levels, were found only to be expressed by hCMEC/D3 
at extremely low level, outside the range of a physiologically significant amount. The 
pattern of expression was similar between primary HBEC and hCMEC/D3 for CCR1-5 and 
CXCR1-3 but the absolute level of expression could not be compare because the technique 
of immunocytochemistry used was not quantitative.
Chemokines are important in directing the leukocytes toward the site of inflammation 
infiltrating across the vascular bed into the tissue. In the case of brain inflammation, the 
immune cells have to cross the barrier which is formed by the brain endothelium. One of 
the aims of this study was to determine whether chemokines could exert an effect on the 
BBB to facilitate the infiltration of the leukocytes into the brain, in addition to their effect
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on leukocytes. CXCL10, amongst the chemokines produced by the brain endothelium was 
selected, as it has been consistantly found to be up-regulated in the CSF and in MS lesions 
(Simpson et al., 2000b; Mahad et al., 2002). No effect of CXCL10 could be detected on 
either the permeability or the adhesive properties of the brain endothelial cells in vitro. As 
in vivo injection of CXCL10 is sufficient to induce infiltration of leukocytes, this could 
suggest that the role of endothelial cells is secondary to the infiltration of leukocytes and 
that activation of leukocytes is sufficient for the transmigration of the cells. Alternatively it 
could suggest that there is a complex response to CXCL10 in vivo. Other cells could 
respond to CXCL10, releasing factors that would trigger the activation of the endothelium. 
In vivo, there are also a number of chemokines present such as CCL2 and CCL5, which 
could have synergistic effects whereas stimulation with one chemokine alone would not be 
sufficient. The relevance of an effect of CXCL10 on the BBB in vivo could be questionable 
as it is generally concomitant with upregulation of IFN-y. IFN-y may itself lead to the 
opening of the BBB (Annunziata et al., 2002) and to endothelial activation such as the up­
regulation of its adhesive properties (Annunziata et al., 2002).
6.1 Future studies
As part of future work, the function of CXCR3 on HBEC still remains to be elucidated.
CXCR3 is known as an angiostatic chemokine although this needs to be confirmed on
hCMEC/D3 cells. In order to determine whether CXCL10 can act on brain endothelial
cells to promote leukocyte infiltration, it would be interesting to investigate whether
intrathecal injections of CXCL10 in a dose similar to that released by the HBEC (around
200ng/ml) into the brain of rat or mice could trigger the infiltration of the leukocytes into
the brain. This experiment could answer the question of whether the brain environment
could suppress leukocyte infiltration that has been observed in peripheral tissue in response
to CXCL10 injection. Furthermore, investigating markers for inflammatory activation
(adhesion molecules or MHC class I) or the opening of the BBB (trypan blue or junction
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protein expression) would allow investigation as to whether CXCL10 could act directly on 
the endothelium to promote leukocytes infiltration. It could be argued that leukocytes 
could get activated in response to CXCL10 and in return activate the endothelium in a 
chain of events, so that the effect of CXCL10 on endothelial cells would be secondary to 
the leukocyte activation by CXCL10. Severe combined immunodeficient mice would 
provide a useful control to ensure that CXCL10 exerts a direct effect on the endothelial 
cells. If intrathecal injection of CXCL10 into these mice induces the same changes on the 
endothelium in severe combined immunodeficient mice as in normal mice, this could 
confirm that CXCL10 acts via CXCR3 on the endothelial cells to promote leukocyte 
infiltration. By contrast, if  there is a difference in the level of activation of the endothelium, 
that would demonstrate that the activation of the endothelium in response to CXCL10 is 
secondary to leukocyte activation.
The importance and role of the chemokines released by different cells within the CNS 
would also be an important and interesting question to answer. Recent advances in mice 
engineering have allowed production of mice in which a specific gene could either be 
blocked or induced within one cell type using a specific marker such as GFAP for 
astrocytes. Using a brain endothelial marker and blocking the production of CXCL10 in an 
EAE model could allow determination of whether chemokines released from the 
endothelial cells promote or inhibit leukocyte extravasation into the brain. This could also 
be important for designing future therapy targeting chemokine production, as when the 
chemokines from CNS cells such as astrocytes or microglia determine the migration of 
leukocytes, new drugs should then be able to cross the BBB.
Opening of the BBB and increased chemokine production is a characteristic feature of 
EAE and MS. cAMP can act on both these characteristics feature by decreasing the 
permeability of the endothelium in vivo and by decreasing the release of CXCL10, one of
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the chemokines that is a major chemoattractant for activated T lymphocytes. The effect of 
an inhibitor of phophodiesterase, preventing the degradation of cAMP, such as RO 20- 
1724, in EAE could be interesting to study as a therapeutic agent.
6.2 Final conclusion
The aim of this study was to identify chemokines and chemokine receptors expressed by 
HBEC in vitro, and correlate those with the chemokines and chemokine receptors found to 
be up-regulated in MS. CXCL8 and CXCL10 were highly produced by HBEC when 
stimulated by cytokines. Interestingly, CXCR1 and CXCR3, the receptor for CXCL8 and 
CXCL10 respectively, were both found to be higly expressed by HBEC in vitro, and the 
expression of these receptors were confirm in situ by immunogold and electron microscopy. 
Also there were no changes in CXCR1 level of expression in the lesions when compared to 
NAWM and a tendancy to decrease for CXCR3. In order to determine whether CXCR3 
activation on HBEC could promote leukocyte migration by an increase in permeability or a 
change in adhesion molecules, hCMEC/D3 cells, an immortalized human brain endothelial 
cell line, were stimulated by CXCL10. In vitro stimulation of CXCR3 by CXCL10 did not 
appear to have an effect or the permeability of an endothelial cell monolayer, nor on the 
adhesion property of the endothelium to monocytes, suggesting that CXCL10 plays little 
role at the level of the BBB in leukocyte extravasation. However, further work needs to be 
undertaken.
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